

CURRICULUM VITAE

Name: **ERIC HOLLANDER, MD, DFAPA, FACNP**

Current Position: Professor of Psychiatry and Behavioral Science
Director, Autism and Obsessive-Compulsive Spectrum Program,
and Anxiety and Depression Program,
Psychiatry Research Institute of Montefiore-Einstein (PRIME)
Director, Syndromal ASD and Orphan Disorder Program
Member, Einstein-Mt. Sinai Diabetes Research Center
Member, Einstein Interdisciplinary Developmental Disorder Research Center
Albert Einstein College of Medicine

Contact Information: Albert Einstein College of Medicine
Psychiatry Research Institute of Montefiore-Einstein (PRIME)
1225 Morris Park Ave
Bronx, NY 10461

Telephone Number: 718-839-7516

FAX Number: 718-839-7575

E-Mail: eholland@montefiore.org; eric.hollander@einsteinmed.edu

Born: Los Angeles, California, USA (6/19/57)

Education:

1978	B.A.	Brandeis University, Waltham, MA
1982	M.D.	State University of New York Downstate Medical College, Brooklyn, NY

Internship:

1982 - 1983	Internal Medicine	Mount Sinai Hospital, NY, NY
-------------	-------------------	------------------------------

Residency:

1983 - 1986	Psychiatry	Mount Sinai Hospital, NY, NY
1985 - 1986	Chief Resident- Psychiatry Research	Clinical Research Unit and Alzheimer's Disease Research Center - Mount Sinai School of Medicine, NY, NY

Fellowship:

1986 - 1988	NIMH Psychiatry Research Fellowship	Columbia University College of Physicians & Surgeons and NYS Psychiatric Institute
1988 - 1989	Dana Foundation Fellow	Columbia University
1988 - 1993	NIMH Research Scientist	Columbia University

Licensure:

Development Award
New York State License: 155389, Year: 1983

DEA License: AH2289420

Board Certification:

Diplomate - American Board of Psychiatry and Neurology (29504) 1987

Awards and Honors:

2020, Editor in Chief – Journal of Psychiatric Research
2020, Founders Award recipient, Anxiety Disorders Association of America
2019 Faculty Member of the Year Award for Psychiatry, F1000Prime
2016, Best Doctors, New York Magazine, and Castle Conelly
2015, Best Doctors, New York Magazine, and Castle Conelly
2014, Best Doctors, New York Magazine, and Castle Conelly
2013, Best Doctors, New York Magazine, and Castle Conelly
2012, Best Doctors, New York Magazine, and Castle Conelly
2011, Best Doctors, New York Magazine, and Castle Conelly
2010, Best Doctors, New York Magazine, and Castle Conelly
2009, Chair, SAB, Icare4Autism
2009, Distinguished Investigator Award, NARSAD
2009, Best Doctors in America
2009, Best Doctors, New York Magazine, and Castle Conelly
2007, DSM-V Anxiety Disorders and Behavioral Addictions Taskforce
2007, President - International Society for Research In Impulsivity (ISRI)
2007, Best Doctors, NY Magazine
2007, Best Doctors in America
2005, Chair - NIH STAART Autism Steering Committee
2005, Director – International College of Obsessive Compulsive Spectrum Disorders (ICOCS)
2005, Chair – DSM-V Research Planning Agenda Workgroup on Obsessive Compulsive Behavior Spectrum Disorders
2005, Member – APA Practice Guidelines – Obsessive Compulsive Disorder
2003, Distinguished Fellow – American Psychiatric Association

2002, Fellow – American College of Neuropsychopharmacology

2002 – Present, Chair - DSM-V Work Group on Obsessive Compulsive Spectrum Disorders, APA

2002, Chair, Autism Clinical Trials Task Force, Cure Autism Now (CAN)/Autism Speaks

1998, NARSAD Distinguished Investigator Award

1998, DSM-IV-R Work Group Chair, Impulse Control Disorder Section

1996, Founding Editor, *CNS Spectrums: The International Journal of Neuropsychiatric Medicine*

1996, Scientific Advisory Board, Anxiety Disorders Association of America

1994, Best Mental Health Specialists in the U.S.A. - Good Housekeeping

1993, International OCD Council Founding Member

1993, Secretary, OCD Section, World Psychiatric Association

1992, Member, DSM-IV Work Group - Obsessive Compulsive Disorder

1992, Member, DSM-IV Work Group - Body Dysmorphic Disorder

1992, Scientific Advisory Board, OC Foundation

1990, American Psychiatric Association/Wisniewski Young Psychiatrist Research Award, First Place, New York, NY

1990, Collegium Internationale Neuro-Psychopharmacologium
Rafaelsen Fellowship Award, Kyoto, Japan

1988-1993, Research Scientist Development Award
National Institute of Mental Health

1988-1989, Dana Foundation Fellow (Columbia University)

1986, American Psychiatric Association/Penwalt Resident Research Award, First Place, Washington, DC

1986, Marcel Heiman Memorial Award for Outstanding Research
Mount Sinai School of Medicine, Department of Psychiatry

1986, M. Ralph Kaufman Prize, Outstanding Resident in Psychiatry
Mount Sinai School of Medicine, Department of Psychiatry

1985-1986, Solomon W. Ginsburg Fellow: Group for the Advancement of Psychiatry

Patents and Inventions:

Oxytocin in Autism and Social Attachment Disorders (US patent application, Patent Granted in EU)

Mementine in Autism, Compulsive and Impulsive Disorders (US patent application)

Fluoxetine in Autism (Orphan Designation: Food and Drug Administration)

Internet Addiction - YBOCS (US Copyright)

Pathological Gambling – YBOCS (US Copyright)

Fluvoxamine Gambling Treatment Program (SAMHSA)

Hospital Appointments:

1986 - 1992	Assistant Attending Psychiatrist, The Presbyterian Hospital
1992 - 1993	Associate Attending Psychiatrist, The Presbyterian Hospital
1988 - 1993	Attending Psychiatrist, The New York State Psychiatric Institute
1988 - 1993	Director, Obsessive Compulsive Disorder Biological Studies Program The New York State Psychiatric Institute
1989 - 1993	Director, Anxiety Diagnostic & Recruitment Unit, NYS Psychiatric Institute
1993 - 1994	Associate Director, Academic Affairs, Queens Hospital Center
1993 - 1994	Vice Chairman, Department of Psychiatry, Mount Sinai School of Medicine
1993 - 2008	Director, Clinical Psychopharmacology, Mount Sinai School of Medicine
1994 - 2003	Clinical Director, Seaver Autism Research Center
1994 - 2008	Director, Compulsive, Impulsive and Anxiety Disorders Program
1996 - 2008	Attending Psychiatrist, The Mount Sinai Hospital
2003 – 2008	Director, Seaver Autism Research Center
2003 – 2008	Director, Greater NY Autism Research Center of Excellence
2005 – 2008	Chairman of Psychiatry, Mount Sinai Medical Center and School of Medicine
2009 - Present	Director of Autism and Obsessive-Compulsive Spectrum Program, Anxiety and Depression Program, and Syndromal ASD and Orphan Disorder Program Albert Einstein College of Medicine and Psychiatry Research Institute of Montefiore-Einstein (PRIME)

Academic Appointments:

1986 - 1988	Instructor in Clinical Psychiatry, Columbia University P & S
1988 - 1992	Assistant Professor of Clinical Psychiatry, Columbia University P & S
1992 - 1993	Associate Professor of Clinical Psychiatry, Columbia University P & S
1993 - 1996	Associate Professor of Psychiatry, Mount Sinai School of Medicine
1996 - 2008	Professor of Psychiatry, Mount Sinai School of Medicine
2005 – 2008	Esther and Joseph Klingenstein Professor of Psychiatry and Chairman of Psychiatry, Mount Sinai School of Medicine
2009 - Present	Professor of Psychiatry and Behavioral Sciences Albert Einstein College of Medicine

Administrative:

Director-Spectrum Neuroscience and Treatment Institute

Director-International College of Obsessive Compulsive and Spectrum Disorders

Chair, SAB, ICare4Autism

Member, Eintein-Mount Sinai Diabetes Research Center
Albert Einstein College of Medicine

Member, Rose F. Kennedy Intellectual and Developmental Disabilities Research Center (IDDRC)
Albert Einstein College of Medicine

Director, Anxiety Diagnostic and Recruitment Unit
MHCRC, New York State Psychiatric Institute

Director, Compulsive and Impulsive Disorders Program
New York State Psychiatric Institute

Director, Open Treatment Component
Mental Health Clinical Research Center
New York State Psychiatric Institute

Member, Quality Assurance Committee
New York State Psychiatric Institute
Queens Hospital Center

Member, Incident Review Committee
New York State Psychiatric Institute

Member, Medical Staff Committee
New York State Psychiatric Institute
Queens Hospital Center

Member, Continuing Medical Education Committee
Columbia University, College of Physicians and Surgeons

Member, Medical Education Committee, Medical Ethics
Group for the Advancement of Psychiatry

Member, Scientific Program Committee
Society for Biological Psychiatry

Consultant, Health and Hospitals Corporation
Psychopharmacology Issues

Member, Managed Care Committee - Psychiatry
Mount Sinai School of Medicine

Member, Operating Committee
Mount Sinai School of Medicine

Member, Continuing Medical Education Committee, Postgraduate School
Mount Sinai School of Medicine

Member, Promotions Committee

Mount Sinai School of Medicine

Chair, Outpatient Psychiatry Research Committee
Mount Sinai School of Medicine

Chair, Psychiatry Research Incident Review Board
Mount Sinai School of Medicine

Chair, Space Appropriations Committee, Psychiatry Outpatient Research Center, Atran E
Mount Sinai School of Medicine

Member, Special Investigation Committee-Scientific Integrity
Mount Sinai School of Medicine

Member-Internal Committee-Neurology Departmental Review
Mount Sinai School of Medicine

Co-Chair-Planning Committee-Institute for Brain Disorders
Mount Sinai School of Medicine

Committees

Incident Review Committee - NYS Psychiatric Institute

Faculty Staff Committee - NYS Psychiatric Institute

Quality Assurance Committee - NYS Psychiatric Institute, Queens Hospital Center

Chairman - Grand Rounds Committee - Queens Hospital Center

Chairman - Journal Club Committee - Queens Hospital Center

Operating Committee - MSSM Psychiatry Department

Senior Investigators Committee - MSSM Psychiatry Department

Clinical Directors Committee - MSSM Psychiatry Department

Affiliate Clinical Directors Committee - MSSM Psychiatry Department

Trauma Committee - Victim Services, Inc.

Trauma Planning Subcommittee - Victim Services, Inc.

Service Directors Committee - Queens Hospital Center

Managed Care Committee - Mt. Sinai School of Medicine

Continuing Medical Education Committee - Mt. Sinai School of Medicine

Promotions Committee - Mt. Sinai School of Medicine

Institutional Review Board (IRB) - Montefiore Medical Center University Hospital of Albert Einstein College of Medicine

TEACHING SECTION:

Fellowship Director:

Autism and Obsessive Compulsive Spectrum Fellowship, Einstein-Montefiore

Anxiety and Depression Fellowship, Einstein-Montefiore

Syndromal Autism and Orphan Disorders Fellowship, Einstein-NYS Office of Mental Health

Director/PI – NIMH Fellowship in Translational Psychopharmacology – Mount Sinai

Editor in Chief: Journal of Psychiatric Research

Editor: International Journal of Psychiatry and Clinical Practice (IJPCP)

Founding Editor: *CNS Spectrums: The International Journal of Neuropsychiatric Medicine*

Editorial Advisory Board:

Comprehensive Psychiatry
World Journal of Biological Psychiatry
Autism Research
Gambling
Neuropsychopharmacology (1997 – 1999)
Medscape Psychiatry & Mental Health
Psychiatric Annals
Focus on OCD
Primary Psychiatry
Mental Fitness
International Journal of Psychiatry in Clinical Practice
Journal of Gambling Studies
Wager
Clinical Neuropsychiatry
Contemporary Psychiatry
Mount Sinai Journal of Medicine (Associate Editor)
Revista de Psiquiatria y Salud Mental

Reviewer:

Archives of General Psychiatry
American Journal of Psychiatry
Biological Psychiatry
Psychiatry Research
Journal of Neuropsychiatry and Clinical Neuroscience
Journal of the American Medical Association
Journal of Nervous and Mental Disorders

Direct Mentoring of Fellows:

1. Dan J. Stein, M.D.
Columbia University/NYS Psychiatric Institute Postdoctoral Research Fellow
NARSAD Young Investigator Award - “Psychobiology of the Personality Dimensions”
Chairman of Psychiatry, University of Capetown

2. Daphne Simeon, M.D.
Columbia University/NYS Psychiatric Institute Postdoctoral Research Fellow
NIMH Postdoctoral Research Fellowship
NARSAD Young Investigator Award - “Depersonalization: Diagnosis, Biology, Treatment”
Associate Professor of Psychiatry, AECOM, NIMH funded
3. Michael Hwang, M.D.
Program for Minority Research Training in Psychiatry, American Psychiatric Association
“Neurological Aspects of OCD and TS”
4. Allison McCarley
Program for Minority Research Training in Psychiatry, American Psychiatric Association
“Sexual Side Effects of Serotonin Reuptake Blockers:
Stanley Scholar Program, Columbia University
5. Robert Grossman, M.D.
NIMH Postdoctoral Research Fellow - Mt. Sinai School of Medicine
Psychobiology of Self-Injurious Behavior
6. Scott Cherkasky, M.D.
Mt. Sinai Geriatric Research Fellow
OCD in the Geriatric Population
7. Cheryl Wong, M.D.
ACNP/Glaxo Wellcome Fellow
APA/PMRTP Research Fellow
8. Charles Cartwright, M.D.
NAAR/BMS Neuropsychopharmacology of Autism Fellow
9. Sherie Novotny, M.D.
NARSAD Young Investigator Award – “Pharmacological Treatment of Autism: Treating the Dimensions”
Mt. Sinai and Seaver Center Research Fellow
10. Alicia Kaplan, M.D.
Mt. Sinai and Seaver Center Research Fellow
11. Sallie Jo Hadley, M.D.
Mt. Sinai and Seaver Center Research Fellow
12. Stacey Wasserman, M.D.
Mt. Sinai and Seaver Center Research Fellow
13. Alicia Kaplan, M.D.
Mt. Sinai School of Medicine
14. Evdokia Anagnostou, M.D.
Mt. Sinai and Seaver Center Research Fellow
15. Latha Soorya, Ph.D.
Mt. Sinai School of Medicine, NIH Fellow
Training In Psychopharmacology and Outcomes Research, NIMH funded
16. Ljilja Radulovic, M.D.
Mt. Sinai School of Medicine

17. Heather Berlin, Ph.D.
Mt. Sinai School of Medicine, NIH Fellow
Training In Psychopharmacology and Outcomes Research
18. Jennifer Bartz, Ph.D.
Mt. Sinai and Seaver Center Research Fellow, NIMH funded
19. Danielle Halperin, Ph.D.
NIDA T32 fellow
20. Ting Wang, Ph.D.
NIDA T32 fellow, NIMH funded
21. Ilana Slaff, M.D.
Seaver/YAI Fellow
22. Steve Poskar, M.D.
Autism and Obsessive-Compulsive Spectrum Program Fellow
23. Laura Antar, M.D.
Autism and Obsessive-Compulsive Spectrum Program Fellow
24. Jonathan Kirsch, MD
Autism and Obsessive-Compulsive Spectrum Program Fellow
25. Rachel Noone, MD
Autism and Obsessive-Compulsive Spectrum Program Fellow
26. Clewert Sylvester, MD
Anxiety and Depression Program Fellow
27. Marissa Miyazaki, MD
Anxiety and Depression Program Fellow
28. Anahid Kabasakalian, MD
Autism and Obsessive-Compulsive Spectrum Program Fellow
29. Genoveva Uzunova, MD
Syndromal ASD and Orphan Disorder Program
30. Pooja Palkar, MD
Anxiety and Depression Program
40. Asif Rahman, BA
Autism and Obsessive-Compulsive Spectrum Program Fellow
41. Vera Negovorova, MD
Autism and Obsessive-Compulsive Spectrum Program Fellow
42. Elisabetta Burchi, MD
Autism and Obsessive-Compulsive Spectrum Program Fellow
43. Michael Diamond, MD
Autism and Obsessive-Compulsive Spectrum Program Fellow

Dissertation Committee and Dissertation Questioner:

1. Concetta DeCaria - Doctor of Philosophy in Psychology (Neuropsychology)
Dissertation: "Psychobiology of Pathological Gambling",
CUNY, NY

2. Martijn Figee – Doctor of Philosophy in Neuroscience and Psychiatry
Dissertation: "Deep Brain Stimulation in OCD: Salience and Addiction"
Academic Medical Center, Amsterdam

Lectures/ Courses Taught: Einstein, Mount Sinai School of Medicine, Columbia P& S

Cannabidiol in Autism and Oxytocin in Prader-Willi Syndrome – Lecture – Psychiatry Grand Rounds –
Montefiore/AECOM

Psychopharmacology Supervision (weekly) – PGY III Psychiatry residents, Montefiore/AECOM

Developmental Disabilities in Adulthood – Lecture – PGY II Psychiatry Residents – Montefiore/AECOM

Child Psychopharmacology – Lecture – Psychology Internship – Montefiore/AECOM

DSM-V Lectures – PGY IV Psychiatry residents – Montefiore/AECOM

Mentor – NIMH Fellowship in Psychopharmacology - MSSM

Brain and Behavior Lectures – MS I - MSSM

Phenomenology Course – PGY II Psychiatry Residents

Neuroscience Course – PGY III Residents

Outpatient Psychopharmacology Course - PGY III Residents

Psychopharmacology Supervision - PGY III Residents

Anxiety Disorder Lectures - MS I and MS II Medical Students

OCD Lectures - PGY II and III Psychiatry and Neurology Residents

Neuroscience Review Course - Neurology Department

Outpatient Psychopharmacology Clinic - PGY III Residents

OCD CME Course Director - 8 Conferences at Mt. Sinai and Columbia

Journal Club and Grand Rounds - chair, Mt. Sinai/Queens Hospital Center

Pharmacology Lectures - MS IV Medical Students

Chairman and Organizer, 7 Conferences on the Diagnosis, Neurobiology, Genetics and Treatment of Autism in association
with CAN, NAAR, ASA, and NARSAD

Chairman and Organizer

International Autism Conference- Albert Einstein College of Medicine, 2011

International Autism Conference- Jerusalem, Israel, 2010

Chairman and Organizer

First International Conference on OCD, Capri, March 1993

Second International Conference on OCD, Guadeloupe, March 1996
Third International Conference on OCD, Madeira, Portugal, 1998
Fourth International Conference on OCD, St. Thomas, V.I., 2000
Fifth International Conference on OCD, Sardinia, 2001
Sixth International Conference on OCD, Lanzarote, 2003

Participant, Anxiety Disorders in African-Americans Conference, 1993

Fellowship Supervisor, Program for Minority Research Training in Psychiatry
American Psychiatric Association

Professional Organizations:

Academia, Medicina & Psychiatria Foundation (Fellow)

American College of Neuropsychopharmacology
Fellow (2002)
Member (1998-Present)
Finance Committee (1999-present)
Section Editor, ACNP, Psychopharmacology: The Fifth Generation of Progress
Editorial Advisory Board, Neuropsychopharmacology
Associate Member (1992-1996)

American Federation for Clinical Research

American Medical Association

American Psychiatric Association (Distinguished Fellow)
Member, Committee on Resident Research Award Review

American Psychopathological Association

American Society of Clinical Psychopharmacology

Anxiety Disorders Association of America (Scientific Advisory Board)

Asociacion Argentina de Trastornos de Ansiedad

Collegium Internationale Neuro-Psychopharmacologicum

European College of Neuropsychopharmacology - Corresponding Member

Group for the Advancement of Psychiatry
Solomon Ginsburg Fellow (1985-1986), Medical Education Committee

International College of Obsessive Compulsive Spectrum Disorders (Company Director)
International Council on OCD (Founding Member)

International Society for Research on Impulsivity and Impulse Control Disorders
President – 2007
President Elect - 2006
(Secretary Treasurer - FY2005)

National Board of Medical Examiners (Test Material Development Committee)

New York Psychiatric Society (Member)

Obsessive Compulsive Foundation (Scientific Advisory Board)

Society of Biological Psychiatry
Scientific Program Committee
George N. Thompson Award Committee
World General Medical Council (Fellow)

World Health Organization Committee on Priority Treatments for Mental Health Disorders
Priority Treatments for Obsessive Compulsive Disorder

Consulting:

US Congress and Senate, Joint Committee on NIH Funding Issues

Psychopharmacology Consult, Health and Hospitals Corporation

Scientific Advisory Boards
Obsessive Compulsive Foundation
Anxiety Disorders Association of America
Autism Society of America Foundation
QSAC
NAMI
Cure Autism Now

First International OCD Conference Organizer - Solvay/Upjohn - 1993, Capri
Second International OCD Conference Organizer - Solvay/Upjohn - 1996, Guadeloupe
Third International OCD Conference Organizer - Solvay/Upjohn - 1998, Madeira
Fourth International OCD Conference Organizer – Solvay/Upjohn – 2000, St. Thomas
Fifth International OCD Conference Organizer – Solvay/Upjohn – 2001, Sardinia
First, Second, Third Columbia University OCD Conference Organizer - Ciba Geigy/CME
First Mt. Sinai/OC Foundation OCD Conference - 1994 - Solvay/Upjohn
First, Second, Third Mt. Sinai/Seaver Center Autism Conference
First Mt. Sinai/Seaver Center Autism Conference for Educators

Patient Advocacy Groups

Obsessive-Compulsive Foundation
Member, Scientific Advisory Board
Director, Scientific Awards Committee
Member, Minorities and Research Committee

International Obsessive-Compulsive Council
Founding Member
Secretary

Anxiety Disorders Association of America
Member, Scientific Advisory Board

World Psychiatric Association, Section on Anxiety and OCD
Secretary

Cure Autism Now,
Chair, Scientific Advisory Group – Treatment Guidelines
Chair, Autism Clinical Trials Task Force (ACTTF)
Chair – Clinical Trials Network (CTN)

Icare4Autism, Chair, SAB

Grant Reviewer

NIMH – 1996-2008 - RO1, K grants, RUPP-PI
NIDA – 1995-2003 - RO1, K grants
DOD – 2016 – Clinical Trial and Idea Awards, ASD

GRANT SECTION:

Current Pending Federal Grants (Principal Investigator):

PCORI (PI: Hollander) GRANT PENDING
PATIENT-CENTERED OUTCOMES RESEARCH INSTITUTE
First-Line Treatment Options in Adults with Obsessive-Compulsive Disorder
Direct Cost: \$3,000,000 - Total Cost: \$3,873,112

Current Funded Federal Grants (Principal Investigator):

NCT03197662 (PI: Hollander) 08/30/17-08/30/2021
FDA, Orphan Products Division
A Phase 2 Trial of Oxytocin vs. Placebo for the Treatment of Hyperphagia in Children and Adolescents with Prader-Willi Syndrome. IND#121109, received 08/27/2014
Total Costs: \$1,491,355.00

NCT03202303 (PI: Eric Hollander) 10/01/17-10/01/21
DOD CDMRP AUTISM RESEARCH PROGRAM CLINICAL TRIAL AWARD
Cannabidiol (CBD) vs. Placebo in Children with Autism Spectrum Disorder (ASD)
Total Costs: \$1,336,635

NICHHD-2016-LAPS01 (PI: Hollander) 11/01/16-01/01/21
EUNICE KENNEDY SHIVER NICHHD
Long Term Antipsychotic Pediatric Safety Trial (LAPS)
Total Cost: 100,000

PWS CBDV (PI: Hollander) 01/01/2019 – 01/01/2021
FOUNDATION FOR PRAEDER-WILLI RESEARCH
Cannabidiol (CBD) vs. Placebo in Children with Prader- Willi Syndrome (PWS)
Total Cost: \$108,000

Prior Funded Grants: Principal Investigator

Federal Grants:

FDA – Fluoxetine in Pediatric Body Dysmorphic Disorder (2005-2010).
(FD-R-002613-01) Annual Direct Cost \$ 289,387 Total Direct Cost \$ 884,873.

NIH – Greater New York Autism Research Center of Excellence: (2003-2009).
The STAART Program. (1 U54 MH66673-01). Annual Direct Cost \$ 1,417,295
Total Direct Cost \$ 7,149,157.

NIH – Greater New York Autism Research Center of Excellence: (2003-2009).
The STAART Program. (1 U54 MH66673-01). Liquid Citalopram Supplement.

Annual Direct Cost \$ 100,000.

NIMH - NRSA Institutional Research Training Grants – Training in Psychopharmacology and Outcomes Research (1 T32 MH62996-01). (2003-2008).

Annual Direct Cost \$ 50,127 Total Costs \$ 455,353.

FDA – Fluoxetine vs. Placebo In Adult Autistic Disorder. (2001-2006).

(FD-R-002026-01) Annual Direct Cost \$ 203,771 Total Direct Cost \$ 607,930.

FDA - Liquid Fluoxetine vs. Placebo in Child/Adolescent Autism. (1998-2003).

(FD-R-001404-01) Annual Direct Cost \$ 116,242 Total Direct Cost \$ 349,637

Total Cost \$ 592,635.

NIMH - Pharmacotherapy of Adolescent Body Dysmorphic Disorder (1999-2003).

(1 RO1 MH58935-01A1) Annual Direct Cost \$ 66,578 Total Direct Cost \$ 112,850

Total Cost \$ 475,247.

NIMH - Divalproex Sodium/Placebo In Borderline PD (1 RO3 MH56974-01). (1998-2002).

Annual Direct Cost \$ 49,988 Total Direct Cost \$ 99,762 Total Cost \$ 169,097.

NIDA - Serotonergic/Norepinephrine Function in Pathological Gambling. (1997-2002).

(1 RO1 DA10234-01A2) Annual Direct Cost \$ 251,126 Total Direct Cost \$ 984,926

Total Cost \$ 1,669,450.

NIMH Research Scientist Development Award - “Psychobiology of Obsessive Compulsive and Related Disorders”, NIMH. MH-00750. (1988-1993).

Annual Costs \$ 72,150, Total Costs \$ 360,750.

FDA Orphan Drug Grant - Clomipramine/Desipramine Crossover in BDD (1994-1997).

(FD-R-000941-01) Annual Direct Costs - \$ 198,871 Total Direct Cost \$ 398,600

Industry Studies:

BP30153(PI: Hollander)

08/01/16-02/01/19

F. HOFFMAN-LA ROCHE LTD

A Multi-center, randomized, double-blind, 12 week, parallel group, placebo-controlled proof of concept study to investigate the efficacy and safety of RO5285119 in individuals with Autism Spectrum Disorder (ASD)

Total Cost: \$120,000

BP40331 (PI: Hollander)

01/01/18-06/01/19

F. HOFFMAN-LA ROCHE LTD

A study to evaluate and explore scales for repetitive and restricted behaviors and digital biomarkers in children, adolescents and adults with Autism Spectrum Disorder (ASD)

Total Cost: \$ 99,000

WN39434 (PI: Hollander)

08/01/16-01/01/20

GENENTECH INC,

A phase III, randomized, double-blind, Placebo-controlled, efficacy, and safety study of Balovaptan in Adults with Autism Spectrum Disorder with a 2-Year open label extension

Total Cost: \$990,000

00104 (PI: Hollander)

CUREMARK/QUINTILES

01/01/15 – 01/01/20

An Open-Label Extension Study of CM-AT for the Treatment of Children with Autism

Total Costs: \$109,460.00

NBI-98854-TS2003 (PI:Hollander)
NEUROCRINE BIOSCIENCES

11/01/17-01/31/19

A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Dose Optimization Study to Assess the Safety, Tolerability, and Efficacy of NBI- 98854 for the Treatment of Pediatric Subjects with Tourette Syndrome
Total Cost: \$214,194

(2015 – 2018) 17-AVP-786-206 (PI: Hollander)

Avanir Pharmaceuticals

A Phase 2 multicenter randomized double-blind placebo-controlled study to assess the efficacy, safety and tolerability of AVP-786 for the treatment of Intermittent Explosive Disorder

Total Cost: \$147,956

(2014-2016) FOUNDATION FOR PRADER WILLI RESEARCH (PI: Hollander)

Oxytocin vs. Placebo for the treatment of Hyperphagia in Prader-Willi Syndrome

Total Direct Costs: \$100,000 Total Costs: \$108,000

LUAA21004_002 (PI: Hollander)

TAKEDA

A Randomized, Double-Blind, Placebo-Controlled, Phase 4, Relapse Prevention Study Evaluating the Efficacy and Safety of Vortioxetine (5, 10 and 20 mg) in Adults With Major Depressive Disorder.

Total Direct Costs: \$433,466

BP28420 (PI: Hollander)

F. HOFFMAN-LA ROCHE LTD

A Multi-center, randomized, double-blind, 12 week, parallel group, placebo-controlled proof of concept study to investigate the efficacy and safety of RO5285119 in individuals with Autism Spectrum Disorder (ASD)

Total Cost: \$120,000

RGH-MD-72 (PI: Hollander)

FOREST RESEARCH INSTITUTE

A phase 3, double-blind, placebo-controlled study of cariprazine as adjunctive therapy in major depressive disorder

Total Costs: \$367,224

D1050302 (PI: Hollander)

SUNOVION PHARMACEUTICALS INC.

A 104 week, flexible-dose, open-label, multicenter, extension study to evaluate the long-term safety and effectiveness of lurasidone in pediatric subjects with schizophrenia and subjects with irritability associated with autistic disorder.

Total Costs: \$92,665

00103 (PI: Hollander)

CUREMARK LLC

A Double-Blind Placebo Controlled Study of CM-AT for the Treatment of Autism in Children with All Levels of Fecal Chymotrypsin

Total Costs: \$202,200

RGH-MD-76 (PI:Hollander)

FOREST RESEARCH INSTITUTE

A phase 3, long-term, open-label study of safety and tolerability of cariprazine as adjunctive therapy in major

depressive disorder.
Total Costs: 93,243.71

14865A (PI: Hollander)
H. LUNDBECK

Interventional, randomised, double-blind, parallel-group, placebo-controlled, flexible dose study of brexpiprazole as adjunctive treatment to paroxetine or sertraline in adult patients suffering from post-traumatic stress disorder (PTSD)
Total Costs: 121,640

(2013-2014) D1050325(PI: Hollander)
SUNOVION PHARMACEUTICALS INC.

A 6-week, randomized, parallel, double-blind, placebo-controlled, fixed-dose, multicenter study to evaluate the efficacy and safety of lurasidone in children and adolescent subjects with irritability associated with Autistic Disorder
Total Costs :\$99,920

(2011-2013) SIMONS FOUNDATION (PI: Hollander)
Trichuris Suis Ova in Autism Spectrum Disorder
Annual Direct Cost \$104,162 Total Directs \$112,464

(2013-2014) MEM-MD-91(PI: Hollander)
FOREST RESEARCH INSTITUTE, INC

An open-label study of the safety and tolerability of memantine in pediatric patients with autism, asperger's disorder or pervasive developmental disorder not otherwise specified (PDD-NOS)
Total Costs \$60,000

(2013-2014) MEM-MD-69(PI: Hollander)
FOREST RESEARCH INSTITUTE, INC

An open-label extension study of the safety and tolerability of memantine in pediatric patients with Autism, Asperger's Disorder or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
Total Costs \$36,000

(2010-2013) SAV-MD-21 (PI: Hollander)
FOREST INDUSTRIES INC

Milnacipran in Autism and the Functional Locus Coeruleus and Noradrenergic model of Autism
Annual Direct Cost: \$238,000 Total Cost: \$297,500

(2011-2013) SIMONS FOUNDATION (PI: Hollander)
Thermal Regulation and Autism Spectrum Disorder
Annual Direct Cost: \$110,254 Total Cost: \$132,304

(2011-2013) ROCHE PHARMACEUTICALS (PI: Hollander)

A multi-centre, randomized, double-blind, placebo-controlled, cross-over study to examine the safety and tolerability, pharmacokinetic and exploratory pharmacodynamic effects of a single dose of R05028442 in adults with autism spectrum disorder.
Annual Direct Costs: \$167,287 Total Cost: \$260,787

(2011-2012). TRANSCEPT PHARMACEUTICALS – Ondansetron in Adult Patients with Obsessive-Compulsive Disorder (OND-003)

(2008-2010). NARSAD Distinguished Investigator Award. Intranasal Oxytocin for Social Cognition and Repetitive Behavior Domains in Autism. Annual Cost \$ 100,000

(1994-2008). Seaver Foundation - Seaver Autism Research Center
(Eric Hollander, M.D., Director) Annual Cost \$ 1,250,000 Total Cost \$ 13,000,000.

(2007-2009). UJAFJP – Seaver Center Social Skills Project
Annual Direct Cost \$ 74,166

(2006-2007). CAN – Clinical Trials Network Infrastructure.
Annual Direct Cost \$ 102,488 Total Direct Cost \$ 112,737.

(2006-2007). CAN – A multi-site double-blind placebo-controlled trial of memantine vs. placebo in children with autism targeting motor skills.
Annual Direct Cost \$ 54,393 Total Direct Cost \$ 59,842.

(2006-2008). BMS – Aripiprazole Treatment in Children with Autistic Disorder
Annual Direct Cost \$ 19,835

(2001-2006). NINDS – Divalproex Sodium/Placebo In Child/Adolescent Autism.
(1 R21 NS43979-01) Annual Direct Cost \$ 100,000 Total Direct Cost \$ 300,000.

(2002-2003). Abbott Laboratories – An Open-Label Trial of Divalproex Sodium Extended Release In Borderline Personality Disorder. Total Direct Cost \$ 143,115.00.

(2001-2003). Pfizer Pharmaceuticals – Efficacy of Sertraline in the Treatment of Binge Eating Disorder Among Obese Children and Adolescents. Total Direct Cost \$ 50,000.

(2001-2003). Forrest Laboratories – Treatment of Internet Addiction with Citalopram.
Total Direct Cost \$ 50,000.

(2001-2003). Contral Pharma – Nalmefene in the Treatment of Pathological Gambling: A Placebo Controlled Dose Reponse Study. Total Direct Cost \$ 100,000.

(2001-2003). Pfizer – Multicenter Trial of Ziprasidone Augmentation in Serotonin Reuptake Inhibitor-Resistant Obsessive-Compulsive Disorder. Total Direct Cost \$ 144,663.

(2001-2003). Callisto – Autoimmune Investigations In Obsessive-Compulsive Disorders.
Total Direct Cost \$ 10,000.

(2001-2003). Pfizer – Phase II, Twelve Week, Double Blind and Placebo Controlled Study To Evaluate the Safety and Efficacy of Two Doses of CP-448,187 (1.5mg and 3.0mg) In Subjects with Obsessive Compulsive Disorder. Total Direct Cost \$ 100,000.

(1998-2003). Abbott Laboratories – Divalproex Sodium vs. Placebo In Childhood/Adolescent Autism: A Double-Blind Placebo Controlled Study Followed by Fluoxetine Augmentation.
Total Cost \$ 86,000.

(1998-2003). Lilly Laboratories – Olanzapine vs. Placebo Crossover Study of Autistic Disorder: Effect of fMRI Imaging. Total Cost \$ 150,000.

(1998-2003). Bristol-Myers Squibb - Serzone Treatment Study in Pathological Gambling.
Total Direct Cost \$ 40,000.

(1998-2003). Solvay Pharmaceuticals - Double-Blind Parallel Trial of Lithobid, Lithium Carbonate and Placebo In Lithium Treatment Naive Bipolar and Cyclothymic Patients Presenting To A Pathological Gambling Clinic. Total Annual Direct Cost \$ 127,306 Total Cost \$ 254,612.

(1998-2003). PBO Foundation - Research and Clinical Program for OCD and Related Disorders.

Total Annual Direct Cost \$ 90,910.

(1997-2003). Janssen Pharmaceuticals - Risperidone in Refractory OCD: Positron Emission Tomography Imaging. Annual Direct Cost \$ 120,000.

(1995-2003). Lilly Research Labs - Prozac and Regional Metabolic Activity in Autism. Total Direct Cost \$ 30,000.

(1998-2003). Smith-Kline Beecham – A Double-Blind Placebo-Controlled Flexible Dose Study of the Efficacy and Tolerability of Paroxetine on Generalized Anxiety Disorder. Total Direct Cost \$ 60,120.

(1999-2003). Solvay Pharmaceuticals – A Multicenter, Double-Blind, Randomized, Parallel Group Study of the Efficacy and Safety of a Flexible Dose Regimen of Fluvoxamine CR versus Placebo in Outpatients with Obsessive Compulsive Disorder. Total Direct Cost \$ 100,000.

(1999-2003). Abbott Pharmaceuticals – Divalproex Sodium vs Placebo in Intermittent Explosive Disorder. Total Direct Cost \$ 100,000.

(1999-2003). Solvay Pharmaceuticals – Fluvoxamine vs. Placebo In the Treatment of Generalized Social Phobia. Total Direct Cost \$ 100,000.

(1997-2001). Glaxo-Wellcome - Sumatriptan Challenge In Autism and Asperger's Disorder. Total Direct Cost \$ 50,000.

(1998-2000). Cure Autism Now - Fluoxetine/Placebo Treatment of Childhood/Adolescent Autism: Clinical Predictors & Dimensional Severity. Total Cost \$ 56,100.

(1998-1999). Cure Autism Now - D8/17 Positivity in Autism: Implications for Etiology, Subtyping and Treatment. Total Cost \$ 15,000.

(1998-1999). NARSAD Distinguished Investigator Award - D8/17 Positivity in Autism: Implications for Etiology, Subtyping and Treatment. Total Cost \$ 85,525.

(1995-1998). Abbott Pharmaceuticals - Valproate Treatment of Borderline Personality Disorder. Total Direct Cost \$ 25,000.

(1997-1998). SmithKline Beecham Pharmaceuticals - A Double-Blind, Placebo-Controlled, Flexible Dosing Trial to Evaluate the Efficacy of Modified Release Paroxetine In the Treatment of Panic Disorder. Annual Direct Cost \$ 25,000.

(1997-1998). Upjohn Pharmaceuticals - Double Blind Placebo Controlled Fluvoxamine Treatment of Pathological Gambling. Annual Direct Cost \$ 100,000.

(1994-1996) Upjohn Pharmaceuticals - Double Blind Placebo Controlled Fluvoxamine Treatment of Pathological Gambling. Annual Direct Cost \$ 100,000.

(1993-1994). Solvay Pharmaceuticals - Fluvoxamine/Clomipramine Treatment of OCD. Annual Direct Cost \$ 52,500.

(1992-1993). Smith Kline Pharmaceuticals - Effect of Paroxetine on SPECT/Cerebral Blood Flow in OCD. Annual Direct Cost \$ 15,000.

(1989-1994). Mental Health Clinical Research Center (NIMH) - Open Treatment

Component (DF Klein, PI) \$ 200,420.

(1990-1992). American Psychiatric Association/McArthur Foundation - DSM-IV Field Trial for Obsessive-Compulsive Disorder. Annual Direct Cost \$ 10,000.

(1991-1993). Smith Kline Beecham Pharmaceuticals - Paroxetine Treatment of Obsessive-Compulsive Disorder. Annual Direct Cost \$ 100,000.

(1990-1991). Child Psychiatry Research Center Grant - Psychobiology of Childhood Obsessive-Compulsive Disorder. \$ 2,220.

(1990-1991). Child Psychiatry Research Center Grant - Follow-up Study: Collaborative Perinatal Project Soft Signs and Anxiety Disorders. \$ 2,000.

(1990-1991). Biomedical Research Support Grant - Research Foundation for Mental Hygiene to New York State Psychiatric Institute. Psychobiology of Impulsive Personality Disorders. \$ 3,000.

(1988-1989). Biomedical Research Support Grant - Research Foundation for Mental Hygiene to New York State Psychiatric Institute. 5HT Enhanced Cerebral Blood Flow and Auditory Evoked Potentials and Repeat Challenges During Treatment in OCD. \$ 6,200.

(1988-1989). Biomedical Research Support Grant - Columbia University College of Physicians and Surgeons. Apomorphine Challenges in Cocaine Abuse. \$ 5,000.

(1987-1988). Biomedical Research Support Grant - Research Foundation for Mental Hygiene to New York State Psychiatric Institute. Biological Challenges in Normal Controls. \$ 4,500.

(1987). Biomedical Research Support Grant - Research Foundation for Mental Hygiene to New York State Psychiatric Institute. Biological Challenges in Obsessive-Compulsive Disorder. \$ 3,642.

(1987). Biomedical Research Support Grant - Research Foundation for Mental Hygiene to New York State Psychiatric Institute. Neuropsychiatric Investigations of Obsessive-Compulsive Disorder. \$ 4,964.

B. Co-Principal Investigator

(2000-2004). CDC – Pharmacotherapy of Sexually Compulsive MSM – Jonathan Morgenstern, PI, Annual Direct Cost \$ 244,172 Total Direct Cost \$ 712,324.

(1998-2003). Solvay Pharmaceuticals - Brain Imaging of the Effects of Lithobid and Lithium Carbonate In Bipolar and Cyclothymic Patients - Monte Buchsbaum, PI, Total Direct Cost \$ 252,000.

NIMH - MH43845-Psychobiology of Obsessive Compulsive Disorder. 35% Effort. (Dr. M. Liebowitz, PI), Total Direct Costs \$ 356,412.

NIMH - MH44175-A Family Study of Obsessive Compulsive Disorder. 10% Effort. (Dr. Abby Fyer, PI). Total Direct Costs \$ 464,798.

(1991). Biomedical Research Support Grant - Research Foundation for Mental Hygiene - Neuropharmacology and Neuropsychology of Pathological Gambling. (C. DeCaria, PI). \$ 4,490.

(1991). Biomedical Research Support Grant - Research Foundation for Mental Hygiene - CT Findings and Soft-Signs in OCD (D. Stein, PI). \$ 2,000.

C. Director

Mental Health Clinical Research Center (NIMH). Anxiety Diagnostic and Recruitment Center Component (DF Klein, PI). \$ 508,000.

D. Co-Investigator

(2000-2006). NIDA – Interdisciplinary Training In Drug Abuse Research (T32 DA 07135-21) – Stuart C. Sealfon, M.D., P.I., Annual Direct Cost \$ 359,568 Total Direct Cost \$ 1,797,840.

NIMH-Endogenous ERP's in Obsessive Compulsive Disorder. RO1 Grant. (J. Towey, PI) Total Direct Costs \$ 133,461.

NIMH-Chlorimipramine and Behavior Therapy for Obsessive Compulsive Disorder. RO1 Grant. (M. Liebowitz, PI) Total Direct Costs \$ 766,224.

(1996-2000). NIMH First Award - Fluoxetine vs. Placebo Treatment of Depersonalization Disorder (MH55582) - Daphne Simeon, PI, Annual Direct Cost \$ 70,000.

(1996-1998). Theodore & Vada Stanley Foundation - Positron Emission Tomography and Emotion Interpretation in Autistic Adults - Bonnie Aronowitz, PI, Annual Direct Cost \$ 64,000.

(1988-1989). Biomedical Research Support Grant - Research Foundation for Mental Hygiene to New York State Psychiatric Institute. M-CPP Challenge in Eating Disorders (C. Buttinger, PI) \$ 5,000.

E. Overall Preceptor

NAAR/Bristol-Myers Squibb Research Fellowship in Autism and Neuropharmacology
Neuropharmacology, Neuroimaging, Immunology, Molecular Biology, and Molecular Genetics
Charles Cartwright, M.D. Total Annual Direct Cost \$ 60,000

NAAR/Bristol-Myers Squibb Research Fellowship in Autism and Neuropharmacology
Neuropharmacology, Neuroimaging, Molecular Neurobiology
Sherie Novotny, M.D. Total Annual Direct Cost \$ 60,000

Current Research Activities:

Neuropsychopharmacology
Functional Imaging
Clinical Trials
Translational Research

Of

Autism
Obsessive-Compulsive and Spectrum Disorders (ie Body Dysmorphic Disorder)
Impulse Control Disorders and Behavioral Addictions (ie Pathological Gambling)
Orphan Diseases (i.e. Prader-Willi Syndrome and Tuberous Sclerosis Complex)

Selected Invited Presentations:

Over 400 scientific presentations at American Psychiatric Association, Society of Biological Psychiatry, American College of Neuropsychopharmacology, NY Academy of Science, MIT Neurosciences, World Federation of Societies of Biological Psychiatry, Psychiatry Research Society, International Catecholamine Conf, Neuropharmacology of Serotonin Conf, AEP, CINP, ECNP and at many grant rounds at psychiatry departments in the USA and Europe/South America/Africa.

Chairman-Scientific Symposium

- 1988 Society of Biological Psychiatry - "Obsessive Compulsive Disorders"
- 1989 American Psychiatric Association - "Predictors of Treatment Outcome in OCD"
- 1989 American Psychiatric Association - "Overlap of Tourette's Syndrome & OCD"
- 1989 World Federation Societies Biological Psychiatry
"Update on Drug Treatment of OCD" and "Psychobiology of OCD"
- 1990 American Psychiatric Association - "Update on the Treatment of OCD"
- 1990 American Psychiatric Association - "Overlap of Eating Disorders and OCD"
- 1991 Columbia University CME - "New Directions in OCD"
- 1992 American Psychiatric Association - "Obsessive-Compulsive Related Disorders"
- 1992 American Psychiatric Association - "Impulsivity and Compulsivity"
- 1993 First International OCD Conference, Capri
- 1993 American Psychiatric Association - "OCD Spectrum Disorders"
- 1994 American Psychiatric Association - "OCD Spectrum" and "Neuropsychology of OCD"
- 1994 CINP, Washington, DC - "New Developments: Functional Imaging of OCD and TS"
- 1995 American Psychiatric Association -
"Overview and Psychopharmacology of Body Dysmorphic Disorder"
"Impulsivity and Compulsivity: Phenomenology and Treatment"
- 1996 American College of Neuropsychopharmacology -
"Oxytocin in Neuropsychiatric Illness: Studies Relevant to Autism";
"Strategies for Defining a More Homogeneous Phenotype of Autism for Family/
Genetic Studies"
- 1996 American Psychiatric Association - "OCD: State of the Art and Practical Management"
- 1997 American Psychiatric Association -
"Gambling: Biological/Genetic, Treatment, Government and Gaming Concerns"
"Predictors of Treatment Response in Mood and OCD-Related Disorders"
"Recent Advances in Autism and Asperger's Disorder"
"CNS Spectrums - Emerging Neuropsychiatric Concepts"
- 1998 American Psychiatric Association -
"Genetics of OCD"
- 1998 American College of Neuropsychopharmacology
"Neuropsychopharmacology of Pathological Gambling"
- 1999 American Psychiatric Association -
"New Perspectives in the Treatment of Impulsivity"
- 2000-present
Over 35 symposia at APA, ACNP, ECNP, Biol Psychiatry, NCDEU, ICOCS, ICare4Autism annual meetings

BIBLIOGRAPHY

A. Original Publications in Reviewed Journals

1. Nurnberger JI, Simmons-Alling S, Kessler L, Jimerson S, Shreiber J, Hollander E, Tamminga C, Nadi N, Goldstein DS, Gershon ES. Separate mechanisms for behavioral, cardiovascular, and hormonal responses to dextroamphetamine in man. Psychopharmacology, 84:200-204, 1984.

2. Hollander E, Mohs RC, Davis KL. Cholinergic approaches to the treatment of Alzheimer's disease. British Medical Bulletin 42:97-100, 1986.
3. Hollander E, Mohs RC, Davis KL. Antemortem markers of Alzheimer's disease. Neurobiology of Aging 7:367-387, 1986.
4. Davidson M, Kendler KS, Mohs RC, Hollander E, Ryan T, Davis KL. Effect of apomorphine infusion on plasma homovanillic acid in normal subjects. J Psychiatric Research 20(2):131-135, 1986.
5. Davidson M, Mohs RC, Hollander E, Davis BM, Ryan T, Horvath TB, Davis KL. Physostigmine in patients with Alzheimer's disease. Psychopharmacology Bulletin 22:101-105, 1986.
6. Davis KL, Hollander E, Davidson M, Davis BM, Mohs RC, Horvath TB. Induction of depression with oxotremorine in patient with Alzheimer's disease. American Journal of Psychiatry 144:468-471, 1987.
7. Hollander E, Davidson M, Mohs RC, Horvath TB, Davis BM, Zemishlany Z, Davis KL. RS 86 in the treatment of Alzheimer's disease: cognitive and biologic effects. Biological Psychiatry 22(9):1067-1078, 1987.
8. Davidson M, Mohs RC, Hollander E, Zemishlany Z, Powchik P, Ryan T, Davis KL. Lecithin and piracetam in Alzheimer's disease. Biological Psychiatry 22(1):112-114, 1987. (letter)
9. Liebowitz MR, Fyer AJ, Gorman JM, Campeas R, Levin A, Sandberg D, Hollander E, Papp L. Pharmacotherapy of social phobia: a condition distinct from panic attacks. Psychosomatics 28(6):305-308, 1987.
10. Hollander E. Non-tartrazine allergy with desipramine. Am J Psychiatry 144(9):1247, 1987. (letter)
11. Liebowitz MR, Campeas R, Hollander E. MAOI's: impact on social behavior. Psychiatry Research 22(1):89-90, 1987. (letter)
12. Hollander E, Fay M, Cohen B, Campeas R, Gorman JM, Liebowitz MR. Serotonergic and noradrenergic sensitivity in obsessive-compulsive disorder: behavioral findings. Am J Psychiatry 145(8):1015-1017, 1988.
13. Davidson M, Mohs RC, Kendler KS, Davis B, Johns CA, Hollander E, Horvath TB, Davis KL. Plasma homovanillic acid concentration in schizophrenic patients. Biomedicine and Pharmacotherapy (in press).
14. Liebowitz MR, Gorman JM, Fyer AJ, Campeas R, Levin AP, Sandberg D, Hollander E, Papp L, Goetz D. Pharmacotherapy of social phobia: an interim report of a placebo controlled comparison of phenelzine and atenolol. J Clin Psychiatry 49(7):252-257, 1988.
15. Hollander E, Fay M, Liebowitz MR. Clonidine and clomipramine in obsessive compulsive disorder. Am J Psychiatry 145(3):388-389, 1988. (letter)
16. Hollander E, Liebowitz MR. Augmentation of antiobsessional treatment with fenfluramine. Am J Psychiatry 145(10):1314-1315, 1988. (letter)
17. Hollander E, Papp L, Campeas R, DeCaria C, Liebowitz MR. More on self mutilation and obsessive compulsive disorder. Can J Psychiatry 33(7):675, 1988. (letter)
18. Fyer AJ, Liebowitz MR, Gorman JM, Campeas R, Levin A, Sandberg D, Fyer M, Hollander E, Papp LA, Goetz D, Klein DF. Effects of clonidine on alprazolam discontinuation in panic patients: a pilot study. J Clin Psychopharmacol, 8(4):270-274, 1988.
19. Hollander E, Liebowitz MR, Gorman JM, Cohen B, Fyer AJ, Klein DF. Cortisol and sodium lactate - induced panic. Arch Gen Psychiatry 46(2):135-140, 1989.

20. Hollander E, DeCaria C, Liebowitz MR. Biological aspects of obsessive compulsive disorder. Psychiatric Annals 19(2):80-87, 1989.
21. Hollander E, Liebowitz MR, Cohen B, Gorman JM, Fyer AJ, Papp LA, Klein DF. Prolactin and sodium lactate - induced panic. Psychiatry Res 28(2):181-191, 1989.
22. Hollander E, Liebowitz MR, Winchel RW, Klumker A, Klein DF. Treatment of body dysmorphic disorder with serotonin reuptake blockers. Am J Psychiatry 146(6):768-770, 1989.
23. Papp LA, Martinez JM, Klein DF, Ross D, Liebowitz MR, Fyer AJ, Hollander E, Gorman JM. Arterial blood gas changes in panic disorder and lactate-induced panic. Psychiatry Research 28(2):171-180, 1989.
24. Goetz RR, Gorman JM, Dillon DJ, Papp LA, Hollander E, Fyer AJ, Liebowitz MR, Klein DF. Do panic patients indiscriminately endorse somatic complaints? Psychiatry Res 29(2):207-213, 1989.
25. Liebowitz MR, Hollander E, Schneier F, Campeas R, Hatterer J, Papp L, Fairbanks J, Sandberg D, Davies S, Stein M. Fluoxetine treatment of obsessive compulsive disorder: an open clinical trial. J Clinical Psychopharmacology 9(6):423-427, 1989.
26. Hollander E, Fairbanks J, DeCaria C, Liebowitz MR. Derealization without depersonalization. Am J Psychiatry 146:1360-1361, 1989. (letter)
27. Hollander E, Fairbanks J, DeCaria C, Liebowitz MR. Pharmacological dissection of panic and depersonalization. Am J Psychiatry 146(3):402, 1989. (letter)
28. Liebowitz MR, Hollander E. Lactate-induced anxiety. Biological Psychiatry 25(6):669-670, 1989.
29. Papp LA, Goetz R, Cole R, Klein DF, Jordan F, Liebowitz MR, Fyer AJ, Hollander E, Gorman JM. Hypersensitivity to carbon dioxide in panic disorder. Am J Psychiatry 146(6): 779-781, 1989.
30. Hollander E, Schiffman E, Cohen B, Rivera-Stein M, Rosen W, Gorman JM, Fyer A, Papp L, Liebowitz MR. Signs of central nervous system dysfunction in obsessive-compulsive disorder. Archives of General Psychiatry 47(1):27-32, 1990.
31. Hollander E, DeCaria CM, Schneier FR, Schneir HA, Liebowitz MR, Klein DF. Fenfluramine augmentation of serotonin reuptake blockade antiobsessional treatment. J Clin Psychiatry 51(3):119-123, 1990.
32. Hollander E, Liebowitz MR, DeCaria C, Fairbanks J, Fallon B, Klein DF. Treatment of depersonalization with serotonin reuptake blockers. J Clin Psychopharmacology 10(3):200-203, 1990.
33. Hatterer JA, Gorman JM, Fyer AJ, Campeas RB, Schneier FR, Hollander E, Papp LA, Liebowitz MR. Pharmacotherapy of four men with paruresis. Am J Psychiatry 147(1):109-111, 1990.
34. Liebowitz MR, Hollander E, Fairbanks J, Campeas R. Fluoxetine for adolescents with obsessive-compulsive disorder. Am J Psychiatry 147(3):370-371, 1990. (letter)
35. Hollander E, Liebowitz MR, DeCaria C, Klein DF. Fenfluramine, cortisol, and anxiety. Psychiatry Research 31(2):211-213, 1990. (letter)
36. Schneier FR, Liebowitz MR, Davies SO, Fairbanks J, Hollander E, Campeas R, Klein DF. Fluoxetine in panic disorder. J Clin Psychopharmacol 10(2):119-121, 1990.
37. Liebowitz MR, Hollander E, Schneier F, Campeas R, Fallon B, Welkowitz L, Cloitre M, Davies S. Anxiety and depression: discrete diagnostic entities? J Clin Psychopharmacol 10(3 Suppl):61S-66S, 1990.

38. Towey J, Bruder G, Hollander E, Friedman D, Erhan H, Liebowitz MR, Sutton S. Endogenous event-related potentials in obsessive-compulsive disorder. Biol Psychiatry 28(2):92-98, 1990.
39. Hollander E, DeCaria CM, Liebowitz MR, Klein DF. Body dysmorphic disorder (Dr. Hollander and associates reply to Thomas) Am J Psychiatry 147:817, 1990.
40. Liebowitz MR, Schneier F, Campeas R, Gorman J, Fyer A, Hollander E, Hatterer J, Papp L. Phenelzine and atenolol in social phobia. Psychopharmacol Bull 26(1):123-125, 1990.
41. Liebowitz MR, Hollander E, Schneier F, Campeas R, Welkowitz L, Hatterer J, Fallon B. Reversible and irreversible monoamine oxidase inhibitors in other psychiatric disorders. Acta Psychiatrica Scandinavica 360:29-34, 1990.
42. Hollander E, Nunes E, DeCaria CM, Quitkin FM, Cooper T, Wager S, Klein DF. Dopaminergic sensitivity and cocaine abuse: response to apomorphine. Psychiatry Research 33(2):161-169, 1990.
43. Hollander E, DeCaria C, Gulley R, Nitsescu A, Suckow RF, Gorman JM, Klein DF, Liebowitz MR. Effects of chronic fluoxetine treatment on behavioral and neuroendocrine response to meta-chlorophenylpiperazine in obsessive-compulsive disorder. Psychiatry Research 36(1):1-17, 1991.
44. Hollander E, Neville D, DeCaria C, Mullen L, Schneier FR, Liebowitz MR. On dysmorphophobia misdiagnosed as obsessive-compulsive disorder. Psychosomatics 31(4):468-469, 1990. (letter)
45. Hollander E, Neville D, DeCaria CM, Mullen L. Neurological and structural involvement in OCD. Neuropsychiatry Neuropsychol Behav Neurology 3:314-315, 1990.
46. Fallon BA, Liebowitz MR, Hollander E, Schneier FR, Campeas RB, Fairbanks J, Papp LA, Hatterer JA, Sandberg D. The pharmacotherapy of moral or religious scrupulosity. J Clinical Psychiatry 51(12):517-521, 1990.
47. Hollander E, DeCaria CM, Aronowitz B, Klein DF, Liebowitz MR, Shaffer D. A pilot follow-up study of childhood soft-signs and the development of adult psychopathology. J Neuropsychiatry Clin Neurosci 3(2):186-189, 1991.
48. Liebowitz MR, Schneier F, Campeas R, Hollander E, Hatterer J, Fyer A, Gorman J, Papp L, Davies S, Gully R, Klein DF. Phenelzine vs. atenolol in social phobia: a placebo controlled comparison. Arch Gen Psychiatry 49(4):290-300, 1992.
49. Hollander E, DeCaria CM, Nitsescu A, Gulley R, Suckow RF, Cooper TB, Gorman JM, Klein DF, MR. Serotonergic function in obsessive compulsive disorder: behavioral and neuroendocrine responses to oral m-chlorophenylpiperazine and fenfluramine in patients and healthy volunteers. Arch Gen Psychiatry 49(1):21-28, 1992.
50. Hollander E, DeCaria C, Nitsescu A, Cooper T, Stover B, Gulley R, Klein DF, Liebowitz MR. Noradrenergic function in obsessive compulsive disorder: behavioral and neuroendocrine responses to clonidine and comparison to healthy controls. Psychiatry Research 37:161-177, 1991.
51. Papp LA, Klein DF, Martinez J, Schneier F, Cole R, Hollander E, Fyer AJ, Jordan F, Gorman JM. The diagnostic and substance specificity of carbon dioxide induced panic. Am J Psychiatry 150(2):250-257, 1993.
52. Hollander E, Mullen L, DeCaria C, Skodol A, Schneier FR, Liebowitz MR, Klein DF. Obsessive-compulsive disorder, depression, and fluoxetine. J Clin Psychiatry 52(10):418-422, 1991.
53. Hollander E, Neville D, Frenkel M, Josephson S, Liebowitz MR. Body dysmorphic disorder: diagnostic issues and related disorders. Psychosomatics 33(2):156-165, 1992.
54. Stein DJ, Brun RD, Josephson SC, Hollander E. Obsessional severity in Tourette's syndrome. J Clin Psychiatry 52(9):388, 1991. (letter)
55. Hollander E, Stein DJ, DeCaria CM, Saoud JB, Klein DF, Liebowitz MR. A pilot study of biological predictors of treatment outcome in obsessive compulsive disorder. Biol Psychiatry 33(10):747-749, 1993.

56. Stein D, Frenkel M, Hollander E. Classification of Koro. Am J Psychiatry 148:1279-1280, 1991. (letter)
57. Fallon BA, Javitch JA, Hollander E, Liebowitz MR. Hypochondriasis and obsessive-compulsive disorder: overlaps in diagnosis and treatment. J Clin Psychiatry 52(11):457-460, 1991.
58. Stein DJ, Hollander E, Mullen L, Saoud J, Robinson D, Liebowitz MR. Comparison of clomipramine, alprazolam and placebo in the treatment of obsessive-compulsive disorder. Human Psychopharmacol 7(6):389-395, 1992.
59. Stein DJ, Hollander E, Anthony D, Schneier FR, Fallon BA, Liebowitz MR, Klein DF. Serotonergic medications for sexual obsessions, sexual addictions and paraphilias. J Clin Psychiatry 53(8):267-271, 1992.
60. Stein DJ, Hollander E. Low dose pimozide augmentation of serotonin reuptake blockers in the treatment of trichotillomania. J Clin Psychiatry 53(4):123-126, 1992.
61. Josephson SC, Hollander E, Fallon B. Obsessive-compulsive disorder, body dysmorphic disorder and hypochondriasis: clinical features and treatment response in twenty one cases. J Clin Psychiatry (in review).
62. Carrasco JL, Hollander E, Schneier FR, Liebowitz MR. Treatment outcome of obsessive-compulsive disorder with comorbid social phobia. J Clin Psychiatry 53(11):387-391, 1992.
63. Hollander E, DeCaria C, Saoud J, Klein DF, Liebowitz MR. Neurological soft-signs in obsessive-compulsive disorder. (in reply). Arch Gen Psychiatry 48:278-279, 1991.
64. Hollander E, Stein DJ, Saoud JB, DeCaria CM, Cooper TB, Truong S, Liebowitz MR, Stanley M. Effects of fenfluramine on plasma homovanillic acid in healthy controls. J Neural Transm Gen Sect 90(1):81-84, 1992.
65. Schneier FR, Chin SJ, Hollander E, Liebowitz MR. Fluoxetine in social phobia. J Clin Psychopharmacology 12(1):62-64, 1992.
66. Fallon BA, Campeas R, Schneier FR, Hollander E, Feerick J, Hatterer J, Goetz D, Davies S, Liebowitz MR. Open trial of intravenous clomipramine in 5 treatment-refractory patients with obsessive-compulsive disorder. J Neuropsychiatry Clin Neuroscience 4(1):70-75, 1992.
67. Liebowitz MR, Hollander E, Fallon B, Welkowitz L, Schneier F, Campeas R. OCD and related disorders. International Clinical Psychopharmacology (in press).
68. Gorman JM, Papp LA, Martinez J, Goetz RR, Hollander E, Liebowitz MR, Jordan F. High-dose carbon dioxide challenge test in anxiety disorder patients. Biological Psychiatry 28(9):743-747, 1990.
69. Stein DJ, Hollander E, DeCaria C, Truong S. OCD: a disorder with anxiety, aggression, impulsivity and depressed mood. Psychiatry Research 36(2):237-239, 1991. (letter)
70. Stein DJ, Hollander E. Antemortem markers. In: Principles and Practice of Geriatric Psychiatry, Copeland JRM, Abou-Saleh MR, Blazer DG, eds. John Wiley & Sons Ltd., West Sussex, England, 1994, 335-340.
71. Stein DJ, Hutt C, Spitz J, Hollander E. Compulsive picking and obsessive-compulsive disorder. Psychosomatics 34(2):177-181, 1993.
72. Stein DJ, Hollander E, Skodol A. Pharmacotherapy of hospitalized personality disorder patients: four decades of clinical experience. Res Commun Biol Psychol Psychiat 20:81-94, 1995.
73. Stein DJ, Hollander E. Dermatology and conditions related to obsessive-compulsive disorder. J Am Acad Dermatol 26:237-242, 1992.

74. Stein DJ, Hollander E, Skodol AE. Anxiety disorders and personality disorders: a review. J Personality Disorders 7(2):87-104, 1993.
75. Marazziti D, Hollander E, Lensi P, Ravagli S, Cassano GB. Peripheral markers of serotonin and dopamine function in obsessive-compulsive disorder. Psychiatry Research 42(1):41-51, 1992.
76. Stein DJ, Shoulberg N, Helton K, Hollander E. The neuroethological model of obsessive-compulsive disorder. Compr Psychiatry 33(4):274-281, 1992.
77. Hollander E, McCarley A. Yohimbine treatment of sexual side effects induced by serotonin reuptake blockers. J Clin Psychiatry 53(6):207-209, 1992.
78. Hollander E, Carrasco JL, Mullen LS, Trungold S, DeCaria CM, Towey J. Left hemispheric activation in depersonalization disorder: a case report. Biol Psychiatry 31(11):1157-1162, 1992.
79. Hollander E, Hwang MY, Mullen LS, DeCaria C, Stein DJ, Cohen L. Clinical and research issues in depersonalization syndrome. Psychosomatics 34(2):193-194, March-April, 1993. (letter)
80. Hollander E, Mullen LS, Carrasco JL, DeCaria CM, Stein DJ. Symptom relapse in bulimia nervosa and obsessive-compulsive disorder after treatment with serotonin antagonists. J Clin Psychiatry 53(1):28, 1992. (letter)
81. Stein DJ, Hollander E, Chan S, DeCaria CM, Hilal S, Liebowitz MR. Computerized tomography and soft-signs in obsessive-compulsive disorder. Psychiatry Research 50(3):143-150, 1993.
82. Hollander E, Frenkel M, DeCaria C, Trungold S, Stein DJ. Treatment of pathological gambling with clomipramine. Am J Psychiatry 149(5):710-711, 1992. (letter).
83. Schneier FR, Carrasco JL, Hollander E, Campeas R, Fallon B, Saoud J, Feerick J, Liebowitz MR. Alpidem in the treatment of panic disorder. J Clin Psychopharmacol 13(2):150-153, 1993.
84. Hollander E, Stein DJ, DeCaria CM, Cohen L, Islam M, Frenkel M. Disorders related to OCD -neurobiology. Clinical Neuropharmacology 15:suppl 1:259A-260A, 1992.
85. Hollander E, Cohen L, DeCaria CM, Stein DJ, Trungold-Apter S, Islam M. Fluoxetine and depersonalization syndrome. Psychosomatics 33(3):361-362, 1992. (letter)
86. Stein DJ, Hollander E. Further comments on the obsessive-compulsive related disorders and dermatology. J Am Acad Dermatology 12:1034-1035, 1992.
87. Prichep LS, Mas F, Hollander E, Liebowitz M, John ER, Almas M, DeCaria CM, Levine RH. Quantitative electroencephalographic subtyping of obsessive-compulsive disorder. Psychiatry Research 50(1):25-32, 1993.
88. Schneier FR, Saoud JB, Campeas R, Fallon BA, Hollander E, Coplon J, Liebowitz MR. Buspirone in social phobia. J Clin Psychopharm 13(4):251-256, 1993.
89. Stein DJ, Mullen L, Islam MN, Cohen L, DeCaria CM, Hollander E. Compulsive and impulsive symptomatology in trichotillomania. Psychopathology 28(4):208-213, 1995.
90. Stein DJ, Hollander E, Cohen L, Frenkel M, Saoud JB, DeCaria C, Aronowitz B, Levin A, Liebowitz MR, Cohen L. Neuropsychiatric impairment in impulsive personality disorders. Psychiatry Res 48(3):257-266, 1993.
91. Hollander E, Stein DJ, Saoud JB, DeCaria CM, Cooper TB, Trungold S, Stanley M, Liebowitz MR. Effects of fenfluramine on plasma pHVA in OCD. Psychiatry Research 42(2):185-188, 1992. (letter)
92. Fallon BA, Liebowitz MR, Salmon E, Schneier FR, Jusino C, Hollander E, Klein DF. Fluoxetine for hypochondriacal patients without major depression. J Clin Psychopharmacol 13(6):438-441, 1993.

93. Stein DJ, Hollander E, Simeon D, Cohen L, Hwang M. Pregnancy and obsessive-compulsive disorder. Am J Psychiatry 150(7):1131-1132, 1993. (letter)
94. Hollander E, Cohen L, Simeon D, Rosen J, DeCaria C, Stein DJ. Fluvoxamine treatment of body dysmorphic disorder. J Clin Psychopharmacol 14(1):75-77, 1994.
95. Stein DJ, Hollander E. A neural network model of obsessive-compulsive disorder. J of Mind and Behavior 15:25-40, 1994.
96. Hollander E, Greenwald S, Neville D, Johnson J, Hornig CD, Weissman MM. Uncomplicated and comorbid obsessive-compulsive disorder in an epidemiological sample. Depression and Anxiety 4(3):111-119, 1996/1997.
97. Stein DJ, Keating J, Zar HJ, Hollander E. A survey of the phenomenology and pharmacotherapy of compulsive and impulsive aggressive symptoms in Prader-Willi syndrome. J Neuropsychiatry Clin Neurosci 6(1):23-29, 1994.
98. Towey J, Bruder G, Tenke C, Leite P, DeCaria CM, Friedman D, Hollander E. Event-related potential and clinical correlates of neurodysfunction in obsessive-compulsive disorder. Psychiatry Research 49(2):167-181, 1994.
99. Hwang MY, Stein D, Simeon D, Hollander E. Clozapine, obsessive symptoms, and serotonergic mechanisms. Am J Psychiatry 150(9):1435, 1993. (letter)
100. Hwang MY, Martin AM, Lindenmayer JP, Stein D, Hollander E. Treatment of schizophrenia with obsessive-compulsive features with serotonin reuptake inhibitors. Am J Psychiatry 150(7):1127, 1993. (letter)
101. Hollander E, Hwang MY. Reply to Terao: Titration of serotonin reuptake blockers. J Clin Psychiatry 54:115, 1993.
102. Keating JT, Stein DJ, Frenkel M, Hollander E. Neurological illness and obsessive-compulsive disorder: case report and review of the literature. Neuropsychiatry Neuropsychol Behav Neurology (in review).
103. Hollander E, Cohen L, Richards M, Mullen L, DeCaria CM, Stern Y. A pilot study of the neuropsychology of obsessive-compulsive disorder and Parkinson's disease: basal ganglia disorders. J Neuropsychiatry Clin Neurosci 5(1):104-107, 1993.
104. Stein DJ, Borchelt P, Hollander E. Pharmacotherapy of naturally occurring anxiety symptoms in dogs. Res Comm Psychol Psychiatry Behav 19(1-2):39-48, 1994.
105. Stein DJ, Hollander E. Impulsive-aggression and obsessive-compulsive disorder. Psychiatric Annals 23(7):389-395, 1993.
106. Hollander E, Stein DJ, DeCaria CM, Cohen L, Saoud JB, Skodol AE, Kellman D, Rosnick L, Oldham J. Serotonergic sensitivity in borderline personality disorder: preliminary findings. Am J Psychiatry 151(2):277-280, 1994.
107. Stein DJ, Hollander E. Reply to Dr. Koblenzer (letter). J Am Acad Dermatol (in press).
108. Hollander E, Cohen LJ, Stein D. Commentary on 'neurochemical predictors and correlates of vulnerability to cocaine use' by King and Flowers. In NIDA Technical Review: Individual Differences in the Biobehavioral Etiology of Drug Abuse, NIDA Research Monograph 159, 1996, pp. 264-268.
109. Hollander E, Cohen LJ, Stein D. Commentary on 'vulnerability to substance abuse in eating disorders' by Kaye and Wisniewski. In NIDA Technical Review: Individual Differences in the Biobehavioral Etiology of Drug Abuse, NIDA Research Monograph 159, 1996, pp. 312-317.
110. Hollander E, Cohen L, Stein DJ, Simeon D, Hwang M, DeCaria CM. Fluvoxamine treatment of obsessive compulsive spectrum disorders. Ann Clin Psychiatry (in press).

111. Carrasco J, Saiz-Ruiz J, Hollander E, Cesar J, Lopez-Ibor JJ. Low platelet monoamine oxidase activity in pathological gambling. Acta Psychiatr Scand 90(6):427-431, 1994.
112. Stein DJ, Dodman NH, Borchelt P, Hollander E. Behavioral disorders in veterinary practice: relevance to psychiatry. Comprehensive Psychiatry 35(4):275-285, 1994.
113. Stein DJ, Hollander E, Josephson SC. Serotonin reuptake blockers for the treatment of obsessional jealousy. J Clin Psychiatry 55(1):30-33, 1994.
114. Hadigan CM, Walsh BT, Buttinger C, Hollander E. Behavioral and neuroendocrine responses to m-CPP in anorexia nervosa. Biol Psychiatry 37(8):504-511, 1995.
115. Hollander E, Cohen L, Simeon D. Body dysmorphic disorder. Psychiatric Annals 23(7):359- 364, 1993.
116. Hollander E. Obsessive compulsive spectrum disorders: an overview. Psychiatric Annals 23(7):355-358, 1993.
117. Simeon D, Hollander E. Depersonalization disorder. Psychiatric Annals 23(7):382-388, 1993.
118. Hwang MY, Hollander E. Schizo-obsessive disorders. Psychiatric Annals 23(7):396-401, 1993.
119. Towey JP, Tenke CE, Bruder GE, Leite P, Friedman D, Liebowitz M, Hollander E. Brain event-related correlates of overfocussed attention in obsessive-compulsive disorder. Psychophysiology 31:535-543, 1994.
120. Stein DJ, Hollander E, Liebowitz MR. Neurobiology of impulsivity and impulse control disorders. J Neuropsychiatry Clin Neurosci 5(1):9-17, 1993.
121. Hollander E. Commentary: disorders related to OCD. Focus on OCD 1:13-14, 1993.
122. Hollander E, DeCaria C, Stein D, Simeon D, Cohen L, Hwang M, Islam M. Behavioral response to m-CPP. Biol Psychiatry 35(6):426-427, 1994. (letter).
123. Stein DJ, Hollander E. Dermatology and conditions related to obsessive-compulsive disorder. Dermatology Digest 3:4, 1993.
124. Stein DJ, Hollander E. Neurobiology of personality disorder: room for research. Human Psychopharmacology 7:409-410, 1992. (letter)
125. Simeon D, Hollander E, Stein DJ, DeCaria CM, Cohen L, Saoud JB, Islam N, Hwang M. Induction of depersonalization by the serotonin agonist m-CPP. Psychiatry Res 58(2):161-164, 1995.
126. Stein DJ, Hollander E. OCD expert (computer program). Mental Health Connections, Lexington, MA, 1993.
127. Hollander E, Cohen LJ, DeCaria CM, Saoud JB, Stein DJ, Trugold S, Cooper TB, Islam MN, Liebowitz MR, Klein DF. Timing of neuroendocrine responses and effect of m-CPP and fenfluramine plasma levels in OCD. Biol Psychiatry 34(6):407-413, 1993.
128. Hollander E, Cohen LJ. The assessment and treatment of refractory anxiety. J Clin Psychiatry 55:[2, suppl]:27-31, 1994.
129. Aronowitz B, Liebowitz MR, Hollander E, Fazzini E, Durlach-Mistelli C, Frenkel M, Mosovich S, Garfinkel R, Saoud J, DelBene D, Cohen L, Rubin L. Neuropsychiatric and neuropsychological findings in conduct disorder and attention deficit hyperactivity disorder. J Neuropsychiatry Clin Neurosci 6(3):245-249, 1994.

- 130.Stein DJ, Hollander E. La dermatologie et les affections lie'es au trouble obsessionnel-compulsif. Cutis et Psyche Juin:19-21, 1993.
- 131.Stein DJ, Hollander E. Trichotillomania and the obsessive-compulsive spectrum. Am Soc Clin Psychopharmacol Progress Notes 4:3-4, 1993.
- 132.Stein DJ, Prohovnik I, Goldman RG, Hollander E. Cingulate cortex in compulsivity and impulsivity: a case report. Neuropsychiatry Neuropsychol Bevr Neurol 7(4):308-312, 1994.
- 133.Dago P, Hollander E. Response of non-paraphilic sexual addictions to low-dose fluoxetine. J Clin Psychiatry (in review).
- 134.Stein DJ, Hollander E. Reply to Satel "The diagnostic limits of addiction". J Clin Psychiatry 54:237-238, 1993. (letter).
- 135.Stein DJ, Hollander E, Simeon D, Cohen L. Impulsivity scores in patients with obsessive-compulsive disorder. J Nerv Mental Disorders 182(4):240-241, 1994.
- 136.Stein DJ, Hollander E, Simeon D, Cohen L, Islam MN, Aronowitz B. Neurological soft signs in females trichotillomania patients, obsessive-compulsive disorder patients, and healthy control subjects. J Neuropsychiatry Clin Neurosci 6(2):184-187, 1994.
- 137.Aronowitz BR, Hollander E, DeCaria CM, Saoud JB, Cohen L, Stein D, Liebowitz MR, Rosen WG. Neuropsychology of obsessive compulsive disorder: preliminary findings. Neuropsychiatry Neuropsychol Behav Neurol 7(2):81-86, 1994.
- 138.Cohen LJ, Hollander E, DeCaria C, Stein DJ, Simeon D, Liebowitz MR, Aronowitz BR. Specificity of neuropsychological impairment in obsessive-compulsive disorder: a comparison with social phobic and normal control subjects. J Neuropsychiatry Clin Neurosci 8(1):82-85, 1996.
- 139.Stein DJ, Hollander E, DeCaria C, Cohen L, Simeon D. Behavioural response to m-chlorophenylpiperazine and clonidine in trichotillomania. J Serotonin Research 4:11-15, 1997.
- 140.Stein DJ, Hollander E, Cohen L, Simeon D, Aronowitz B. Serotonergic responsivity in trichotillomania: neuroendocrine effects of m-chlorophenylpiperazine. Biol Psychiatry 37(6):414-416, 1995.
- 141.Stein DJ, Hollander E. A neural network approach to obsessive-compulsive disorder Journal of Mind and Behavior 15(3):223-237, 1994.
- 142.Cohen LJ, Stein DJ, Simeon D, Spadaccini E, Rosen J, Aronowitz B, Hollander E. Clinical profile, comorbidity, and treatment history in 123 hairpullers: a survey study. J Clin Psychiatry 56(7):319-326, 1995.
- 143.Simeon D, Hollander E, Stein DJ, Cohen L, Aronowitz B. Body dysmorphic disorder in the DSM-IV field trial for obsessive-compulsive disorder. Am J Psychiatry 152(8):1207-1209, 1995.
- 144.Stein DJ, Hollander E, Mullen LS, Saoud JB, Robinson D, DeCaria CM, Liebowitz MR. Comparison of clomipramine, alprazolam and placebo in the treatment of obsessive-compulsive disorder. Human Psychopharmacol 7:389-395, 1993.
- 145.Stein DJ, Hollander E, Cohen LJ, Frenkel M, Saoud J, DeCaria CM, Aronowitz B, Levin A, Liebowitz MR, Cohen L. Neuropsychiatric impairment in impulsive personality disorders. Psychiatry Res 48(3):257-266, 1993.
- 146.Cohen L, Hollander E, Badaracco MA. What the eyes can't see: diagnosis and treatment of somatic obsessions and delusions. Harvard Review of Psychiatry 2:160-165, 1994.

147. Skodol AE, Oldham JM, Hyler SE, Stein DJ, Hollander E, Gallaher PE, Lopez AE. Patterns of anxiety and personality disorder comorbidity. J Psychiatric Research 29:361-374, 1995.
148. Stein DJ, Hollander E, DeCaria CM, Simeon D, Cohen L, Aronowitz B. m-Chlorophenylpiperazine challenge in borderline personality disorder: relationship of neuroendocrine response, behavioral response, and clinical measures. Biol Psychiatry 40(6):508-513, 1996.
149. Stein DJ, Simeon D, Frenkel M, Islam MN, Hollander E. An open trial of valproate in borderline personality disorder. J Clin Psychiatry 56(11):506-510, 1995.
150. Simeon D, Hollander E, Cohen L. Body dysmorphic disorder (imagined ugliness) – current clinical considerations. Can Rev Affective Dis pp. 3-7, April, 1994.
151. Stein DJ, Trestman RL, Mitropoulou V, Coccaro EF, Hollander E, Siever LJ. Impulsivity and serotonergic function in compulsive personality disorder. J Neuropsychiatry Clin Neurosci 8(4):393-398, 1996.
152. Stein DJ, Hollander E. Obsessive-compulsive spectrum disorders. J Clin Psychiatry 56(6):265-266, 1995.
153. Koran LM, McElroy SL, Davidson JR, Rasmussen SA, Hollander E, Jenike MA. Fluvoxamine versus clomipramine for obsessive-compulsive disorder: a double-blind comparison. J Clin Psychopharmacology 16:121-129, 1996.
154. Stein DJ, Spadaccini E, Hollander E. Meta-analysis of pharmacotherapy trials for obsessive-compulsive disorder. Int Clin Psychopharmacol 10(1):11-18, 1995.
155. Hollander E, Wong C. Obsessive-compulsive spectrum disorders: introduction. J Clin Psychiatry 56(Suppl 4):3-6, 1995.
156. Hollander E, Wong C. Body dysmorphic disorder, pathological gambling and sexual compulsions. J Clin Psychiatry 56(Suppl 4):7-12, 1995.
157. Simeon D, Stein DJ, Hollander E. Depersonalization disorder and self-injurious behavior. J Clin Psychiatry 56(Suppl 4):36-39, 1995.
158. Hollander E, Wong C, DeCaria C. The relationship between frontal lobe and serotonergic function in OCD. Neuropsychiatry, Neuropsychol Behav Neurol 9:230-233, 1996.
159. Towey JP, Tenke CE, Bruder GE, Leite P, Friedman D, Liebowitz M, Hollander E. Brain event-related potential correlates of overfocused attention in obsessive-compulsive disorder. Psychophysiol 31(6):535-543, 1994.
160. Stein DJ, Simeon D, Cohen LJ, Hollander E. Trichotillomania and obsessive-compulsive disorder. J Clin Psychiatry 56(Suppl 4):28-34, 1995.
161. Hollander E, Weiller F, Cohen L, Kwon JH, DeCaria CM, Liebowitz MR, Stein DJ. Neurological soft signs in social phobia. Neuropsychiatry Neuropsychol Behav Neurol 9:182-185, 1996.
162. Foa EB, Kozak MJ, Goodman WK, Hollander E, Jenike MA, Rasmussen SA. DSM-IV field trial: obsessive-compulsive disorder. Am J Psychiatry 152:90-96, 1995. [published erratum appears in Am J Psychiatry 152:654, 1995]
163. Stein DJ, Hollander E. Neurochemistry of stuttering. Neuropsychiatry Neuropsychol Behav Neurology 8(3):1995 (letter).
164. Hollander E, Prohovnik I, Stein DJ. Increased cerebral blood flow during m-CPP exacerbation of obsessive-compulsive disorder. J Neuropsychiatry Clin Neurosci 7(4):485-490, 1995.

- 165.Hollander E. Behavioral response to pharmacological challenges: potentials and pitfalls. Biol Psychiatry 37(12):831-833, 1995.
- 166.Grossman R, Hollander E. Treatment of obsessive-compulsive disorder with venlafaxine. Am J Psychiatry 153(4):576-577, 1996.
- 167.Grossman R, Cohen L, Rosen J, DeCaria C, Hollander E. Seasonal effects in prolactin response to m-chlorophenylpiperazine challenge in obsessive-compulsive disorder. Biol Psychiatry 39(11):982-985, 1996.
- 168.Wong CM, Hollander E. Headache response to m-chlorophenylpiperazine in obsessive-compulsive disorder and normal controls. Biol Psychiatry 40(6):544-546, 1996.
- 169.Josephson SC, Hollander E. Body dysmorphic disorder by proxy. Letter to the Editor. J Clin Psychiatry 1997;58(2):86-87. (letter)
- 170.Milrod B, Busch FN, Hollander E, Aronson A, Siever L. Clinical case conference: a 23-year old woman with panic disorder treated with psychodynamic psychotherapy. Am J Psychiatry 5:698-703, 1996.
- 171.Stein DJ, Roberts M, Hollander E, Rowland C, Serebro P. Quality of life and pharmacoeconomic aspects of obsessive-compulsive disorder: a south african survey. S Afr Med J 86(12 Suppl):1579, 1582-1585, 1996.
- 172.Hollander E, Wong CM. The relationship between executive function impairment and serotonergic sensitivity in obsessive-compulsive disorder. Neuropsychiatry Neuropsychol Behav Neurology 9(4):230-233, 1996.
- 173.Hollander E, Kwon JH, Stein DJ, Broatch J, Rowland CT, Himelein CA. Obsessive-compulsive and spectrum disorders: overview and quality of life issues. J Clin Psychiatry 57(Suppl 8):3-6, 1996.
- 174.Higgins ES, Hollander E. Summary: new frontiers in obsessive-compulsive spectrum research for psychiatry and primary care. J Clin Psychiatry 57:85-87(suppl 8), 1996.
- 175.DeCaria CM, Hollander E, Grossman R, Wong CM, Mosovich SA, Cherkasky S. Diagnosis, neurobiology, and treatment of pathological gambling. J Clin Psychiatry 57:80-83(suppl 8), 1996.
- 176.Grove G, Coplan JD, Hollander E. The neuroanatomy of 5-HT dysregulation and panic disorder. J Neuropsychiatry Clin Neurosci 9(2):198-207, 1997.
- 177.Hollander E. Obsessive compulsive disorder-related disorders: the role of selective serotonergic reuptake inhibitors. Int Clin Psychopharmacology 11(Suppl 5):75-87, 1996.
- 178.Simeon D, Stein DJ, Gross S, Islam N, Schmeidler J, Hollander E. A double-blind trial of fluoxetine in pathological skin picking. J Clin Psychiatry 58:341-347, 1997.
- 179.Hollander E, Benzaquen SD. Is there a distinct OCD spectrum? CNS Spectrums: Int J Neuropsychiatric Med 1(1):17-26, 1996.
- 180.Phillips KA, Hollander E, Rasmussen SA, Aronowitz BA, DeCaria CM, Goodman WK. A severity rating scale for body dysmorphic disorder: development, reliability, and validity of a modified version of the Yale-Brown Obsessive Compulsive Scale. Psychopharmacol Bull 33(1):17-22, 1997.
- 181.Simeon D, Cohen LJ, Stein DJ, Schmeidler J, Spadaccini E, Hollander E. Comorbid self-injurious behavior in 71 female hair-pullers: a survey study. J Nerv Ment Dis 185(2):117-119, 1997.
182. Haznedar MM, Buchsbaum MS, Metzger M, Solimando A, Spiegel-Cohen J, Hollander E. Anterior cingulate gyrus volume and glucose metabolism in autistic disorder. Am J Psychiatry 154(8):1047-1050, 1997.

183. Grove G, Coplan J, Margolin L, Hollander E. The neuroanatomy of serotonin (5-HT) dysregulation in obsessive-compulsive disorder. CNS Spectrums: Int J Neuropsychiatric Med 1(2):16-23, 1996.
184. Josephson SC, Hollander E, Fallon B, Stein DJ. Obsessive-compulsive disorder, body dysmorphic disorder, and hypochondriasis: three variations on a theme. CNS Spectrums: Int J Neuropsychiatric Med 1(2):24-31, 1996.
185. Wong CM, Hollander E. New dimensions in the OCD spectrum: autism, pathological gambling, and compulsive buying. CNS Spectrums: Int J Neuropsychiatric Med 1(2):44-53, 1996.
186. Hollander E, DelGiudice-Asch G, Simon L, DeCaria CM, Aronowitz B, Mosovich S, Elder G. Repetitive behaviors and D8/17 positivity. (letter) Am J Psychiatry 154(11):1630, 1997.
187. Hollander E, Cartwright C. SSRI's in the treatment of OCD. Depression and Anxiety 8(1):105-113, 1998.
188. Diaz Marsa M, Carrasco JL, Hollander E. Dismorfofobia y espectro obsesivo-compulsivo. Actas Luso-Esp Neurol Psiquiatricas Afines 24(6):331-337, 1996.
189. Hollander E, Holmes R. Interactive treatment algorithms: obsessive-compulsive disorder. Primary Psychiatry 4(6):32-39, 1997.
190. Simeon D, Gross S, Guralnik O, Stein DJ, Schmeidler J, Hollander E. Feeling unreal: 30 cases of DSM-III-R depersonalization disorder. Am J Psychiatry 154(8):1107-1113, 1997.
191. Aronowitz BR, DeCaria C, Allen A, Weiss N, Saunders A, Margolin L, Mosovich S, Buchsbaum M, Hollander E. The neuropsychiatry of autism and asperger's disorder: review of the literature and case reports. CNS Spectrums: Int J Neuropsychiatric Med 2(5):43-60, 1997.
192. Delgiudice-Asch, Hollander E. Altered immune function in autism. CNS Spectrums: Int J Neuropsychiatric Med 2(5):61-68, 1997.
193. Hollander E. Obsessive-compulsive disorder: the hidden epidemic. J Clin Psychiatry 58(12):3-6, 1997.
194. Simeon D, Stein DJ, Hollander E. Treatment of depersonalization disorder with clomipramine Biological Psychiatry 44(4):302-303, 1998.
195. DeCaria CM, Hollander E, Mari E, Wong CM, Mosovich S, Cartwright C, Begaz T. Pharmacologic approaches in the treatment of pathological gambling. Medscape Mental Health 3(3), 1998.
196. DeCaria CM, Hollander E, Simon L, Holmes R. Interventions with autistic clients and their families. Directions in Rehabilitation Counseling (9):117-132, 1998.
197. Hollander E, Stein DJ, Kwon JH, Rowland C, Wong CM, Broatch J, Himelein C. Psychosocial function and economic costs of obsessive-compulsive disorder. CNS Spectrums: Int J Neuropsychiatric Med 2(10):16-25, 1997.
198. Cohen LJ, Stein D, Galyanker I, Hollander E. Towards an integration of psychological and biological models of obsessive-compulsive disorder: phylogenetic considerations. CNS Spectrums: Int J Neuropsychiatric Med 2(10):26-44, 1997.
199. Cartwright C, Hollander E. Pharmacotherapy of obsessive-compulsive disorder--experience with SSRIs. Primary Psychiatry 4(9):38-68, 1997.
200. Hollander E, Cartwright C, Wong CM, DeCaria CM, DelGiudice-Asch G, Buchsbaum MS. A dimensional approach to the autism spectrum. CNS Spectrums: Int J Neuropsychiatric Med 3(3):22-39, 1998.
201. Hollander E, Begaz T, DeCaria CM. Pharmacological approaches in the treatment of pathological gambling. CNS Spectrums: Int J Neuropsychiatric Med 3(6):72-80, 1998.

202. DeCaria CM, Begaz T, Hollander E. Serotonergic and noradrenergic function in pathological gambling. CNS Spectrum: Int J Neuropsychiatric Med 3(6):38-47, 1998.
203. Cohen LJ, Kingston P, Bell A, Kwon J, Aronowitz B, Hollander E. Comorbid personality impairment in body dysmorphic disorder. Comprehensive Psychiatry 1998.
204. Hollander E, Aronowitz B. Comorbid social anxiety and body dysmorphic disorder: managing the complicated patient. J Clin Psychiatry 60(9):27-31, 1999.
205. Cartwright C, DeCaria C, Hollander E. Pathological gambling: a clinical review. J Prac Psych and Behav Hlth 4:277-286, 1998.
206. Hollander E. Treatment of obsessive-compulsive spectrum disorders with SSRIs. British J Psychiatry 173(35):7-12, 1998.
207. Simeon D, Guralnik O, Gross S, Stein DJ, Schmeidler J, Hollander E. The detection and measurement of depersonalization disorder. J Nerv Ment Dis 186:536-542, 1998.
208. Hollander E. Comorbid social anxiety and body dysmorphic disorder: managing the complicated patient. J Clin Psychiatry 60(9):27-31, 1999.
209. Cartwright C, Hollander E. SSRIs in the treatment of obsessive-compulsive disorder. Depression and Anxiety 1:105-113, 1998.
210. Hollander E. Managing aggressive behavior in patients with obsessive-compulsive disorder and borderline personality disorder. J Clin Psychiatry 60:38-44, 1999. (supplement)
211. Hollander E. Managing aggressive behavior in patients with obsessive-compulsive disorder and borderline personality disorder. J Clin Psychiatry 17:28-31, 1999. (monograph)
212. Hollander E, Rosen J. OCD spectrum disorders: impulsivity and the schizo-obsessive subtype. CNS Spectrums: Int J Neuropsychiatric Med 4(5):16-21, 1999. (suppl 3)
213. Hollander E, Brasic JR. Response to "Tourette's syndrome: [I-123]β-CIT SPECT correlates of Vocal tic severity." Neurology (in press).
214. DelGiudice-Asch G, Simon L, Schmeidler J, Cunningham-Rundles C, Hollander E. A pilot open clinical trial of intravenous immunoglobulin in childhood autism. J Autism Dev Disorder 29(2):157-160, 1999.
215. Hollander E, Kwon J, Weiller F, Cohen L, Stein DJ, DeCaria C, Leibowitz M, Simeon D. Serotonergic function in social phobia: comparison to normal control and obsessive-compulsive disorder subjects. Psychiatry Research 79:213-217, 1998.
216. Hollander E, DeCaria C, Mari E, Wong C, Mosovich S, Grossman R, Begaz T. Short-term single blind fluvoxamine treatment of pathological gambling. Am J Psychiatry 155:1781-1783, 1998.
217. Hollander E, DelGiudice-Asch G, Simon L, Schmeidler J, Cartwright C, DeCaria CM, Kwon J, Cunningham-Rundles C, Chapman F, Zabriskie J. B lymphocyte antigen D8/17 and repetitive behaviors in autism. Am J Psychiatry 156:317-320, 1999.
218. Hollander E, Allen A, Prieto Lopez R, Bienstock CA, Grossman R, Siever LJ, Merkatz L, Stein DJ. A preliminary double blind placebo controlled trial of divalproex sodium in borderline personality disorder. J Clin Psychiatry 62:199-203, 2001.

219. Hollander E, Allen A, Kwon J, Aronowitz B, Schmeidler J, Wong C, Simeon D. Clomipramine vs. desipramine crossover trial in body dysmorphic disorder: selective efficacy of serotonin reuptake inhibitors in imagined ugliness. Arch Gen Psychiatry 56:1033-1039, 1999.
220. Rauch SL, Benkelfat C, Dager SR, Greenberg BD, Hendler T, Hollander E, Laruelle M, Rosenberg DR, Saxena S, Zohar J, Baxter, Jr LR. Neuroimaging research and neurocircuitry models of obsessive-compulsive disorder: proceedings of the third IOCDC. CNS Spectrums: Int J Neuropsychiatric Med 4:25-34, 1999. (suppl 3)
221. Presta S, Marazziti D, Dell'Osso L, Pfanner C, Pallanti S, Cassano GB, Hollander E. Kleptomania: clinical features and comorbidity in an Italian sample. Compr Psychiatry 43(1):7-12, 2002.
222. Allgulander C, Bandelow B, Brady K, Bradwejn J, Cassano G, Davidson J, Greist J, Gorman J, Hollander E, Kutcher S, Lecrubier Y, Lopez-Ibor JJ, Marazziti D, Montgomery S, Nutt D, Okasha A, Pollack M, Stein D, Swinson R, van Ameringen M, Zohar J. World Council of Anxiety recommendations for the long-term treatment of obsessive-compulsive disorder. In review.
223. Hadley SJ, Koran LM, Yang H, Li D, Park C, Barbato LM, Gerritsen van der Hoop R, Hollander E. SF-36 quality of life changes for OCD patients during a double-blind placebo controlled trial of fluvoxamine CR. J Clin Psychopharmacology (in review).
224. Cohen LJ, McGeoch P, Kingston P, Hollander E, Galynker I. The dimensional assessment of personality impairment: theoretical framework, format, reliability and construct validity. Journal of Personality Disorders (in press).
225. Hollander E, Pallanti S. Current and experimental therapeutics of OCD. In Davis K, Charney D, Coyle JT, Nemeroff C, eds. Neuropsychopharmacology: The Fifth Generation of Progress. Philadelphia: Lippincott Williams & Wilkins, 2002, p. 1647-1664.
226. Potenza MN, Hollander E. Pathologic gambling and impulse control disorders. In Davis KL, Charney D, Coyle JT, Nemeroff C, eds. Neuropsychopharmacology: The Fifth Generation of Progress. Philadelphia: Lippincott Williams & Wilkins, 2002, p. 1725-1741.
227. Hollander E, Scahill L, Aman M et al. Autism clinical trials: a model for drug development in psychiatric illness. CNS Spectrums. (In preparation)
228. Hollander E, Kaplan A, Schmeidler J, Yang H, Li D, Koran LM, Barbato LM. Neurological soft signs as predictors of treatment response to selective serotonin reuptake inhibitors in obsessive-compulsive disorder. J Neuropsych Clin Neurosci 17(4):472-77, 2005.
229. Hollander E. Spectrum view of impulsivity: neurochemistry, behavior, and treatment approaches. J Clin Psychiatry (in press).
230. Buchsbaum MS, Hollander E, Pallanti S, Baldini-Rossi N, Platholi J, Newmark R, Bloom R, Sood E. Positron emission tomography imaging of risperidone augmentation in SRI-refractory patients. Neuropsychobiology (in press).
231. Stein DJ, Hollander E, Swann AC, McElroy SL. Topiramate: an emerging treatment for disordered impulsivity. (In preparation)
232. Hollander E, Novotny S, Allen A, Aronowitz B, Cartwright C, DeCaria C. The relationship between repetitive behaviors and growth hormone response to sumatriptan challenge in adult autistic disorder. Neuropsychopharmacology 22:163-167, 2000.
233. Hollander E, Kaplan A, Cartwright C, Reichman D. Venlafaxine in children, adolescents and young adults with autism spectrum disorders: an open retrospective clinical report. J Child Neurol 15(2):132-135, 2000.
234. Carrasco JL, Diaz-Marsa M, Hollander E, Cesar J, Saiz-Ruiz J. Decreased platelet monoamine oxidase activity in female bulimia nervosa. European Neuropsychopharm 10(2):113-117, 2000.

235. Diaz-Marsa M, Carrasco JL, Hollander E, Cesar J, Saiz-Ruiz J. Decreased platelet monoamine oxidase activity in female anorexia nervosa. Acta Psychiatrica Scandinavica 101:226-230, 2000.
236. Novotny S, Hollander E, Allen A, Mosovich S, Aronowitz B, Cartwright C, DeCaria C, Dolgoff-Kaspar R. Increased growth hormone response to sumatriptan challenge in adult autistic disorders. Psychiatry Research 94(2):173-177, 2000.
237. Hollander E, DeCaria CM, Finkell JN, Begaz T, Wong CM, Cartwright C. A randomized double-blind fluvoxamine/placebo crossover trial in pathological gambling. Biol Psychiatry 47:813-817, 2000.
238. Marazziti D, Masala I, Rossi A, Hollander E, Presta S, Giannaccini G, Mazzoni MR, Dell'Osso L, Lucacchini A, Cassano GB. Increased inhibitory activity of protein kinase C on the serotonin transporter in OCD. Neuropsychobiology 41:171-177, 2000.
239. Hollander E, Rosen J. Impulsivity. J Psychopharmacol 14(2): S39-S44, 2000.
240. Allen A, Hollander E. Body dysmorphic disorder. In Hollander E and Allen A (eds.) The Psychiatric Clinics of North America: Obsessive-Compulsive Spectrum Disorders, Philadelphia, PA, W.B. Saunders Co., Vol. 23, No. 3, September 2000, pp. 617-628.
241. Hollander E, Buchalter AJ, DeCaria CM. Pathological gambling. In Hollander E and Allen A (eds.) The Psychiatric Clinics of North America: Obsessive-Compulsive Spectrum Disorders, Philadelphia, PA, W.B. Saunders Co., Vol. 23, No. 3, September 2000, pp. 629-642.
242. Hollander E, Kaplan A, Allen A, Cartwright C. Pharmacotherapy for obsessive-compulsive disorder. In Hollander E and Allen A (eds.) The Psychiatric Clinics of North America: Obsessive-Compulsive Spectrum Disorders, Philadelphia, PA, W.B. Saunders Co., Vol. 23, No. 3, September 2000, pp. 643-656.
243. Simeon D, Guralnik O, Hazlett EA, Spiegel-Cohen J, Hollander E, Buchsbaum MS. Feeling unreal: a PET study of depersonalization disorder. Am J Psychiatry 157(11):1782-1788, 2000.
244. Haznedar MM, Buchsbaum MS, Wei T-C, Hof PR, Cartwright C, Bienstock CA, Hollander E. Limbic circuitry in patients with autism spectrum disorders studied with positron emission tomography and magnetic resonance imaging. Am J Psychiatry 157(12):1994-2001, 2000.
245. Vythilingum B, Cartwright C, Hollander E. Pharmacotherapy of obsessive-compulsive disorder: experience with the selective serotonin reuptake inhibitors. Int Clin Psychopharmacol Aug; 15 Suppl 2:S7-13, 2000.
246. Buxbaum JD, Silverman JM, Smith CJ, Kilifarski M, Reichert J, Hollander E, Lawlor BA, Fitzgerald M, Greenberg DA, Davis KL. Evidence for a susceptibility gene for autism on chromosome 2 and for genetic heterogeneity. Am J Hum Genet 68:1514-1520, 2001. Erratum in: Am J Hum Genet 69:470, 2001.
247. Hollander E, Pallanti S. 5HT_{1D} function and repetitive behaviors. Am J Psychiatry 158(6):972-973, 2001.
248. Buchsbaum MS, Hollander E, Haznedar MM, Tang C, Spiegel-Cohen J, Wei T-C, Solimando A, Buchsbaum BR, Robins D, Bienstock C, Cartwright C, Mosovich S. Effect of fluoxetine on regional cerebral metabolism in autistic spectrum disorders: a pilot study. Int J Neuropsychopharmacol 4:119-125, 2001.
249. Hollander E, Dolgoff-Kaspar R, Cartwright C, Rawitt R, Novotny S. An open trial of divalproex sodium in autism spectrum disorder. J Clin Psychiatry 62:530-534, 2001.
250. Hollander E, Evers M. New developments in impulsivity. Lancet 358:949-950, 2001.
251. Simeon D, Guralnik O, Knutelska M, Hollander E, Schmeidler J. Hypothalamic-pituitary-adrenal axis dysregulation in depersonalization disorder. Neuropsychopharmacology 25(5):793-795, 2001.

252. Mathew SJ, Coplan JD, Perko KA, Goetz RR, de la Neuz M, Hollander E, Liebowitz MR, Fallon BA. Neuroendocrine predictors of response to intravenous clomipramine therapy for refractory obsessive-compulsive disorder. Depress Anxiety 14:199-208, 2001.
253. Silverman JM, Smith CJ, Schmeidler J, Hollander E, Lawlor BA, Fitzgerald M, Buxbaum JD, Delaney K, Galvin P; Autism Genetic Research Exchange Consortium. Symptom domains in autism and related conditions: evidence for familiarity. Am J Med Genet 114:64-73, 2002.
254. Hadley SJ, Greenberg J, Hollander E. Diagnosis and treatment of body dysmorphic disorder in adolescents. Curr Psychiatry Rep 4:108-113, 2002.
255. Hollander E, Bienstock CA, Koran LM, Pallanti S, Marazziti D, Rasmussen SA, Ravizza L, Benkelfat C, Saxena S, Greenberg BD, Sasson Y, Zohar J. Refractory obsessive-compulsive disorder: state-of-the-art treatment. J Clin Psychiatry 63(6):20-29, 2002.
256. Pallanti S, Hollander E, Bienstock C, Koran L, Leckman J, Marazziti D, Pato M, Stein D, Zohar J; International Treatment Refractory OCD Consortium. Treatment non-response in OCD: methodological issues and operational definitions. Int J Neuropsychopharmacol 5:181-191, 2002.
257. Evers M, Cunningham-Rundles C, Hollander E. Heat shock protein 90 antibodies in autism. Mol Psychiatry 7 Suppl 2:S26-8, 2002.
258. Pallanti S, Quercioli L, Sood E, Hollander E. Lithium and valproate treatment of pathological gambling: a randomized single-blind study. J Clin Psychiatry 63(7):559-564, 2002.
259. Pallanti S, Baldini Rossi N, Sood E, Hollander E. Nefazodone treatment of pathological gambling: a prospective open-label controlled trial. J Clin Psychiatry 63:1034-1039, 2002.
260. Hollander E. Obsessive-compulsive disorder and spectrum across the life span. Int J Psychiatry Clin Practice 9(2):79-86, 2005.
261. DeCaria CM, Pallanti S, Baldini Rossi N, Nora R, Birnbaum M, Hollander E. Metachlorophenylpiperazine (m-CPP)-induced "high" and prolactin response in pathological gamblers. Addiction (in review).
262. Sood ED, Pallanti S, Hollander E. Serotonin reuptake inhibitors in the treatment of pathological gambling. Essent Psychopharmacol 5:157-169, 2003.
263. Hollander E, Novotny S, Hanratty M, Yaffe R, DeCaria CM, Aronowitz BR, Mosovich S. Oxytocin infusion reduces repetitive behaviors in adults with autistic and Asperger's disorders. Neuropsychopharmacology 28:193-198, 2003.
264. Bandelow B, Zohar J, Hollander E, Kasper S, Moller HJ; World Federation of Societies of Biological Psychiatry Task Force on Treatment Guidelines for Anxiety, Obsessive-Compulsive and Posttraumatic Stress Disorders. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and posttraumatic stress disorders. World J Biol Psychiatry 3(4):171-199, 2002.
265. Hollander E, King A, Delaney K, Smith CJ, Silverman JM. Obsessive-compulsive behaviors in parents of multiplex autism families. Psychiatry Res 117(1):11-16, 2003.
266. Hollander E, Kaplan A, Stahl SM. A double-blind, placebo-controlled trial of clonazepam in obsessive-compulsive disorder. World J Biol Psychiatry 4(1):30-34, 2003.
267. Hollander E, Tracy KA, Swann AC, Coccaro EF, McElroy SL, Wozniak P, Sommerville KW, Nemeroff CB. Divalproex in the treatment of impulsive aggression: efficacy in cluster B personality disorders. Neuropsychopharmacology 28:1186-1197, 2003.

- 268.Hollander E, Friedberg J, Wasserman S, Allen A, Birnbaum M, Koran LM. Venlafaxine in treatment-resistant obsessive-compulsive disorder. J Clin Psychiatry 64:546-550, 2003. Erratum in: J Clin Psychiatry 64:972, 2003.
- 269.Hollander E, Koran LM, Goodman WK, Greist JH, Ninan PT, Yang H, Li D, Barbato LM. A double-blind, placebo-controlled study of the efficacy and safety of controlled release fluvoxamine in patients with obsessive-compulsive disorder. J Clin Psychiatry 64:640-647, 2003.
- 270.Kaplan A, Hollander E. A review of pharmacologic treatments for obsessive-compulsive disorder. Psychiatr Serv 54(8):1111-8, 2003.
- 271.Johnson SM, Hollander E. Evidence that eicosapentaenoic acid is effective in treating autism. J Clin Psychiatry 64(7):848-849, 2003.
- 272.Simeon D, Greenberg J, Knutelska M, Schmeidler J, Hollander E. Peritraumatic reactions associated with the World Trade Center disaster. Am J Psychiatry 160:1702-1705, 2003.
- 273.Simeon D, Nelson D, Elias R, Greenberg J, Hollander E. Relationship of personality to dissociation and childhood trauma in borderline personality disorder. CNS Spectr 8:755-762, 2003.
- 274.Greist JH, Bandelow B, Hollander E, Marazziti D, Montgomery SA, Nutt DJ, Okasha A, Swinson RP, Zohar J; World Council of Anxiety. WCA recommendations for the long-term treatment of obsessive-compulsive disorder in adults. CNS Spectr 8(suppl 1):7-16, 2003.
- 275.Pollack MH, Allgulander C, Bandelow B, Cassano GB, Greist JH, Hollander E, Nutt DJ, Okasha A, Swinson RP; World Council of Anxiety. WCA recommendations for the long-term treatment of panic disorder. CNS Spectr 8(suppl 1):17-30, 2003.
- 276.Stein DJ, Bandelow B, Hollander E, Nutt DJ, Okasha A, Pollack MH, Swinson RP, Zohar J; World Council of Anxiety. WCA recommendations for the long-term treatment of posttraumatic stress disorder. CNS Spectr 8(suppl 1):31-39, 2003.
- 277.Van Ameringen M, Allgulander C, Bandelow B, Greist JH, Hollander E, Montgomery SA, Nutt DJ, Okasha A, Pollack MH, Stein DJ, Swinson RP; World Council of Anxiety. WCA recommendations for the long-term treatment of social phobia. CNS Spectr 8(suppl 1):40-52, 2003.
- 278.Allgulander C, Bandelow B, Hollander E, Montgomery SA, Nutt DJ, Okasha A, Pollack MH, Stein DJ, Swinson RP; World Council of Anxiety. WCA recommendations for the long-term treatment of generalized anxiety disorder. CNS Spectr 8(suppl 1):53-61, 2003.
- 279.Hollander E, Evers M. Review of obsessive-compulsive spectrum disorders: what do we know? where are we going? Clinical Neuropsychiatry 1(1):32-51, 2004.
- 280.Hollander E, Robinson R, Compton D; Autism Clinical Trials Task Force. New developments in Autism Clinical Trials. CNS Spectr 9:20-21, 2004.
- 281.Hollander E, Phillips A, King BH, Guthrie D, Aman MG, Law P, Owley T, Robinson R. Impact of recent findings on study design of future autism clinical trials. CNS Spectr 9:49-56, 2004.
- 282.Kaplan A, Hollander E. Comorbidity in compulsive hoarding: a case report. CNS Spectr 9:71-73, 2004.
- 283.Hollander E, Phillips AT, Yeh C-C. Targeted treatments for symptom domains in child and adolescent autism. Lancet 362:732-734, 2003.
- 284.Hollander E, Rossi NB, Sood E, Pallanti S. Risperidone augmentation in treatment-resistant obsessive-compulsive disorder: a double-blind, placebo-controlled study. Int J Neuropsychopharmacol 6:397-401, 2003.

- 285.Hollander E, Allen A, Steiner M, Wheadon DE, Oakes R, Burnham D; Paroxetine OCD Study Group. Acute and long-term treatment and prevention of relapse of obsessive-compulsive disorder with paroxetine. J Clin Psychiatry 64:1113-1121, 2003.
- 286.Hollander E. Interview on pathological gambling. Essent Psychopharmacol 5(3):225-235, 2003.
- 287.Simeon D, Knutelska M, Nelson D, Guralnik O. Feeling unreal: a depersonalization disorder update for 117 cases. J Clin Psychiatry 64(9):990-997, 2003.
- 288.Buxbaum JD, Silverman J, Keddache M, Smith CJ, Hollander E, Ramoz N, Reichert JG.Linkage analysis for autism in a subset of families with obsessive-compulsive behaviors: evidence for an autism susceptibility gene on chromosome 1 and further support for susceptibility genes on chromosome 6 and 19. Mol Psychiatry 9:144-150, 2004.
289. Pallanti S, Quercioli L, Hollander E. Social anxiety in outpatients with schizophrenia: a relevant cause of disability. Am J Psychiatry 161:53-58, 2004.
- 290.Allen A, Hollander E. Similarities and differences between body dysmorphic disorder and other disorders. Psychiatric Annals 34(12):927-933.
- 291.Hazlett EA, Buchsbaum MS, Hsieh P, Haznedar MM, Platholi J, LiCalzi EM, Cartwright C, Hollander E. Regional glucose metabolism within cortical Brodmann areas in healthy individuals and autism patients. Neuropsychobiology 49:115-125, 2004.
- 292.Novotny S, Hollander E, Phillips A, Allen A, Wasserman S, Iyengar R. Increased repetitive behaviors and prolactin responsivity to m-chlorophenylpiperazine in adults with autism spectrum disorders. Int J Neuropsychopharmacol 2004 Sep;7(3):249-54; 2004 May 7:1-6 [Epub ahead of print].
- 293.Ramoz N, Reichert JG, Corwin TE, Smith CJ, Silverman JM, Hollander E, Buxbaum JD. Lack of evidence for association of the serotonin transporter gene, SLC6A4, with autism. Biol Psychiatry 2006 Apr 6 [Epub ahead of print].
- 294.Zohar J, Kennedy JL, Hollander E, Koran LM. Serotonin-1D hypothesis of obsessive-compulsive disorder: an update. J Clin Psychiatry 65 Suppl 14:18-21, 2004. Review.
- 295.Pallanti S, Hollander E, Goodman WK. A qualitative analysis of nonresponse: management of treatment-refractory obsessive-compulsive disorder. J Clin Psychiatry 65 Suppl 14:6-10, 2004. Review.
- 296.Hollander E, Zohar J. Beyond refractory obsessions and anxiety states: toward remission. J Clin Psychiatry 65 Suppl 14:3-5, 2004.
- 297.Pallanti S, Hollander E, Goodman WK. A qualitative analysis of nonresponse: management of treatment-refractory obsessive-compulsive disorder. J Clin Psychiatry 65 Suppl 14:6-10, 2004.
- 298.Zohar J, Kennedy JL, Hollander E, Koran LM. Serotonin-1D hypothesis of obsessive-compulsive disorder: an update. J Clin Psychiatry 65 Suppl 14:18-21, 2004.
- 299.Rosario-Campos MC, Miguel EC, Quatrano S, Chacon P, Ferrao Y, Findley D, Katsoyich L, Scahill L, King R, Woody SR, Tolin D, Hollander E, Kano Y, Leckman JF. The Dimensional Yale-Brown Obsessive Compulsive Scale (DY-BOCS): an instrument for assessing obsessive-compulsive symptom dimensions. Mol Psychiatry 2006 Jan 24; [Epub ahead of print].
- 300.Anagnostou E, Esposito K, Soorya L, Chaplin W, Wasserman S, Hollander E. Divalproex vs. placebo reduces irritability associated with fluoxetine treatment in autism. Int J Neuropsychopharm (in review).

- 301.Stein DJ, Hollander E, Swann AC, McElroy SL. Topiramate: an emerging treatment for disordered impulsivity. In preparation.
- 302.Simeon D, Greenberg J, Nelson D, Schmeidler J, Hollander E. Dissociation and posttraumatic stress one year after the World Trade Center disaster: follow-up of a longitudinal survey. J Clin Psychiatry 66(2):231-7, 2005.
- 303.Hollander E, Pallanti S, Allen A, Sood E, Baldini-Rossi N. Does sustained-release lithium reduce impulsive gambling and affective instability versus placebo in pathological gamblers with bipolar spectrum disorders? Am J Psychiatry 162(1):137-45, 2005.
- 304.Hollander E, Swann AC, Coccaro EF, Jiang P, Smith TB. Impact of trait impulsivity and state aggression on divalproex vs. placebo response in borderline personality disorder. Am J Psychiatry 162(3):621-4, 2005.
- 305.Haznedar MM, Buchsbaum MS, Hazlett E, LiCalzi EM, Cartwright C, Hollander E. Volumetric analysis and 3-dimensional glucose metabolic mapping of the basal ganglia and thalamus in autism spectrum illnesses. Am J Psychiatry (in review).
306. Pallanti S, DeCaria CM, Grant JE, Urpe M, Hollander E. Reliability and validity of the pathological gambling modification of the Yale-Brown Obsessive-Compulsive Scale (PG-YBOCS). J Gambling Studies 21(4):431-43, 2005.
- 307.Hollander E, Soorya L, Wasserman S, Esposito K, Chaplin W, Anagnostou E. Divalproex sodium vs. placebo in the treatment of repetitive behaviors in autism spectrum disorder. Int J Neuropsychopharmacol 2005 Aug 15;1-5[Epub ahead of print]; Int J Neuropsychopharmacol 9:209-213, 2006.
- 308.Hollander E, Sood E, Pallanti S, Baldini-Rossi, N, Baker B. Pharmacological treatments of pathological gambling. J Gambl Stud 21(1):101-110, 2005.
- 309.Hollander E, Pallanti S, Baldini Rossi N, Sood E, Baker BR, Buchsbaum M. Imaging monetary reward in pathological gamblers. World J Biol Psychiatry 6(2):113-120, 2005.
- 310.Haznedar MM, Roversi F, Pallanti S, Baldini-Rossi N, Schnur DB, LiCalzi EM, Tang C, Hof PR, Hollander E, Buchsbaum MS. Fronto-thalamo-striatal gray and white matter volumes and Anisotropy of their connections in bipolar spectrum illnesses. Biol Psychiatry 57(7):733-42, 2005.
- 311.Hollander E, Wasserman S, Swanson EN, Chaplin W, Zagursky K, Novotny S. Olanzapine vs. placebo in childhood and adolescent autism: a double-blind placebo controlled study. J Am Acad Child Adoles Psychiatry (in review).
- 312 Hollander E, Phillips A, Chaplin W, Zagursky K, Novotny S, Wasserman S, Iyengar R. A placebo controlled crossover trial of liquid fluoxetine on repetitive behaviors in childhood and adolescent autism. Neuropsychopharmacol 30(3):582-9, 2005.
- 313.Hollander E, Anagnostou E, Chaplin W, Esposito K, Haznedar MM, LiCalzi EM, Wasserman S, Soorya L, Buchsbaum M. Striatal volume on magnetic resonance imaging and repetitive behaviors in autism. Biol Psychiatry 2005 Jun 3 [Epub ahead of print]; Biol Psychiatry 58(3):226-232, 2005.
- 314.Silverman JM, Buxbaum JD, Ramoz N, Reichenberg A, Hollander E, Schmeidler J, Smith CJ, Corwin TE, Kryzak LA. Autism related routines and rituals associated with a mitochondrial Aspartate/glutamate carrier polymorphism. Am J Psychiatry (in review).
- 315.Hollander E, Chaplin W, Phillips A, Sumner J, Soorya L, Anagnostou E, Wasserman S. Oxytocin increases social cognition in autism. Am J Psychiatry (in review).
- 316.Kolevzon A, Newcorn JH, Kryzak L, Chaplin W, Watner D, Hollander E, Smith Christopher J, Cook Jr EH, Silverman JM. The relationship between whole blood serotonin and repetitive behaviors in autism. Biol Psychiatry (in review).

- 317.Dell'Osso B, Hollander E. The impact of comorbidity on the management of pathological gambling. CNS Spectr 10(8):619-621, 2005.
- 318.Hollander E, Sood E, Pallanti S, Baldini-Rossi N, Baker B. Pharmacological treatments of pathological gambling. J Gambling Studies 21(1):101-110, 2005.
- 319.Dell'Osso B, Altamura AC, Allen A, Hollander E. Brain stimulation techniques in the treatment of obsessive-compulsive disorder: current and future directions. CNS Spectr 10(12):966-79, 2005.
- 320.Dell'Osso B, Allen A, Hollander E. Fluvoxamine: a selective serotonin re-uptake inhibitor for the treatment of obsessive-compulsive disorder. Expert Opin Pharmacother 6(15):2727-40, 2005.
- 321.Dell'Osso B, Allen A, Hollander E. Comorbidity issues in the pharmacological treatment of pathological gambling: a critical review. Clin Pract Epidemiol Ment Health Oct 10;1:21, 2005.
- 322.Grant JE, Potenza MN, Hollander E, Cunningham-Williams R, Nurminen T, Smits G, Kallio A. Multicenter investigation of the opioid antagonist nalmefene in the treatment of pathological gambling. Am J Psychiatry 163:303-312, 2006.
- 323.Simeon D, Knutelska M, Smith L, Baker BR, Hollander E. A preliminary study of cortisol and norepinephrine reactivity to psychosocial stress in borderline personality disorder with high and low dissociation. Psychiatric Res (in press).
- 324.Ramoz N, Cai G, Reichert JG, Corwin TE, Kryzak L, Smith CJ, Silverman JM, Hollander E, Buxbaum JD. Family-based association study of TPH1 and TPH2 polymorphisms in autism. Am J Med Gen 141:B1-7, 2006 (in press).
- 325.Bartz JA, Hollander E. Is obsessive-compulsive disorder an anxiety disorder? Progress in Neuro-Psychopharmacology & Biological Psychiatry, 2006 Jan 30; [Epub ahead of print].
- 326.Dell'Osso B, Nestadt G, Allen A, Hollander E. Serotonin-norepinephrine reuptake inhibitors in the treatment of obsessive-compulsive disorder: a critical review. J Clin Psychiatry 67:600-610, 2006.
- 327.Dell'Osso B, Altamura AC, Allen A, Marazziti D, Hollander E. Epidemiologic and clinical updates on impulse control disorders: a critical review. European Arch Psychiatry 256(8):464-475.
- 328.Hollander E, Dell'Osso B. Topiramate plus paroxetine in treatment-resistant obsessive-compulsive disorder. Int Clin Psychopharmacol 21(3):189-191, 2006.
- 329.Wainberg M, Irwin T, Muench F, O'Leary A, Morgenstern J, Parsons J, Hollander E. Citalopram vs. placebo in the treatment of compulsive sexual behaviors in gay and bisexual men. J Clin Psychiatry 67(12):1968-1973, 2006.
- 330.Hollander E, Bartz J, Chaplin W, Phillips AT, Sumner J, Soorya L, Anagnostou E, Wasserman S. Oxytocin increases retention of social cognition in autism. Biol Psychiatry (in press).
- 331.Anagnostou E, Hollander E. 4 drugs can improve autism's repetitive behaviors: controlled trials shape evolving treatment approach. Current Psychiatry 5(4):55-64, 2006.
332. Hollander E et al. Serotonin-norepinephrine reuptake inhibitors in the treatment of obsessive-compulsive disorder: a critical review. J Clin Psychiatry 67(4):600-610, 2006.
- 333.Hollander E, Alterman R, Dell'Osso B. Approaching treatment-resistant obsessive-compulsive disorder with brain stimulation interventions: the state of the art. Psychiatric Annals 36(7): 480-488, 2006.
- 334.Simeon D, Baker B, Chaplin W, Braun A, Hollander E. An open-label trial of divalproex extended release in the treatment of borderline personality disorder. CNS Spectr 12(6):439-443, 2007

335. Josephson SC, Hollander E, Sumner J. Comprehensive treatment of three patients with co-morbid OCPD and ADHD. CNS Spectr 12(5):338-342, 2007.
336. Buxbaum JD, Cai G, Chaste P, Nygren G, Goldsmith J, Reichert J, Anckarsater H, Rastam M, Smith CJ, Silverman JM, Hollander E, Leboyer M, Gillberg C, Verloes A, Betancur C. Mutation screening of the PTEN gene in patients with autism spectrum disorders and Macrocephaly. Am J Med Genet B Neuropsychiatr Genet 144(4):484-91, 2007.
337. Autism Genome Project Consortium. Mapping autism risk loci using genetic linkage and Chromosomal rearrangements. Nat Genet 39(3):319-328, 2007.
338. Zohar J, Hollander E, Stein DJ, Westenberg HG; The Cape Town Consensus Group. Consensus statement. CNS Spectr 12(2 Suppl 3):59-63, 2007.
339. Hollander E, Kim S, Khanna S, Pallanti S. Obsessive-compulsive disorder and obsessive-compulsive spectrum disorders: diagnostic and dimensional issues. CNS Spectr 12(2 Suppl 3):5-13, 2007.
340. Muench F, Morgenstern J, O'Leary AO, Parsons JT, Hollander E, Wainberg ML, Lai B, Irwin T. The consequences of compulsive sexual behavior: the preliminary reliability and validity of the Compulsive sexual behavior consequences scale. J Sexual Addiction & Compulsivity (in press).
341. Silverman JM, Buxbaum JD, Ramoz N, Schmeidler J, Reichenberg A, Hollander E, Angelo G, Smith CJ, Kryzak LA. Autism related routines and rituals associated with a mitochondrial Aspartate/glutamate carrier SLC25A12 polymorphism. Am J Med Genetics (Neuropsychiatric Genetics). In press.
342. Dell'Osso B, Mundo E, Buoli M, Hollander E, Altamura AC. Disturbo ossessivo-compulsivo e disturbi correlate: aggiornamenti clinico-biologici e indicazioni future. Minerva Psichiatr 48:195-210, 2007.
343. Dell'Osso B, Marazziti D, Hollander E, Altamura AC. Traditional and newer impulse control disorders: a clinical update. Clinical Neuropsychiatry 4(1):30-38, 2007.
344. Koran LM, Hanna GL, Hollander E, Nestadt G, Simpson HB. Practice guideline for the treatment of patients with obsessive-compulsive disorder. Am J Psychiatry 164(suppl):1-56, 2007.
345. Kim SW, Grant JE, Potenza MC, Blanco C, Hollander E. The gambling symptom assessment Scale (G-SAS): A reliability and validity study. Psychiatry Research. In press.
346. Phillips KA, Hollander E. Treating body dysmorphic disorder with medication: evidence, Misconceptions, and a suggested approach. Body Image: An International Journal of Research. In press.
347. Silverman JM, Buxbaum JD, Ramoz N, Schmeidler J, Reichenberg A, Hollander E, Angelo G, Smith CJ, Kryzak LA. Autism-related routines and rituals associated with a mitochondrial Aspartate/glutamate carrier polymorphism. Am J Med Genet B Neuropsychiatr Genet 147(3):408-10, 2008.
348. Buxbaum JD, Cai G, Nygren G, Chaste P, Delorme R, Goldsmith J, Rastam M, Silverman JM, Hollander E, Gillberg C, Leboyer M, Betancur C. Mutation analysis of the NSD1 gene in patients with autism spectrum disorders and macrocephaly. BMC Medical Genetics 8:68 (14 Nov 2007).
349. Allen A, Hadley SJ, Kaplan A, Simeon D, Friedberg J, Priday L, Baker BR, Greenberg JL, Hollander E. An open-label trial of venlafaxine in body dysmorphic disorder. CNS Spectrums 13(2):138-44, 2008.
350. Diaz-Marsa M, Carrasco JL, Basurte E, Saiz J, Lopez-Ibor JJ, Hollander E. Enhanced cortisol Suppression in eating disorders with impulsive personality features. Psychiatry Res 158(1):93-7. Epub 2008 Jan 8.
351. Hollander E. Obsessive-compulsive spectrum phenomena and the DSM-V developmental process. CNS Spectr 13(2):107-8, 2008.

- 352.Hollander E. Happy new 2008: from mild cognitive impairment to pleasure circuitry. CNS Spectr 13(1):17-18, 2008.
- 353.Hollander E. Brain stimulation, alternative medicine, and impulsivity and compulsivity. CNS Spectr 13(4):271-2, 2008.
- 354.Dell’Osso B, Hadley S, Allen A, Baker B, Chaplin WF, Hollander E. Escitalopram in the Treatment of impulsive-compulsive internet usage disorder: an open-label trial followed by a double-blind discontinuation phase. J Clin Psychiatry 69(3):452-6, 2008.
- 355.Hollander E. “Functional” and “organic”: it is getting harder to tell the difference. CNS Spectr 13(3):183-4, 2008.
- 356.Phillips KA, Hollander E. Treating body dysmorphic disorder with medication: evidence, misconceptions, and a suggested approach. Body Image 5(1):13-27, 2008. Epub 2008 Mar 5.
- 357.Dell’osso B, Allen A, Altamura AC, Buoli M, Hollander E. Impulsive-compulsive buying disorder: clinical overview. Aust N Z J Psychiatry 42(4):259-66, 2008.
- 358.Pallanti S, Masetti S, Bernardi S, Innocenti A, Markella M, Hollander E. Obsessive compulsive Disorder comorbidity in DBA. Clin Pract Epidemiol Ment Health 10;4:6, 2008.
- 359.Trivedi MH, Hollander E, Nutt D, Blier P. Clinical evidence and potential neurobiological underpinnings of unresolved symptoms of depression. J Clin Psychiatry 69(2):246-58, 2008.
- 360.Hollander E, Braun A, Simeon D. Should OCD leave the anxiety disorders in DSM-V? The case for obsessive compulsive-related disorders. Depress Anxiety 25(4):317-329, 2008.
- 361.Gotham K, Risi S, Dawson G, Tager-Flusberg H, Joseph R, Carter A, Hepburn S, McMahon W, Rodier P, Hyman SL, Sigman M, Rogers S, Landa R, Spence MA, Osann K, Flodman P, Volkmar F, Hollander E, Buxbaum J, Pickles A, Lord C. A replication of the Autism Diagnostic Observation Schedule (ADOS) revised algorithms. J Am Acad Child Adolesc Psychiatry. 2008 Apr 21; [Epub ahead of print].
- 362.Parikh MS, Kolevzon A, Hollander E. Psychopharmacology of aggression in children and adolescents in autism: a critical review of efficacy and tolerability. J Child Adolesc Psychopharmacol 18(2): 157-178, 2008.
- 363.Grant J, Kim S, Hollander E, Potenza M. Predicting response to opiate antagonists and placebo in the treatment of pathological gambling. Psychopharmacology (in press).
- 364.Johnson BA, Rosenthal N, Capece JA, Wiegand F, Mao L, Beyers K, McKay A, Ait-Kaoud N, Addolorato G, Anton RF, Ciraulo DA, Kranzler HR, Mann K, O’Malley SS, Swift RM; Topiramate for Alcoholism Advisory Board; Topiramate for Alcoholism Study Group. Improvement of physical health and quality of life of alcohol-dependent individuals with topiramate treatment: US multisite randomized controlled trial. Arch Intern Med 168(11):1188-99.
- 365.Bartz JA, Hollander E. Oxytocin and experimental therapeutics in autism spectrum disorders. In Neumann ID, Landgraf R (eds) Advances In Vasopressin and Oxytocin—From Genes to Behaviour To Disease, Progress In Brain Research (Volume 170), Oxford: Elsevier, 2008, pp.451-462.
- 366.Hollander E. New developments in autism spectrum disorders. Interview by Dr. George Lundberg. Medscape J Med 10:152, 2008.
- 367.Hollander E. Rare metabolic syndromes, a vascular hypotheses of Alzheimer’s disease, and drug development and trauma. CNS Spectr 13:548-9, 2008.
- 368.Grant JE, Kim SW, Hollander E, Potenza MN. Predicting response to opiate antagonists and placebo in the treatment of pathological gambling. Psychopharmacology (Berl) 2008 Jun 26 [Epub ahead of print].

- 369.Hollander E. Differential treatment response, neuroinflammation, and psychosis associated with chromosome deletion. CNS Spectr 13:459-60, 2008.
- 370.Berlin HA, Hamilton H, Hollander E. Experimental therapeutics for refractory obsessive-compulsive disorder: translational approaches and new somatic developments. Mt Sinai J Med 75:174-203, 2008.
- 371.Soorya L, Kiarashi J, Hollander E. Psychopharmacologic interventions for repetitive behaviors in autism spectrum disorders. Child Adolesc Psychiatr Clin N Am 17(4):753-71, 2008.
- 372.Hollander E, Buchsbaum MS, Haznedar MM, Berenguer J, Berlin HA, Chaplin W, Goodman CR, Licalzi EM, Newmark R, Pallanti S. FDG-PET study in pathological gamblers. 1. Lithium Increases orbitofrontal, dorsolateral and cingulated metabolism. Neuropsychobiology 58(1):37-47, 2008.
- 373.Bandelow B, Zohar J, Hollander E, Kasper S, Möller HJ; WFSBP Task Force on Treatment Guidelines for Anxiety, Obsessive-Compulsive and Post-Traumatic Stress Disorders, Zohar J, Hollander E, Kasper S, Möller HJ, Bandelow B, Allgulander C, Ayuso-Gutierrez J, Baldwin DS, Buenvicinus R, Cassano G, Fineberg N, Gabriels L, Hindmarch I, Kaiya H, Klein DF, Lader M, Lecrubier Y, Lépine JP, Liebowitz MR, Lopez-Ibor JJ, Marazziti D, Miguel EC, Oh KS, Preter M, Rupprecht R, Sato M, Starcevic V, Stein DJ, van Ameringen M, Vega J. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders - first revision. World J Biol Psychiatry. 2008;9(4):248-312.
- 374.Cai G, Edelmann L, Goldsmith JE, Cohen N, Nakamine A, Reichert JG, Hoffman EJ, Zurawiecki DM, Silverman JM, Hollander E, Soorya L, Anagnostou E, Betancur C, Buxbaum JD. Multiplex ligation-dependent probe amplification for genetic screening in autism spectrum disorders: Efficient identification of known microduplications and identification of a novel microduplication in ASMT. BMC Med Genomics. 2008 Oct 16;1:50.
- 375.Hollander E. Addressing underserved populations and unmet needs. CNS Spectr. 2008 Oct;13(10):847-8.
- 376.Hollander E. Muscarinic targets for cognition in Schizophrenia; ADHD comorbidity; perinatal risks, treatment resistance and SRIs; and brain lesions presenting as psychiatric illness. CNS Spectr. 2008 Nov;13(11):938-9.
- 377.Pallanti S, Bernardi S, Allen A, Chaplin W, Watner D, DeCaria CM, Hollander E. Noradrenergic function in pathological gambling:blunted growth hormone response to clonidine. J. Psychopharmacol. 2010 Jun; 24(6):847-53. Epub 2008 Nov 21.
- 378.Hollander E. Treatment response and redefining diagnostic boundaries. CNS Spectr. 2008 Dec;13(12):1020-1.
- 379.Hollander E. New technologies: the good, the bad, and the ugly. CNS Spectr. 2009 Jan;14(1):8.
- 380.Bryan H. King, M.D.; Eric Hollander, M.D.; Linmarie Sikich, M.D.; James T. McCracken, M.D.; Lawrence Scahill, M.S.N., Ph.D.; Joel D. Bregman, M.D.; Craig L. Donnelly, M.D.; Evdokia Anagnostou, M.D; Kimberly Dukes, Ph.D.; Lisa Sullivan, Ph.D.; Deborah Hirtz, M.D.; Ann Wagner, Ph.D.; Louise Ritz, M.B.A Lack of Efficacy of Citalopram in Children with Autism Spectrum Disorders and High Levels of Repetitive Behavior. Arch Gen Psychiatry 2009 Jun;66 (6):583-90
- 381.Stein DJ, Denys D, Gloster AT, Hollander E, Leckman JF, Rauch SL, Phillips KA.. Obsessive Compulsive Disorder: Diagnostic and Treatment Issues. Psychiatr Clin North Am. 2009 Sep;32(3):665-85.
- 382.Anello A, Reichenberg A, Luo X, Schmeidler J, Hollander E, Smith CJ, Puleo CM, Kryzak LA, Silverman JM. Brief report: parental age and the sex ratio in autism. J Autism Dev Disord. 2009 Oct;39(10):1487-92. Epub 2009 May 19.
- 383.Smith CJ, Lang CM, Kryzak L, Reichenberg A, Hollander E, Silverman JM. Familial associations of intense preoccupations, an empirical factor of the restricted, repetitive behaviors and interests domain of autism. J Child Psychol Psychiatry. 2009 Aug;50(8):982-90. Epub 2009

384. Kim SW, Grant JE, Potenza MN, Blanco C, Hollander E. The Gambling Symptom Assessment Scale (G-SAS): a reliability and validity study. Psychiatry Res. 2009 Mar 31;166(1):76-84. Epub 2009 Feb 5.
385. Hälbig, TD, Tse W, Frisina PG, Baker BR, Hollander R, Shapiro H, Tagliati M, Koller WC, Olanow CW. Subthalamic deep brain stimulation and impulse control in Parkinson's disease. Eur J Neuro. 2009 Apr; 16(4):493-7.
386. Hollander E. Behavioral addictions and dirty drugs. CNS Spectr. 2009 Feb; 14(2): 60-1.
387. Smith CJ, Lang CM, Kryzak L, Reichenberg A, Hollander E, Silverman JM. Familial associations of intense preoccupations, an empirical factor of the restricted, repetitive behaviors and interests domain of autism. J Child Psychol Psychiatry. 2009 Aug;50(8):982-90. Epub 2009 Feb 27.
388. Hollander E. Optimal dosing of desvenlafaxine, new insights in gambling and anorexia, and caffeine-induced psychosis. CNS Spectr. 2009 Mar;14(3):116-7.
389. Hollander E. A decade of editing CNS spectrums: back to the future. CNS Spectr. 2009 Apr;14(4): 172-4.
390. Anello A, Reichenberg A, Luo X, Schmeidler J, Hollander E, Smith CJ, Puleo CM, Kryzak LA, Silverman JM. Brief report: parental age and the sex ratio in autism. J Autism Dev Disord. 2009 Oct;39(10): 1487-92. Epub 2009 May 19.
391. King BH, Hollander E, Sikich L, McCracken JT, Scahill L, Bregman JD, Donnelly CL, Anagnostou E, Dukes K, Sullivan L, Hirtz D, Wagner A, Ritz L; STAART Psychopharmacology Network. Lack of efficacy of citalopram in children with autism spectrum disorders and high levels of repetitive behavior: citalopram ineffective in children with autism. Arch Gen Psychiatry. 2009 Jun;66(6):583-90.
392. Stein DJ, Denys D, Gloster AT, Hollander E, Leckman JF, Rauch SL, Phillips KA. Obsessive-compulsive disorder: diagnostic and treatment issues. Psychiatr Clin North Am. 2009 Sep;32(3):665-85. Review.
393. Hollander E, Kim S, Braun A, Simeon D, Zohar J. Cross-cutting issues and future directions for the OCD spectrum. Psychiatry Res. 2009 Nov 30;170(1):3-6. Epub 2009 Oct 6.
394. Hollander E, Wang AT, Braun A, Marsh L. Neurological considerations: autism and Parkinson's disease. Psychiatry Res. 2009 Nov 30;170(1):43-51. Epub 2009 Oct 7.
395. Hankin CS, Koran LM, Bronstone A, Black DW, Sheehan DV, Hollander E, Dunn JD, Culpepper L, Knispel J, Dougherty DD, Wang Z. Adequacy of pharmacotherapy among Medicaid-enrolled patients newly diagnosed with obsessive-compulsive disorder. CNS Spectr. 2009 Dec; 14(12):695-703
396. Pallanti S, Bernardi S, Allen A, Hollander E. Serotonin function in pathological gambling: blunted growth hormone response to Sumatriptan. J Psychopharmacol. 2010 Dec;24(12):1802-9. Epub 2009 Oct 13.
397. Fineberg NA, Potenza MN, Chamberlain SR, Berlin HA, Menzies L, Bechara A, Sahakian BJ, Robbins TW, Bullmore ET, Hollander E. Probing compulsive and impulsive behaviors, from animal models to endophenotypes: a narrative review. Neuropsychopharmacology. 2010 Feb;35(3):591-604. Epub Nov 25.
398. Pallanti S, Bernardi S, Antonini S, Singh N, Hollander E. Ondansetron augmentation in treatment-resistant obsessive-compulsive disorder: a preliminary, single-blind, prospective study. CNS Drugs. 2009 Dec 1;23(12):1047-55.
399. Dell'Osso B, Buoli M, Hollander E, Altamura AC. Duration of untreated illness as a predictor of treatment response and remission in obsessive-compulsive disorder. World J Biol Psychiatry. 2010 Feb; 11(1): 59-65
400. Hollander E, Chaplin W, Soorya L, Wasserman S, Novotny S, Rusoff J, Feirsen N, Pepa L, Anagnostou E. Divalproex sodium vs placebo for the treatment of irritability in children and adolescents with autism spectrum disorders. Neuropsychopharmacology. 2010 Mar;35(4):990-8. Epub 2009 Dec 9.
401. Kolevzon A, Newcorn JH, Kryzak L, Chaplin W, Watner D, Hollander E, Smith CJ, Cook EH Jr, Silverman JM. Relationship between whole blood serotonin and repetitive behaviors in autism. Psychiatry Res. 2010 Feb 28;175(3):274-6. Epub 2009 Dec 30.
402. Leckman JF, Denys D, Simpson HB, Mataix-Cols D, Hollander E, Saxena S, Miguel EC, Rauch SL, Goodman WK, Phillips KA, Stein DJ. Obsessive-compulsive disorder: a review of the diagnostic criteria and possible subtypes and dimensional specifiers for DSM-V. Depress Anxiety. 2010 Jun;27(6):507-27. Review.

403. Bernardi S, Cortese S, Solanto M, Hollander E, Pallanti S. Bipolar disorder and comorbid attention deficit hyperactivity disorder. A distinct clinical phenotype? Clinical characteristics and temperamental traits. World J Biol Psychiatry. 2010 Jun;11(4):656-66.
404. Hollander E, Stein DJ, Fineberg NA, Marteau F, Legault M. Quality of life outcomes in patients with obsessive-compulsive disorder: relationship to treatment response and symptom relapse. J Clin Psychiatry. 2010 Jun;71(6):784-92. Epub 2010 May 4.
405. Phillips KA, Stein DJ, Rauch SL, Hollander E, Fallon BA, Barsky A, Fineberg N, Mataix-cols D, Ferrão YA, Saxena S, Wilhelm S, Kelly MM, Clark LA, Pinto A, Bienvenu OJ, Farrow J, Leckman J. Should an obsessive-compulsive spectrum grouping of disorders be included in DSM-V? Depress Anxiety. 2010 Jun 27(6):528-55. Review.
406. Koran LM, Bromberg D, Hornfeldt CS, Shepski JC, Wang S, Hollander E. Extended-release fluvoxamine and improvements in quality of life in patients with obsessive-compulsive disorder. Compr Psychiatry. 2010 Jul-Aug;51(4):373-9. Epub 2009 Dec 21.
407. Pallanti S, Haznedar MM, Hollander E, Licalzi EM, Bernardi S, Newmark R, Buchsbaum MS. Basal Ganglia activity in pathological gambling: a fluorodeoxyglucose-positron emission tomography study. Neuropsychobiology. 2010;62(2):132-8. Epub 2010 Jun 30.
408. Green JJ, Hollander E. Autism and oxytocin: new developments in translational approaches to therapeutics. Neurotherapeutics. 2010 Jul;7(3):250-7.
409. Berlin HA, Koran LM, Jenike MA, Shapira NA, Chaplin W, Pallanti S, Hollander E. Double-blind, placebo-controlled trial of topiramate augmentation in treatment-resistant obsessive-compulsive disorder. J Clin Psychiatry. 2011 May;72(5):716-21. Epub 2010 Aug 10.
410. Bartz JA, Zaki J, Bolger N, Hollander E, Ludwig NN, Kolevzon A, Ochsner KN. Oxytocin Selectivity Improves Empathic Accuracy. Psychol Sci. 2010 Oct 1;21(10):1426-8. Epub 2010 Sep 20.
411. Grant JE, Odlaug BL, Potenza MN, Hollander E, Kim SW. Nalmefene in the treatment of pathological gambling: multicentre, double-blind, placebo-controlled study. Br J Psychiatry. 2010 Oct;197(4):330-1. Erratum in: Br J Psychiatry. 2011 Jan;198:75.
412. Bartz J, Simeon D, Hamilton H, Kim S, Crystal S, Braun A, Vicens V, Hollander E. Oxytocin can hinder trust and cooperation in borderline personality disorder. Soc Cogn Affect Neurosci. 2011 Oct;6(5):556-63. Epub 2010 Nov 29.
413. Bernardi S, Anagnostou E, Shen J, Kolevzon A, Buxbaum JD, Hollander E, Hof PR, Fan J. In vivo 1H-magnetic resonance spectroscopy study of the attentional networks in autism. Brain Res. 2011 Mar 22; 1380:198-205. Epub 2010 Dec 23.
414. Berlin HA, Braun A, Simeon D, Koran LM, Potenza MN, McElroy SL, Fong T, Pallanti S, Hollander E. A double-blind, placebo-controlled trial of topiramate for pathological gambling. World J Biol Psychiatry. 2011 Apr 12 [Epub ahead of print]
415. Fineberg N, Chamberlain S, Hollander E, Boulougouris V, Robbins T. Translational approaches to obsessive-compulsive disorder: from animal models to clinical treatment. Br J Pharmacol. 2011 Oct;164(4):1044-61. Epub 2011 April 12.
416. Simeon D, Bartz J, Hamilton H, Crystal S, Braun A, Ketay S, Hollander E. Oxytocin administration attenuates stress reactivity in borderline personality disorder: A pilot study. Psychoneuroendocrinology. 2011 Oct; 36(9):1418-21. Epub 2011 May 3.
417. Hildebrandt T, Langenbucher JW, Lai JK, Loeb KL, Hollander E. Development and validation of the appearance and performance enhancing drug use schedule. Addict Behav. 2011 Oct;36(10):949-58. Epub 2011 May 11.
418. Scahill L, McCracken JT, Bearss K, Robinson F, Hollander E, King B, Bregman J, Sikich L, Dukes K, Sullivan L, Anagnostou E, Donnelly C, Kim YS, Ritz L, Hirtz D, Wagner A. Design and Subject Characteristics in the Federally-Funded Citalopram Trial in Children with Pervasive Developmental Disorders. J Autism Dev Disord. 2012 Mar;42(3):432-40. Epub 2011 Jun 11.
419. Anagnostou E, Chaplin W, Watner D, Silverman JM, Smith CJ, Zagursky K, Kryzak LA, Corwin TE, Feirsén N, Tanel N, Hollander E. Factor analysis of repetitive behaviors in Autism as measured by the Y-BOCS. J Neuropsychiatry Clin Neurosci. 2011 Summer;23(3):332-9

420. Marazziti D, Rossi L, Baroni S, Consoli G, Hollander E, Catena-Dell'osso M. Novel treatment options of binge eating disorder. Curr Med Chem. 2011 Nov 1;18(33):5159-64.
421. Hankin CS, Koran L, Sheehan DV, Hollander E, Culpepper L, Black DW, Knispel J, Dunn J, Dougherty DD, Bronstone A, Wang Z. Patients with obsessive-compulsive disorder vs depression have comparable health care costs: a retrospective claims analysis of Florida Medicaid enrollees. Ann Clin Psychiatry. 2011 Nov;23(4):285-96
422. Girgis RR, Slifstein M, Xu X, Frankle WG, Anagnostou E, Wasserman S, Pepa L, Kolevzon A, Abi-Dargham A, Laruelle M, Hollander E. The 5-HT(2A) receptor and serotonin transporter in Asperger's disorder: A PET study with [¹¹C]MDL 100907 and [¹¹C]DASB. Psychiatry Res. 2011 Dec 30;194(3):230-4. Epub 2011 Nov 12.
423. Ameis SH, Fan J, Rockel C, Voineskos AN, Lobaugh NJ, Soorya L, Wang AT, Hollander E, Anagnostou E. Impaired structural connectivity of socio-emotional circuits in autism spectrum disorders: a diffusion tensor imaging study. PLoS One. 2011;6(11):e28044. Epub 2011 Nov 23.
424. Hollander E, Soorya L, Chaplin W, Anagnostou E, Taylor BP, Ferretti CJ, Wasserman S, Swanson E, Settipani C. A Double-Blind Placebo-Controlled Trial of Fluoxetine for Repetitive Behaviors and Global Severity in Adult Autism Spectrum Disorders. Am J Psychiatry. 2012 Mar 1;169(3):292-9.
425. Bandelow B, Sher L, Bunevicius R, Hollander E, Kasper S, Zohar J, Moller HJ, WFSBP Task Force on Mental Disorders in Primary Care; WPSBP Task Force on Anxiety Disorders, OCD and PTSD. Guidelines for the pharmacological treatment of anxiety disorders, obsessive-compulsive disorder and posttraumatic stress disorder in primary care. Int J Psychiatry Clin Pract. 2012 Jun; 16(2):77-84.
426. Pallanti S, Di Rollo A, Antonini S, Cauli G, Hollander E, Quercioli L. Low-frequency rTMS over right dorsolateral prefrontal cortex in the treatment of resistant depression: cognitive improvement is independent from clinical response, resting motor threshold is related to clinical response. Neuropsychobiology. 2012 Jun; 65(4):227-35.
427. Fan J, Bernardi S, Dam NT, Anagnostou E, Gu X, Martin L, Park Y, Liu X, Kolevzon A, Soorya L, Grodberg D, Hollander E, Hof PR. Functional Deficits of the attentional networks in autism. Brain Behav. 2012 Sep; 2(5):647-60.
428. Anagnostou E, Soorya L, Chaplin W, Bartz J, Halpern D, Wasserman S, Wang AT, Pepa L, Tanel N, Kushki A, Hollander E. Intranasal oxytocin versus placebo in the treatment of adults with autism spectrum disorders: a randomized controlled trial. Mol Autism. 2012 Dec;3(1):16.
429. Hallett V, Lecavalier L, Sukhodolsky DG, Cipriano N, Aman MG, McCracken JT, McDougle CJ, Tierney E, King BH, Hollander E, Sikich L, Bregman J, Anagnostou E, Donnelly C, Katsoyich L, Dukes K, Vitiello B, Gadow K, Scahill L. Exploring the Manifestations of Anxiety in Children with Autism Spectrum Disorders. J Autism Dev Disord. 2013 Feb.
430. Van Ameringen M, Simpson W, Patterson B, Dell'osso B, Fineberg N, Hollander E, Hranov L, Hranov G, Lochner C, Karamustafalioglu O, Marazziti D, Menchon JM, Nicolini H, Pallanti S, Stein DJ, Zohar J Pharmacological treatment strategies in obsessive compulsive disorder: A cross-sectional view in nine international OCD centers. J Psychopharmacol. 2014 Jan 15.
431. Pallanti S, Bernardi S, Antonini S, Singh N, Hollander E. Ondansetron augmentation in patients with obsessive-compulsive disorder who are inadequate responders to serotonin reuptake inhibitors: Improvement with treatment and worsening following discontinuation. Eur Neuropsychopharmacol. 2013 Dec 11. pii: S0924-977X(13)00348-9. doi: 10.1016/j.euroneuro.2013.12.003. [Epub ahead of print]
433. Hollander E. Compulsivity and impulsivity-personal reflections: why now and why here? CNS Spectr. 2014 Feb;19(1):6-7. doi: 10.1017/S1092852913000886. Epub 2013 Nov 28.
434. Berlin GS, Hollander E. Compulsivity, impulsivity, and the DSM-5 process. CNS Spectr. 2014 Feb;19(1):62-8. doi: 10.1017/S1092852913000722. Epub 2013 Nov 7. Review.
435. Pallanti S, Hollander E. Pharmacological, experimental therapeutic, and transcranial magnetic stimulation treatments for compulsivity and impulsivity. CNS Spectr. 2014 Feb;19(1):50-61. doi: 10.1017/S1092852913000618. Epub 2013 Nov 1. Review

436. Benatti B, Dell'osso B, Arici C, Hollander E, Altamura AC. Characterizing impulsivity profile in patients with obsessive-compulsive disorder. Int J Psychiatry Clin Pract. 2014 Aug;18(3):156-60. doi: 10.3109/13651501.2013.855792. Epub 2013 Nov 13.
436. Hollander E. Social synchrony and oxytocin: from behavior to genes to therapeutics. Am J Psychiatry. 2013 Oct 1;170(10):1086-9. doi: 10.1176/appi.ajp.2013.13070848. No abstract available.
437. Hirota T, Veenstra-Vanderweele J, Hollander E, Kishi T. Antiepileptic Medications in Autism Spectrum Disorder: A Systematic Review and Meta-Analysis. J Autism Dev Disord. 2014 Apr;44(4):948-57. doi: 10.1007/s10803-013-1952-2. Review.
438. King BH, Dukes K, Donnelly CL, Sikich L, McCracken JT, Scahill L, Hollander E, Bregman JD, Anagnostou E, Robinson F, Sullivan L, Hirtz D. Baseline factors predicting placebo response to treatment in children and adolescents with autism spectrum disorders: a multisite randomized clinical trial. JAMA Pediatr. 2013 Nov;167(11):1045-52. doi: 10.1001/jamapediatrics.2013.2698.
439. Dell'Osso B, Benatti B, Buoli M, Altamura AC, Marazziti D, Hollander E, Fineberg N, Stein DJ, Pallanti S, Nicolini H, Van Ameringen M, Lochner C, Hranov G, Karamustafalioglu O, Hranov L, Menchon JM, Zohar J; ICOCS group. The influence of age at onset and duration of illness on long-term outcome in patients with obsessive-compulsive disorder: a report from the International College of Obsessive Compulsive Spectrum Disorders (ICOCS). Eur Neuropsychopharmacol. 2013 Aug;23(8):865-71. doi: 10.1016/j.euroneuro.2013.05.004. Epub 2013 Jun 21.
442. Doyle-Thomas KA, Duerden EG, Taylor MJ, Lerch JP, Soorya LV, Wang AT, Fan J, Hollander E, Anagnostou E. Effects of age and symptomatology on cortical thickness in autism spectrum disorders. Res Autism Spectr Disord. 2013 Jan;7(1):141-150.
444. Pallanti S, Bernardi S, Antonini S, Singh N, Hollander E. Ondansetron augmentation in patients with obsessive-compulsive disorder who are inadequate responders to serotonin reuptake inhibitors: improvement with treatment and worsening following discontinuation. Eur Neuropsychopharmacol. 2014 Mar;24(3):375-80. doi: 10.1016/j.euroneuro.2013.12.003. Epub 2013 Dec 11.
445. Hollander E. Compulsivity and impulsivity-personal reflections: why now and why here? CNS Spectr. 2014 Feb;19(1):6-7. doi: 10.1017/S1092852913000886. Epub 2013 Nov 28. PMID: 24284261
446. Van Ameringen M, Simpson W, Patterson B, Dell'Osso B, Fineberg N, Hollander E, Hranov L, Hranov G, Lochner C, Karamustafalioglu O, Marazziti D, Menchon JM, Nicolini H, Pallanti S, Stein DJ, Zohar J. Pharmacological treatment strategies in obsessive compulsive disorder: A cross-sectional view in nine international OCD centers. J Psychopharmacol. 2014 Jan 15;28(6):596-602. [Epub ahead of print]
447. Uzunova G, Hollander E, Shepherd J. The role of ionotropic glutamate receptors in childhood neurodevelopmental disorders: autism spectrum disorders and fragile x syndrome. Curr Neuropharmacol. 2014 Jan;12(1):71-98. doi: 10.2174/1570159X113116660046.
448. Pallanti S, Grassi G, Antonini S, Quercioli L, Salvadori E, Hollander E. rTMS in resistant mixed states: an exploratory study. J Affect Disord. 2014 Mar;157:66-71. doi: 10.1016/j.jad.2013.12.024. Epub 2013 Dec 28.

449. Lochner C, Fineberg NA, Zohar J, van Ameringen M, Juven-Wetzler A, Altamura AC, Cuzen NL, Hollander E, Denys D, Nicolini H, Dell'Osso B, Pallanti S, Stein DJ. Comorbidity in obsessive-compulsive disorder (OCD): a report from the International College of Obsessive-Compulsive Spectrum Disorders (ICOCS). Compr Psychiatry. 2014 Oct;55(7):1513-9. doi: 10.1016/j.comppsy.2014.05.020. Epub 2014 Jun 9.
450. Chaim CH, Nazar BP, Hollander E, Lessa JL. Pathological gambling treated with lithium: the role of assessing temperament. Addict Behav. 2014 Dec;39(12):1911-3. doi: 10.1016/j.addbeh.2014.05.016. Epub 2014 Jun 5.
451. Seibell PJ, Hollander E. Management of obsessive-compulsive disorder. F1000Prime Rep. 2014 Aug 1;6:68. doi: 10.12703/P6-68. eCollection 2014. Review.
452. Levkovitz Y, Isserles M, Padberg F, Lisanby SH, Bystritsky A, Xia G, Tendler A, Daskalakis ZJ, Winston JL, Dannon P, Hafez HM, Reti IM, Morales OG, Schlaepfer TE, Hollander E, Berman JA, Husain MM, Sofer U, Stein A, Adler S, Deutsch L, Deutsch F, Roth Y, George MS, Zangen A. Efficacy and safety of deep transcranial magnetic stimulation for major depression: a prospective multicenter randomized controlled trial. World Psychiatry. 2015 Feb;14(1):64-73. doi: 10.1002/wps.20199.
453. Bartz JA, Lydon JE, Kolevzon A, Zaki J, Hollander E, Ludwig N, Bolger N. Differential Effects of Oxytocin on Agency and Communion for Anxiously and Avoidantly Attached Individuals. Psychol Sci. 2015 Aug;26(8):1177-86. doi: 10.1177/0956797615580279. Epub 2015 Jun 29. PMID: 26122122
454. Simberlund J, Ferretti CJ, Hollander E. Mesenchymal stem cells in autism spectrum and neurodevelopmental disorders: pitfalls and potential promises. World J Biol Psychiatry. 2015 Jul 31:1-8. [Epub ahead of print]. PMID: 26230216
455. Dell'Osso B, Nicolini H, Lanzagorta N, Benatti B, Spagnolin G, Palazzo MC, Marazziti D, Hollander E, Fineberg N, Stein DJ, Pallanti S, Van Ameringen M, Lochner C, Hranov G, Karamustafalioglu O, Hranov L, Zohar J, Denys D, Altamura AC, Menchon JM. Cigarette smoking in patients with obsessive compulsive disorder: a report from the International College of Obsessive Compulsive Spectrum Disorders (ICOCS). CNS Spectr. 2015 Oct;20(5):469-73. doi: 10.1017/S1092852915000565. Epub 2015 Sep 9. PMID: 26349811
456. Uzunova G, Pallanti S, Hollander E. Excitatory/inhibitory imbalance in autism spectrum disorders: Implications for interventions and therapeutics. World J Biol Psychiatry. 2015 Oct 15:1-13. [Epub ahead of print]. PMID: 26469219
457. Shic F, Smith D, Horsburgh B, Hollander E, Rehg JM, Goodwin M. Catalysts for Change: The Role of Small Business Funders in the Creation and Dissemination of Innovation. J Autism Dev Disord. 2015 Dec;45(12):3900-4. doi: 10.1007/s10803-015-2636-x. PMID: 26481385
458. Grant JE, Fineberg N, van Ameringen M, Cath D, Visser H, Carmi L, Pallanti S, Hollander E, van Balkom AJ. New treatment models for compulsive disorders. Eur Neuropsychopharmacol. 2015 Nov 18. pii: S0924-977X(15)00358-2. doi: 10.1016/j.euroneuro.2015.11.008. [Epub ahead of print] PMID: 26621260
459. Pallanti S, Marras A, Salerno L, Makris N, Hollander E. Better than treated as usual: Transcranial magnetic stimulation augmentation in selective serotonin reuptake inhibitor-refractory obsessive-compulsive disorder, mini-review and pilot open-label trial. J Psychopharmacol. 2016 Feb 3. pii: 0269881116628427. [Epub ahead of print] PMID:26843373
460. Hunter SF, Agius M, Miller DM, Cutter G, Barbato L, McCague K, Meng X, Agashivala N, Chin P, Hollander E.

Impact of a switch to fingolimod on depressive symptoms in patients with relapsing multiple sclerosis: An analysis from the EPOC (Evaluate Patient Outcomes) trial. J Neurol Sci. 2016 Jun 15;365:190-8. doi: 10.1016/j.jns.2016.03.024. Epub 2016 Mar 22. PMID: 27206905

461. Hollander E, Hong K. Relapse Prevention and Need for Ongoing Treatment in Body Dysmorphic Disorder. Am J Psychiatry, (in press).

462. Sara B Vasudeva, Eric Hollander, MD Body Dysmorphic Disorder in Patients with Autism Spectrum Disorder: A Reflection of Increased Local Processing and Self-Focus. Am J Psychiatry (in press).

463. Hollander E, Uzunova G. Are there new advances in the pharmacotherapy of autism spectrum disorders? World Psychiatry (in press).

464. Hollander E, Doernberg E, Shavitt R, Waterman RJ, Soreni N, Veltman DJ, Sahakian BJ, Fineberg NA. The cost and impact of compulsivity: A research perspective. Eur Neuropsychopharmacol. 2016 May;26(5):800-9.

465. Pallanti S, Marras A, Salerno L, Makris N, Hollander E. Better than treated as usual: Transcranial magnetic stimulation augmentation in selective serotonin reuptake inhibitor-refractory obsessive-compulsive disorder, mini-review and pilot open-label trial. J Psychopharmacol. 2016 Jun;30(6):568-78.

466. Hunter SF, Agius M, Miller DM, Cutter G, Barbato L, McCague K, Meng X, Agashivala N, Chin P, Hollander E. Impact of a switch to fingolimod on depressive symptoms in patients with relapsing multiple sclerosis: An analysis from the EPOC (Evaluate Patient Outcomes) trial. J Neurol Sci. 2016 Jun 15;365:190-8.

467. Palkar P, Kabasakalian A, Taylor B, Doernberg E, Ferretti CJ, Uzunova G, Hollander E. Behavioral phenotype in a child with Prader-Willi syndrome and comorbid 47, XYY. Intractable Rare Dis Res. 2016 Aug;5(3):235-7

468. Doernberg E, Hollander E. Neurodevelopmental Disorders (ASD and ADHD): DSM-5, ICD-10, and ICD-11. CNS Spectr. 2016 Aug;21(4):295-9. doi: 10.1017/S1092852916000262.

469. Menchón JM, van Ameringen M, Dell'Osso B, Denys D, Figee M, Grant JE, Hollander E, Marazziti D, Nicolini H, Pallanti S, Ruck C, Shavitt R, Stein DJ, Andersson E, Bipeta R, Cath DC, Drummond L, Feusner J, Geller DA, Hranov G, Lochner C, Matsunaga H, McCabe RE, Mpavaenda D, Nakamae T, O'Kearney R, Pasquini M, Pérez Rivera R, Poyurovsky M, Real E, do Rosário MC, Soreni N, Swinson RP, Vulink N, Zohar J, Fineberg N. Standards of care for obsessive-compulsive disorder centres. Int J Psychiatry Clin Pract. 2016 Sep;20(3):204-8.

470. Dell'Osso B, Benatti B, Hollander E, Fineberg N, Stein DJ, Lochner C, Nicolini H, Lanzagorta N, Palazzo C, Altamura AC, Marazziti D, Pallanti S, Van Ameringen M, Karamustafalioglu O, Drummond LM, Hranov L, Figee M, Grant JE, Zohar J, Denys D, Menchon JM. Childhood, adolescent and adult age at onset and related clinical correlates in obsessive-compulsive disorder: a report from the International College of Obsessive-Compulsive Spectrum Disorders (ICOCS). Int J Psychiatry Clin Pract. 2016 Nov;20(4):210-7.

471. Dell'Osso B, Benatti B, Hollander E, Altamura AC. Clinical features associated with increased severity of illness in tertiary clinic referred patients with obsessive compulsive disorder. Int J Psychiatry Clin Pract. 2016 Nov 4:1-6. [Epub ahead of print]

472. Umbricht D, Del Valle Rubido M, Hollander E, McCracken JT, Shic F, Scahill L, Noeldeke J, Boak L, Khwaja O, Squassante L, Grundschober C, Kletzl H, Fontoura P. A Single Dose, Randomized, Controlled Proof-Of-Mechanism Study of a Novel Vasopressin 1a Receptor Antagonist (RG7713) in High-Functioning Adults with Autism Spectrum Disorder. Neuropsychopharmacology. 2016 Nov 16. [Epub ahead of print]

473. Mitelman SA, Bralet MC, Haznedar MM, Hollander E, Shihabuddin L, Hazlett EA, Buchsbaum MS. Diametrical relationship between gray and white matter volumes in autism spectrum disorder and schizophrenia. Brain Imaging Behav. 2016 Nov 23. [Epub ahead of print]

474. Dell'Osso B, Benatti B, Altamura AC, Hollander E. Prevalence of Selective Serotonin Reuptake Inhibitor-Related Apathy in Patients With Obsessive Compulsive Disorder. J Clin Psychopharmacol. 2016 Dec;36(6):725-726.
475. Hollander E, Uzunova G. Are there new advances in the pharmacotherapy of autism spectrum disorders? World Psychiatry. 2017 Feb;16(1):101-102.
476. Dell'Osso B, Benatti B, Arici C, Palazzo C, Altamura AC, Hollander E, Fineberg N, Stein DJ, Nicolini H, Lanzagorta N, Marazziti D, Pallanti S, van Ameringen M, Lochner C, Karamustafalioglu O, Hranov L, Figuee M, Drummond L, Rodriguez CI, Grant J, Denys D, Menchon JM, Zohar J. Prevalence of suicide attempt and clinical characteristics of suicide attempters with obsessive-compulsive disorder: a report from the International College of Obsessive-Compulsive Spectrum Disorders (ICOCS). CNS Spectr. 2017 Mar 16:1-8. [Epub ahead of print]
477. Vasudeva SB, Hollander E. Body Dysmorphic Disorder in Patients With Autism Spectrum Disorder: A Reflection of Increased Local Processing and Self-Focus. Am J Psychiatry. 2017 Apr 1;174(4):313-316.
478. Mitelman SA, Bralet MC, Mehmet Haznedar M, Hollander E, Shihabuddin L, Hazlett EA, Buchsbaum MS. Positron emission tomography assessment of cerebral glucose metabolic rates in autism spectrum disorder and schizophrenia. Brain Imaging Behav. 2017 Apr 19. [Epub ahead of print]
479. Chiarello F, Spitoni S, Hollander E, Matucci Cerinic M, Pallanti S. An Expert Opinion on PANDAS/PANS: Highlights and Controversies. International journal of psychiatry in clinical practice. 2017 Apr 3;21(2):91-8.
480. Umbricht D, del Valle Rubido M, Hollander E, McCracken JT, Shic F, Scahill L, Noeldeke J, Boak L, Khwaja O, Squassante L, Grundschober C. A Single Dose, Randomized, Controlled Proof-of-Mechanism Study of a Novel Vasopressin 1a Receptor Antagonist (RG7713) in High-Functioning Adults with Autism Spectrum Disorder. Neuropsychopharmacology. 2017 Aug;42(9):1914.
490. Mitelman SA, Buchsbaum MS, Young DS, Haznedar MM, Hollander E, Shihabuddin L, Hazlett EA, Bralet MC. Increased White Matter Metabolic Rates in Autism Spectrum Disorder and Schizophrenia. Brain imaging and Behavior. 2017 Nov 22:1-6.
491. Dell'Osso, B., Benatti, B., Rodriguez, C.I., Arici, C., Palazzo, C., Altamura, A.C., Hollander, E., ... & Zohar, J. (2017) Obsessive-compulsive disorder in the elderly: A report from the International College of Obsessive-Compulsive Spectrum Disorders (ICOCS). European Psychiatry, 45, 36 – 40
423. Kabasakalian A., Ferretti C.J., Hollander E. (2017) Oxytocin and Prader-Willi Syndrome. In: Hurlmann R., Grinevich V. (eds) Behavioral Pharmacology of Neuropeptides: Oxytocin. Current Topics in Behavioral Neurosciences, vol 35. Springer, Cham
493. Mitelman, S. A., Bralet, M. C., Haznedar, M. M., Hollander, E., Shihabuddin, L., Hazlett, E. A., & Buchsbaum, M. S. (2018). Positron emission tomography assessment of cerebral glucose metabolic rates in autism spectrum disorder and schizophrenia. Brain imaging and behavior, 12(2), 532-546.
494. Hong, K., Nezgovorova, V., Uzunova, G., Schluskel, D., & Hollander, E. (2018). Pharmacological Treatment of Body Dysmorphic Disorder. Current neuropsychopharmacology.
495. Burchi, E., Hollander, E., & Pallanti, S. (2018). From treatment response to recovery: a realistic goal in OCD. International Journal of Neuropsychopharmacology, 21(11), 1007-1013.
496. Hollander, E., Uzunova, G., Taylor, B. P., Noone, R., Racine, E., Doernberg, E.,... & Ferretti, C. J. (2018). Randomized crossover feasibility trial of helminthic Trichuris suis ova versus placebo for repetitive behaviors in adult autism spectrum disorder. The World Journal of Biological Psychiatry, 1-9.
497. Del Valle Rubido, M., McCracken, J. T., Hollander, E., Shic, F., Noeldeke, J., Boak, L., ... & Umbricht, D. (2018). In Search of Biomarkers for Autism Spectrum Disorder. Autism Research, 11(11), 1567-1579.

498. Fineberg, N. A., Demetrovics, Z., Stein, D. J., Ioannidis, K., Potenza, M. N., Grünblatt, E., ...Hollander, E., ... & Grant, J. E. (2018). Manifesto for a European research network into Problematic Usage of the Internet. *European Neuropsychopharmacology*, 28(11), 1232-1246.
499. Hollander, E., Jacob, S., Jou, R., McNamara, N., Sikich, L., Tobe, R., Smith, J., Sanders, K., Squassante, L., Murtagh, L., Gleissl, T., Wandel, C., & Veenstra-VanderWeele, J. (2022). Balovaptan vs Placebo for Social Communication in Childhood Autism Spectrum Disorder: A Randomized Clinical Trial. *JAMA psychiatry*, 79(8), 760–769. <https://doi.org/10.1001/jamapsychiatry.2022.1717>
500. Bradshaw, J., Gillespie, S., McCracken, C., King, B. H., McCracken, J. T., Johnson, C. R., Lecavalier, L., Smith, T., Swiezy, N., Bearss, K., Sikich, L., Donnelly, C., Hollander, E., McDougale, C. J., & Scahill, L. (2021). Predictors of Caregiver Strain for Parents of Children with Autism Spectrum Disorder. *Journal of autism and developmental disorders*, 51(9), 3039–3049. <https://doi.org/10.1007/s10803-020-04625-x>
501. Carmi, L., Tendler, A., Bystritsky, A., Hollander, E., Blumberger, D. M., Daskalakis, J., Ward, H., Lapidus, K., Goodman, W., Casuto, L., Feifel, D., Barnea-Ygaël, N., Roth, Y., Zangen, A., & Zohar, J. (2022). Efficacy and Safety of Deep Transcranial Magnetic Stimulation for Obsessive-Compulsive Disorder: A Prospective Multicenter Randomized Double-Blind Placebo-Controlled Trial. *Focus (American Psychiatric Publishing)*, 20(1), 152–159. <https://doi.org/10.1176/appi.focus.20103>
502. Jacob, S., Anagnostou, E., Hollander, E., Jou, R., McNamara, N., Sikich, L., Tobe, R., Murphy, D., McCracken, J., Ashford, E., Chatham, C., Clinch, S., Smith, J., Sanders, K., Murtagh, L., Noeideke, J., & Veenstra-VanderWeele, J. (2022). Large multicenter randomized trials in autism: key insights gained from the balovaptan clinical development program. *Molecular autism*, 13(1), 25. <https://doi.org/10.1186/s13229-022-00505-6>
503. Benatti, B., Celebre, L., Girone, N., Priori, A., Bruno, A., Viganò, C., Hollander, E., & Dell'Osso, B. (2020). Clinical characteristics and comorbidity associated with female gender in obsessive-compulsive disorder. *Journal of psychiatric research*, 131, 209–214. <https://doi.org/10.1016/j.jpsychires.2020.09.019>
504. Del Valle Rubido, M., Hollander, E., McCracken, J. T., Shic, F., Noeideke, J., Boak, L., Khwaja, O., Sadikhov, S., Fontoura, P., & Umbricht, D. (2020). Exploring Social Biomarkers in High-Functioning Adults with Autism and Asperger's Versus Healthy Controls: A Cross-Sectional Analysis. *Journal of autism and developmental disorders*, 50(12), 4412–4430. <https://doi.org/10.1007/s10803-020-04493-5>
505. Taylor, B. P., Liu, J., Mowrey, W., Eule, E., Bolognani, F., & Hollander, E. (2022). The Montefiore-Einstein Rigidity Scale-Revised (MERS-R): Development, administration, reliability, and validity in child and adult Autism Spectrum Disorder (ASD). *Journal of psychiatric research*, 147, 142–147. <https://doi.org/10.1016/j.jpsychires.2021.12.055>
506. Benatti, B., Girone, N., Celebre, L., Vismara, M., Hollander, E., Fineberg, N. A., Stein, D. J., Nicolini, H., Lanzagorta, N., Marazziti, D., Pallanti, S., van Ameringen, M., Lochner, C., Karamustafalioglu, O., Hranov, L., Figuee, M., Drummond, L. M., Grant, J. E., Denys, D., Fontenelle, L. F., ... Dell'Osso, B. (2022). The role of gender in a large international OCD sample: A Report from the International College of Obsessive-Compulsive Spectrum Disorders (ICOCS) Network. *Comprehensive psychiatry*, 116, 152315. <https://doi.org/10.1016/j.comppsy.2022.152315>
507. Simonoff, E., Mowlem, F., Pearson, O., Anagnostou, E., Donnelly, C., Hollander, E., King, B. H., McCracken, J. T., Scahill, L., Sikich, L., & Pickles, A. (2022). Citalopram Did Not Significantly Improve Anxiety in Children with Autism Spectrum Disorder Undergoing Treatment for Core Symptoms: Secondary Analysis of a Trial to Reduce Repetitive Behaviors. *Journal of child and adolescent psychopharmacology*, 32(4), 233–241. <https://doi.org/10.1089/cap.2021.0137>
508. Del Valle Rubido, M., Hollander, E., McCracken, J. T., Shic, F., Noeideke, J., Boak, L., Khwaja, O., Sadikhov, S., Fontoura, P., & Umbricht, D. (2020). Correction to: Exploring Social Biomarkers in High-Functioning Adults with Autism and Asperger's Versus Healthy Controls: A Cross-Sectional Analysis. *Journal of autism and developmental disorders*, 50(12), 4431–4432. <https://doi.org/10.1007/s10803-020-04522-3>
509. Hollander, E., Levine, K. G., Ferretti, C. J., Freeman, K., Doernberg, E., Desilva, N., & Taylor, B. P. (2021). Intranasal oxytocin versus placebo for hyperphagia and repetitive behaviors in children with Prader-Willi Syndrome: A

randomized controlled pilot trial. *Journal of psychiatric research*, 137, 643–651.
<https://doi.org/10.1016/j.jpsychires.2020.11.006>

510. Tobe, R., Zhu, Y., Gleissl, T., Rossomanno, S., Veenstra-VanderWeele, J., Smith, J., & Hollander, E. (2023). Predictors of placebo response in three large clinical trials of the V1a receptor antagonist balovaptan in autism spectrum disorder. *Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology*, 10.1038/s41386-023-01573-9. Advance online publication. <https://doi.org/10.1038/s41386-023-01573-9>

B1. Edited and Authored Books:

1. Hollander E (editor): Obsessive-Compulsive Related Disorders. American Psychiatric Press, Inc. Washington, DC, 1993.
2. Hollander E, Zohar J, Marazziti D, Olivier B (editors): Current Insights in Obsessive Compulsive Disorder. John Wiley and Sons, Ltd. Sussex, England, 1994.
3. Hollander E, Stein DJ (editors): Impulsivity and Aggression. John Wiley and Sons, Ltd., Sussex, England, 1995.
4. Oldham JO, Hollander E, Skodol A (editors): Impulsivity and Compulsivity. American Psychiatric Press, Inc., Washington, DC, 1995.
5. Sanchez-Plannell J, Hollander E (editors): Controversies in Dysmorphophobia and Body Dysmorphic Disorder. American Psychiatric Press, Inc., Washington, DC (in press).
6. Hollander E, Stein DJ (editors): Obsessive Compulsive Disorders. Marcel Dekker, Inc., New York, NY, 1997.
7. Stein DJ, Hollander E (editors): Trichotillomania: New Developments. American Psychiatric Press, Inc., Washington, DC, 1999.
8. Simeon D, Hollander E (editors): Self-Injurious Behaviors: Assessment and Treatment. American Psychiatric Press, Inc., Washington, DC, 2001.
9. Hollander E, Wong CM: Contemporary Diagnosis and Management of Depression, Anxiety, and Obsessive-Compulsive Disorders. Handbooks in Health Care Company, 2000.
10. Summers M, with Eric Hollander, M.D.: Everything In Its Place: My Trials and Triumphs With Obsessive Compulsive Disorder. Penguin Putnam, New York, 1999.
11. Stein DJ and Hollander E. Anxiety disorders comorbid with depression: social anxiety disorder, post-traumatic stress disorder, generalized anxiety disorder and obsessive-compulsive disorder. Martin Dunitz Ltd., London, England, 2002.
12. Hollander E, Simeon D. Concise Guide to Anxiety Disorders. American Psychiatric Publishing Inc., Washington, D.C., 2003.
13. Stein DJ, Hollander E (editors): Textbook of Anxiety Disorders. American Psychiatric Publishing, Inc., Washington, DC, 2002.
14. Stein DJ, Hollander E (editors): Tratado de los Trastornos de Ansiedad. Ars Medica, Barcelona, Spain, 2004.
15. Hollander E (editor): Autism Spectrum Disorders. Marcel Dekker, Inc., New York, 2003.

16. Hollander E, Evers M (editor): Contemporary Diagnosis and Management of Mood and Anxiety Disorders. Handbooks In Health Care Company, 2003.
17. Hollander E, Bakalar N. Coping with Social Anxiety: The Definitive Guide to Effective Treatment Options. Henry Holt and Company, New York, 2005.
18. Hollander E, Stein DJ (editors): Clinical Manual of Impulse Control Disorders. American Psychiatric Publishing, Inc., Washington, DC, 2006.
19. Hollander E, Anagnostou E (editors): Clinical Manual for the Treatment of Autism. American Psychiatric Publishing, Inc., Washington, DC, 2007.
20. Stein DJ, Hollander E, Rothbaum B: Textbook of Anxiety Disorders (second edition). American Psychiatric Publishing, Inc., Washington, DC, 2009.
21. Hollander E, Klevzon A, Coyle J: Textbook of Autism Spectrum Disorders. American Psychiatric Publishing, Inc., Washington, DC, 2010.
22. Hollander E, Zohar J, Sirovatka PJ, Regier DA (editors): Obsessive-Compulsive Spectrum Disorders: Refining the Research Agenda for DSM-V. American Psychiatric Association, Arlington, VA, 2011
23. Hollander E, Fine D, Hagerman R (editors): Autism Spectrum Disorders. American Psychiatric Publishing, Inc. Arlington, VA (2018).

B2. Book Chapters and Review Articles:

1. Johns CA, Mohs RC, Hollander E, Davis BM, Greenwald BS, Horvath TB, Davis KL. Clinical studies of the cholinergic deficit in Alzheimer's disease. In: International Conference: The Dynamics of Cholinergic Function, Monograph edited by I. Hanin. Plenum Press, New York, 1986.
2. Hollander E, Liebowitz MR, Gorman JM. Anxiety disorders. In: American Psychiatric Press Textbook of Psychiatry, Talbott JA, Hales RE, Yudofsky SG, eds. American Psychiatric Press, Washington, D.C., 1988, pp. 443-493.
3. Hollander E, Fay M, Klein DF, Liebowitz MR. Catecholaminergic and monoaminergic effects in obsessive-compulsive disorder. In: Progress in Catecholamine Research, Part C: Clinical Aspects, edited by Belmaker KH, Sandler M, Dahlstrom A. New York:Alan R. Liss, Inc., 1988, pp. 377-383.
4. Davidson M, Hollander E, Cohen L, Mohs R, Davis KL: Cholinergic agonists in Alzheimer disease patients. In: Current Research In Alzheimer Therapy, edited by E. Jacobini and R. Becker. Taylor and Francis, Inc., New York, 1988, pp. 333-337.
5. Hollander E, Kapell LA, Mohs RC, Davidson M, Davis BM, Horvath TB, Davis KL. Oral Physostigmine in the treatment of Alzheimer's disease. Geriatric Medicine Today 6(4): 68-76, 1987.
6. Liebowitz MR, Fyer AJ, Gorman JM, Campeas RB, Sandberg DP, Hollander E, Papp LA, Klein DF. Tricyclic therapy of the DSM-III anxiety disorders: a review with implications for further research. J Psychiatry Res 22 (suppl 1):7-31, 1988.
7. Hollander E, DeCaria C, Liebowitz MR. Biological aspects of obsessive compulsive disorder. Psychiatry Digest 9:6-8, 1989.
8. Hollander E, Liebowitz MR, DeCaria CM. Conceptual and methodological issues in studies of obsessive-compulsive and Tourette's disorders. Psychiatr Dev 7(4):267-296, 1989.

9. Hollander E, Klein DF. Differential diagnosis of anxiety disorders. In Panic Anxiety States, edited by P. Kielholz, C. Adams. Deutscher Arzte-Verlag, Koln, 1989.
10. Hollander E, Klein DF. Medication. In: Handbook of Phobia Therapy: Rapid Symptom Relief In Anxiety Disorders, Lindemann C (ed.) Northvale, N.J.: Jason Aronson, Inc., 1989, pp. 405-425.
11. Hollander E, Levin AJ, Liebowitz MR. Biological tests in the differential diagnosis of anxiety disorders. In Clinical Aspects of Panic Disorder, Ballanger J, ed. New York, Wiley-Liss, 1990, pp. 29-44.
12. Hollander E, Liebowitz MR. Generalized anxiety disorders and panicogenic syndromes. In: Anxiety and the Heart, Byrne DG and Roserman R, eds. New York, Hemisphere Publishing Corp., 1990, pp. 53-72.
13. Liebowitz MR, Hollander E. Obsessive-compulsive disorder: psychobiological integration. In: Psychobiology of Obsessive Compulsive Disorder, Zohar J, Insel TR, Rasmussen S, eds. New York, Springer Publishing, 1991, pp. 227-255.
14. Hollander E, Hatterer J, Klein DF. Antidepressants for the treatment of panic and agoraphobia. In: Handbook of Anxiety Disorders Vol. 4: The Treatment of Anxiety, Noyes R, Roth M, Burrows GD, eds. Elsevier Science Publishers B.V., Amsterdam 1990, pp. 207-232.
15. Hollander E. Serotonergic drugs and the treatment of disorders related to obsessive-compulsive disorder. In: Current Treatments of Obsessive-Compulsive Disorder, Pato M, Zohar J, eds. American Psychiatric Press, Inc., Washington, DC, 1991, pp. 173-191.
16. Hollander E, Liebowitz MR, Rosen WT. Neuropsychiatric and neuropsychological studies in obsessive compulsive disorder. In: Psychobiology of Obsessive Compulsive Disorder, Zohar J, Insel TR, Rasmussen S, eds. New York, Springer Publishing Co., 1991, pp. 126-145.
17. Stein D, Hollander E. Anxiety: stress. In Mental Health in the Workplace: A Practical Psychiatric Guide, edited by Kahn JP. Van Nostrand Reinhold, New York, 1993, pp. 241-272.
18. Hollander E. Introduction. In: Obsessive-Compulsive Related Disorders. Hollander E, ed. American Psychiatric Press, Washington, DC 1993, pp. 1-16.
19. Josephson SC, Hollander E. Am I hypochondriac? OCD Newsletter 4:5-8, 1990.
20. Hollander E, Schiffman E, Cohen B, Rivera-Stein MA, Rosen W, Gorman JM, Fyer AJ, Papp L, Liebowitz MR. Signs of central nervous system dysfunction in obsessive-compulsive disorder. Psychiatry Digest 7:11-12, 1990 and Arch Gen Psychiatry 47(1):27-32, 1990.
21. Hollander E, Schiffman E, Cohen B, Rivera-Stein M, Rosen W, Gorman JM, Fyer AJ, Papp L, Liebowitz MR. Signos de disfuncion del sistema nervioso central en el trastorno obsesivo-compulsivo. Psychiatry Digest 1:8-9, 1991.
22. Hollander E, Nunes E, DeCaria CM, Quitkin F, Cooper TB, Klein DF. Dopaminergic sensitivity and cocaine abuse: response to apomorphine. Psychiatry/Neurology Digest (in press).
23. Hollander E, DeCaria CM, Frenkel M, Stein D, Truongold S. Compulsive gambling, body dysmorphic disorder and Tourette's syndrome: obsessive-compulsive related disorders. OCD Newsletter May, 1991. pp. 6.
24. Phillips KA, Hollander E. Body dysmorphic disorder: DSM IV source book review. In: Volume II DSM IV Source Book, Widiger TA, Frances AJ, Pincus HA, et al, eds. American Psychiatric Press, Inc., Washington, DC (in press).
25. Hollander E, Stein D, DeCaria CM, Frenkel M, Truongold S, Liebowitz MR. Obsessive compulsive related disorders. Biological Psychiatry, Vol. 1. Excerpta Medica International Congress Series, Racagni G, Brunello N, Fukuda T, eds. Elsevier Science Publishers, Amsterdam, pp. 680-682, 1991.

26. Stein DJ, Hollander E. Cognitive science and obsessive-compulsive disorder. In: Cognitive Science and Clinical Disorders, Young JE, Stein DJ, eds. Academic Press, San Diego, CA, 1992, pp. 235-246.
27. Liebowitz MR, Schneier FR, Hollander E, Welkowitz LA, Saoud JB, Feerick J, Campeas R, Fallon B, Street L, Gitow A. Treatment of social phobia with drugs other than benzodiazepines. J Clin Psychiatry 52(suppl)10-15, 1991.
28. Anthony D, Hollander E. Sexual compulsions. In: Obsessive-Compulsive Related Disorders, Hollander E, ed. American Psychiatric Press, Inc., Washington, DC, 1993, pp. 139-150.
29. DeCaria CM, Hollander E. Pathological (Compulsive) Gambling. In: Obsessive-Compulsive Related Disorders, Hollander E, ed. American Psychiatric Press, Inc., Washington, DC, 1993, pp. 151-178.
30. Hollander E, DeCaria C, Nitsescu A, Cooper T, Stover B, Gulley R, Klein DF, Liebowitz MR. Noradrenergic function in obsessive compulsive disorder and normal controls: neuroendocrine and behavioral responses to clonidine challenge. Psychiatry Digest 3:29-30, 1992.
31. Stein DJ, Hollander E. Pharmacotherapy of borderline personality disorder. International Psychiatry Today 2:1-9, 1992.
32. Hollander E, Phillips KA. Body image and experience disorders. In: Obsessive Compulsive Related Disorders, Hollander E, ed. American Psychiatric Press, Inc., Washington, DC, 1993, pp. 17-48.
33. Hollander E, Stein DJ, DeCaria CM. Impulsivity and compulsivity: symptoms and diagnosis. International Psychiatry Today 2:11-12, 1993.
34. Stein DJ, Hollander E. Trichotillomania: neurobiological and psychosocial perspectives. In: Loss, Grief and Care, edited by Kutscher AH. (in press).
35. Stein DJ, Hollander E, Islam MM, Saoud J, DeCaria CM, Cohen L, Mullen L. Impulsive and compulsive symptoms and the obsessive-compulsive spectrum. Harvard J Psychiatry (in review).
36. Stein DJ, Hollander E, Klein DF. Biological markers of depression and anxiety. Medicographia 16:18-21, 1994.
37. Simeon D, Hollander E. Anxiety disorders, phobias and obsessive-compulsive disorders. In: Core Readings in Psychiatry. An Annotated Guide to the Literature. Sacks MH, Sledge WH, Warren C, eds. American Psychiatric Press, Inc., Washington, DC, 1995.
38. Hollander E, Simeon D, Gorman JG. Anxiety Disorders. In: The American Psychiatric Press Textbook of Psychiatry (2nd Edition), Hales RE, Yudofsky SC, Talbott JA, eds. American Psychiatric Press, Inc., Washington, DC, 1994, pp. 495-564.
39. Hollander E. Obsessive-compulsive spectrum disorders. Progress Notes 4(1)2-4, 1993.
40. Simeon D, Hollander E. Self-mutilation and the relationship to OCD. OCD Newsletter 7:(1)6;1993.
41. Hwang M, Hollander E. Delusional OCD. OCD Newsletter 7:8, 1993.
42. Hollander E, Cohen L. OCD in African-Americans: psychobiology and psychopharmacology. In: Anxiety Disorders in African-Americans, Friedman S, ed. Springer Press, 1994, pp. 185-202.
43. Stein DJ, Hollander E. The spectrum of obsessive-compulsive related disorders. In: Obsessive-Compulsive Related Disorders, Hollander E, ed. American Psychiatric Press, Inc., Washington, DC, 1993, pp. 241-272.
44. Stein DJ, Hollander E, Cohen L. Neuropsychiatry of OCD. In: Olivier B, Hollander E, Marazziti D, Zohar J, eds. Obsessive Compulsive Disorder. John Wiley and Sons, Ltd. Sussex, England, pp. 167-182.

45. Stein DJ, Patterson R, Hollander E. Expert systems for psychiatric pharmacotherapy. Psychiatric Annals 24(1):37-41, 1994.
46. Hollander E. Potential clinical applications of serotonin drugs. International Clinical Psychopharmacology Serotonin Supplement (in press).
47. Simeon D, Hollander E, Cohen L. Obsessive-compulsive related disorders. In: Olivier B, Hollander E, Marazziti D, Zohar J, eds. Obsessive-Compulsive Disorder. John Wiley and Sons, Ltd. Sussex, England, pp. 53-63.
48. Stein DJ, Simeon D, Hollander E. Imagined ugliness and plastic surgery: current research on body dysmorphic disorder. In: Psychosocial Aspects of Plastic Surgery (in press).
49. Stein DJ, Hollander E, DeCaria C. Personality disorders and OCD. In: Hollander E, Zohar J, Marazziti D, Olivier B, eds. Obsessive-Compulsive Disorder. John Wiley and Sons, Ltd., Sussex, England, pp. 41-51.
50. Stein DJ, Hollander E, Klein DF. Anxio-depression: evolution des idees. In: Olie JP, Poirier MF, Loo H. Les Maladies Depressives. Paris: Flammarion, 1995.
51. Stein DJ, Towey J, Hollander E. Neuropsychiatry of impulsive-aggression. In: Impulsivity and Aggression, Hollander E, Stein DJ, John Wiley and Sons, Sussex, England, pp. 91-105.
52. Greist J, Hollander E, Jenike M. Obsessive compulsive disorder: a monograph. Health Science Media, Atlanta, Georgia, 1994.
53. Greist J, Hollander E, Jenike M. Obsessive compulsive disorder: a video. Health Science Media, Atlanta, Georgia, 1994.
54. Hollander E, Cohen LJ. The psychobiology and psychopharmacology of compulsive spectrum disorders. In: Impulsivity and Compulsivity, Oldham J, Hollander E, Skodol A, eds. American Psychiatric Press, Inc., pp. 143-166, 1996.
55. Stein DJ, Hollander E. Sexual dysfunction associated with the drug treatment of psychiatric disorders: incidence and treatment. CNS Drugs 2(1):78-86, 1994.
56. Hollander E. Review article: disorders related to OCD. Focus on OCD 2(1):2-3, 1994.
57. Hollander E. Treatment of obsessive-compulsive disorder. Currents of Affective Illness. (August, 1994)
58. Hollander E. Treatment of obsessive compulsive spectrum disorders. Currents of Affective Illness. (September, 1994)
59. Hollander E. Commentary: related disorders. Focus on OCD 2(1):12-13, 1994.
60. Stein DJ, Hollander E. Serotonin specific re-uptake inhibitors in obsessive compulsive disorder and related disorders. In: Feighner J and Boyer WF, eds. Selective Serotonin Re-Uptake Inhibitors: Advances In Basic Research and Clinical Practice. John Wiley & Sons, Ltd., Sussex, England, pp. 135-153, 1996.
61. Grossman R, Simeon D, Hollander E. Depersonalization disorder. In: Obsessive-Compulsive Disorder Casebook, Volume II: Spectrum Disorders (in press).
62. Hollander E, Wong C. Developments in the treatment of obsessive-compulsive disorder. Primary Psychiatry 2:28-33, 1995.
63. Wong C, Hollander E. Other impulse control disorders (kleptomania, compulsive buying, pathological gambling, pyromania). In: Obsessive Compulsive Disorder Casebook, Volume II: Spectrum Disorders (in press).

64. Cohen LJ, Stein D, Hollander E. Towards an integration of psychological and biological models of OCD: phylogenetic considerations. Am J Psychiatry (in review).
65. Hollander E, Simeon D, Gorman JM. Anxiety disorders. In: Synopsis of Psychiatry, Hales RE and Yudofsky SC. American Psychiatric Press, Inc., Washington, DC, 1996, pp. 469-524.
66. Hollander E, Badenoch J. New developments in the treatment of OCD. Treatment Today 7:44-45, 1995.
67. Wong C, Hollander E. Obsessive-compulsive spectrum disorders. OCD Newsletter, June 1995.
68. DeCaria CM, Aronowitz BR, Twersky-Kengmana R, Hollander E. Neuropsychology of childhood mental disorders: integration of phenomenological, neurobiological and neuropsychological findings. In: Neuropsychological Functions in Psychiatric Disorders, Calev A, ed., American Psychiatric Press, Inc., Washington, DC, pp 135-231, 1999.
69. Hollander E, Stein D. Preface. In: Obsessive-Compulsive Disorders: Etiology, Diagnosis and Treatment. New York: Marcel Dekker, Inc., v-viii, 1997.
70. Stein D, Hollander E. Obsessive-compulsive spectrum disorders. In: Obsessive-Compulsive Disorders: Etiology, Diagnosis, and Treatment. New York: Marcel Dekker, Inc., 47-74. 1997.
70. Cohen L, Stein D, Hollander E. Neuropsychiatry of OCD. In: Obsessive-Compulsive Disorders: Etiology, Diagnosis, and Treatment. New York: Marcel Dekker, Inc., 75-88, 1997.
71. Stein D, Simeon D, Hollander E. Neurochemistry of OCD. In: Obsessive-Compulsive Disorders: Etiology, Diagnosis, and Treatment. New York: Marcel Dekker, Inc., 89-98, 1997.
72. Grossman R, Hollander E. Body dysmorphic disorder. In: Current Psychiatric Therapy II, Dunner D, ed. Philadelphia: W.B. Saunders Company, 1996, p. 364-368.
73. Dager SR, Hollander E. Obsessive compulsive disorder (OCD). In: Current Psychiatric Therapy II, Dunner D, ed. Philadelphia: W.B. Saunders Company, 1996, p. 322-326.
74. Wong CM, Hollander E. New dimensions in the OCD spectrum: autism, pathological gambling and compulsive buying. Primary Psychiatry 3:20-34, 1996.
75. Grossman R, Hollander E. Compulsive self-injurious behaviors. OCF Newsletter (in press).
76. Hollander E, Chapman A. Obsessive-compulsive spectrum disorders. In: Proceedings of the Freiburg Obsessive Compulsive Conference, Hohagen F, ed. (in press).
77. Cherkasky S, Hollander E. Neuropsychiatric aspects of impulsivity and aggression. In American Psychiatric Press Textbook of Neuropsychiatry, Third Edition. Yudofsky SC, Hales RE, eds. Washington, D.C.: American Psychiatric Press, 485-500, 1997.
78. Foa EB, Jenike M, Kozak MJ, Joffe R, Baer L, Pauls D, Beidel DC, Rasmussen SA, Goodman W, Swinson RP, Hollander E, Turner SM. Obsessive compulsive disorder. In: DSM-IV Sourcebook, Volume 2. Widiger TA, Frances AJ, Pincus HA, Ross R, First MB, Davis WW, eds. American Psychiatric Press, Inc., Washington, DC, 1996, pp. 549-575.
79. Simeon D, Hollander E. Anxiety disorders, phobias, and obsessive-compulsive disorder. In Core Readings in Psychiatry: An Annotated Guide to the Literature, Second Edition. Sachs MH, Sledge WH, Warren C, eds. American Psychiatric Press, Inc., Washington, DC, 1995, pp. 173-193.
80. Phillips KA, Hollander E. Body dysmorphic disorder. In DSM-IV Sourcebook, Volume 2. Widiger TA, Frances AJ, Pincus HA, Ross R, First MB, Davis WW, eds. American Psychiatric Press, Inc., Washington, DC, 1996, pp. 949-960.

81. Cherkasky S, Hollander E. Obsessive compulsive disorder. Int Rev Psychiatry (in press).
82. Hollander E, Stein D, Kwon J, Broatch J, Himelein C, Rowland C. A pharmacoeconomic and quality of life study of OCD. OC Newsletter, p. 7, Apr 1996.
83. Aronowitz BR, Hollander E. Treating the treatment resistant patient. In den Boer JA, Westenberg HGM, eds. Focus on Obsessive Compulsive Disorder (in press).
84. Hollander E, Jenike MA, Shahady EJ. Help for hands that can't stop washing. Patient Care 30:66-68, 1996.
85. Wong CM, Hollander E. Autism and related disorders. Int Psychiatry Today 6:12, 1996.
86. Hollander E, Benzaquen SD. Obsessive-compulsive spectrum disorders. State of the Art in Clinical Psychiatry (in press).
87. Hollander E, Benzaquen SD. The obsessive-compulsive spectrum disorders. International Review of Psychiatry 9:99-109, 1997.
88. Hollander E, Benzaquen SD. The obsessive-compulsive spectrum disorder. In den Boer JA Westenberg HGM, eds. Focus on Obsessive Compulsive Disorders. Amsterdam, The Netherlands: Syn-Thesis Publishers, 33-44, 1997.
89. Aronowitz BR, Hollander E. Treating the treatment-resistant patient. In den Boer JA, Westenberg HGM, eds. Focus on Obsessive Compulsive Disorders. Amsterdam, The Netherlands: Syn-Thesis Publishers, 151-168, 1997.
90. Hollander E, Wong CM. Spectrum, boundary and subtyping issues: implications for treatment refractory obsessive-compulsive disorder. In Obsessive-Compulsive Disorder: Challenges In Treatment, Goodman WK, Rudorfer MV, Maser J, eds. , Lawrence Erlbaum Associates, Inc., pp. 3-22, 2000.
91. Hollander E, Grossman R, Stein DJ, Kwon J. Borderline personality disorder and impulsive-aggression: the role for divalproex sodium treatment. J California Alliance for the Mentally Ill (in press).
92. Hollander E, Grossman R, Stein DJ, Kwon J. Borderline personality disorder and impulsive-aggression: the role for divalproex sodium treatment. Psychiatric Annals 26(7):S464-S469, 1996.
93. Simeon D, Hollander E. Dissociative disorders not otherwise specified. In Comprehensive Textbook of Psychiatry, Seventh Edition, Kaplan HI and Sadock BJ, eds. Williams & Wilkins, Baltimore, MD 1570-1575, 2000.
94. Hollander E, Kwon J. The Seaver Autism Research Center at the Mt. Sinai School of Medicine. The Advocate, May-June, 12-13, 1997.
95. Hollander E, Weilgus Kornwasser J. Counting the cost: the psychosocial and economic burden of OCD. Focus on OCD 5(1):3-5, 1997.
96. Hollander E. Typology and treatment response within an obsessive-compulsive spectrum: part I. Currents 4:5-12, 1997.
97. Hollander E. Typology and treatment response within an obsessive-compulsive spectrum: part II. Currents 5:5-12, 1997.
98. Foa EB, Kozak MJ, Goodman WK, Hollander E, Jenike MA, Rasmussen SA. DSM-IV field trial: obsessive-compulsive disorder. In DSM-IV Sourcebook: Volume 4 (Widiger TA, Frances AJ, Pincus HA, Ross R, First MB, Davis W, Kline M, eds.), American Psychiatric Press, Washington, D.C., 1998, pp. 761-776.
99. Hollander E, Greenberg J. Pharmacological treatment of the impulsive-aggression symptom domain in borderline personality disorder. Psychiatric Times, suppl., 1-4.

100. Hollander E, Simeon D, Gorman JM. Anxiety disorders. In The American Psychiatric Press Textbook of Psychiatry, Third Edition, Hales RE, Yudofsky SC, Talbott JA, eds. American Psychiatric Press, Inc., Washington, D.C., 1999.
101. Hollander E, Simeon D, Gorman JM. Anxiety disorders. In Essentials of Clinical Psychiatry, Hales RE, Yudofsky SC, eds. American Psychiatric Press, Inc., Washington, D.C., 1999.
102. Hollander E, Weiller F, Cohen L, Kwon JH, DeCaria CM, Liebowitz MR, Stein DJ. Neurological soft signs in social phobia. Focus on Depression & Anxiety 8(1):38-39, 1997.
103. DelGiudice-Asch G, Hollander E. Immune dysfunction in autism. In Hollander E (ed.) Autism Spectrum Disorders. Marcel Dekker, Inc., New York, 2003.
104. Stein DJ, O'Sullivan RL, Hollander E. The neurobiology of trichotillomania. In Trichotillomania. Stein DJ, Christenson GA, Hollander E, eds. American Psychiatric Press, Inc. Washington, DC, 1999.
105. Hollander E, Jenike MA. When OCD takes hold. Patient Care 33:134-153, 1999.
106. Hollander E, Rosen J. Obsessive-compulsive spectrum disorders: a review. In World Psychiatric Association Series Evidence and Experience in Psychiatry. Maj M, Sartorius N, Okasha A, Zohar J, eds. Vol. 4, Second Edition, Chapter 5, pp. 203-224, 2002.
107. Hollander E, Cohen L, Simon L. Impulse-control disorders measures. In Handbook of Psychiatric Measures, Task Force for the Handbook of Psychiatric Measures, A. John Rush, Jr., et al. Washington, D.C., American Psychiatric Press, Inc., 2000, pp. 687-712.
108. Hollander E. Psychiatric System Interface Disorders Text Revision Work Group. American Psychiatric Association: Diagnosis and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision. Washington, D.C., American Psychiatric Association, 2000.
109. Hollander E. Insuring a sound financial future for the ACNP. ACNP Bulletin Volume 6, Number 4, p. 11.
110. Professional's Handbook of Psychotropic Drugs. Foreword by Eric Hollander, M.D. Pennsylvania: Springhouse Corporation, 2001.
111. Hollander E, Allen A. Serotonergic drugs and the treatment of disorders related to obsessive-compulsive disorder. In Pato MT and Zohar J Current Treatments of Obsessive-Compulsive Disorder, 2nd Edition. Washington, D.C., American Psychiatric Publishing, Inc., 2001, pp. 193-220.
112. Allen A, Hollander E. Psychopharmacological treatments of body image disturbances. In Body Image: A Handbook of Theory, Research, and Clinical Practice, Cash TF and Pruzinsky T, eds. New York: The Guilford Press, 2002.
113. Hadley SJ, Newcorn JH, Hollander E. The neurobiology and psychopharmacology of body dysmorphic disorder. In Disorders of Body Image, Castle DJ, Phillips KA, eds., Wrightson Biomedical Publishing, Ltd., Philadelphia, 2002.
114. Stein DJ, Hollander E. Anxiety and stress. In Mental Health and Productivity in the Workplace: A Handbook for Organizations and Clinicians, Kahn JP, Langlieb A, eds., Jossey-Bass/Pfeiffer, 2003, pp. 407-432.
115. Hollander E, Simeon D. Treatment of personality disorders. In American Psychiatric Publishing Textbook of Psychopharmacology, Third Edition, Schatzberg AF and Nemeroff CB, eds. American Psychiatric Publishing, Inc., Arlington, VA, 2004, pp. 1049-1066.
116. Hadley SJ, Greenberg J, Hollander E. Comorbid social anxiety disorder and body dysmorphic disorder. Stress Anxiety and Depression (STAND), www.depression.org, 2002.

117. Hollander E, Posner N, Cherkasky S. Neuropsychiatric aspects of aggression and impulse control disorders. In Yudofsky SC, Hales RE, eds., Textbook of Neuropsychiatry and Clinical Neurosciences, 4th ed. American Psychiatric Press, Inc., Washington, DC, 2002.
118. Novotny S, Evers M, Barboza K, Rawitt R, Hollander E. Neurobiology of affiliation: implications for autism spectrum disorders. In Martin A, Scahill L, Charney DS, Leckman JF, eds., Textbook of Child and Adolescent Psychopharmacology. Oxford University Press, New York, NY, 2002, pp.195-209.
119. Greenberg J, Hollander E. Brain function in impulsive disorders. Psychiatric Times 20(3):81-85, 2003.
120. Hollander E, Section Editor. Anxiety Disorders. Current Psychiatry Reports. (in preparation)
121. Allen A, Hollander E. Psychopharmacological treatments for body image disturbances. In Body Image: A Handbook of Theory, Research, and Clinical Practice. Cash TF, Pruzinsky T, eds. New York: The Guilford Press, 2002, p. 450-458.
122. Pallanti S, Baldini Rossi N, Friedberg J, Hollander E. Psychobiology of impulse-control disorders not otherwise specified (NOS). In Biological Psychiatry, D'haenen H, den Boer JA, Wilner P, eds. London: John Wiley & Sons, Ltd., 2002, pp. 1315-1329.
123. Hollander E, Simeon D. Anxiety disorders. In American Psychiatric Publishing Textbook of Clinical Psychiatry, 4th edition. Washington, D.C.: American Psychiatric Publishing, 2003, pp. 543-630.
124. Novotny S, Hollander E. Regional cerebral metabolism and treatment in autism spectrum disorders. Psychiatry Times Vol. XX, Issue 5, May 2003, pp. 52, 54.
125. Hollander E, Nowinski CV. Core symptoms, related disorders, and course of autism. In Hollander E, ed. Autism Spectrum Disorders. New York: Marcel Dekker, Inc., 2003, pp. 15-38.
126. King AF, Rawitt RR, Barboza KC, Hollander E. Cognitive and neuropsychological assessment of children with autism spectrum disorders. In Hollander E, ed. Autism Spectrum Disorders. New York: Marcel Dekker, Inc., 2003, pp. 87-99.
127. DelGiudice G, Hollander E. Immune dysfunction in autism. In Hollander E, ed. Autism Spectrum Disorders. New York: Marcel Dekker, Inc., 2003, pp. 153-173.
128. Evers M, Novotny S, Hollander E. Autism and environmental toxins. In Hollander E, ed. Autism Spectrum Disorders. New York: Marcel Dekker, Inc., 2003, pp. 175-198.
129. Novotny S, Hollander E. Antidepressants and anticonvulsants/mood stabilizers in the treatment of autism. In Hollander E, ed Autism Spectrum Disorders. New York: Marcel Dekker, Inc., 2003, pp. 231-245.
130. Hollander E, Rawitt RR. Future trends. In Hollander E, ed. Autism Spectrum Disorders. New York: Marcel Dekker, Inc., 2003, pp. 419-422.
131. Stein DJ, Hollander E, Klein DF. Anxio-depression: evolution des idees. In: Olie J-P, Poirier M-F, Loo H. Les Maladies Depressives. Paris: Flammarion, 2003, pp. 196-201.
132. Anagnostou E, Hollander E. Autism Spectrum Disorders. In Tarazi FI, Schetz JA, eds. Neurological and Psychiatric Disorders: From Bench to Bedside. New Jersey: The Humana Press, Inc., p. 131-149.
133. Hollander E, Samons DM. Efficacy of paroxetine for relapse prevention in social anxiety disorder. Current Psychiatry Reports 5(4): 249, 2003. (clinical trials report)
134. Hollander E, Friedberg JP, Wasserman S, Yeh C-C, Iyengar R. The case for the OCD spectrum. In Abramowitz JS and Houts AC, eds., Handbook of Controversial Issues in Obsessive-Compulsive Disorder, New York: Springer Science + Business Media, Inc., pp. 95-118.

135. Hollander E, Yeh CC. Reply to Abramowitz and Deacon: Beyond Anxiety: Etiological and Functional Overlaps Between OCD and OC Spectrum Disorders. In In Abramowitz JS and Houts AC, eds, Handbook of Controversial Issues in Obsessive-Compulsive Disorder, New York: Springer Science + Business Media, Inc., pp. 137-140.
136. Hollander E, Kahn, J. Review: in obsessive-compulsive disorder, clomipramine may be more effective than selective serotonin reuptake inhibitors after controlling for other factors . Evid Based Ment Health 6:23, 2003.
137. Allen A, King A, Hollander E. Obsessive-compulsive spectrum disorders. Dialogues Clin Neurosci 5:259-271, 2003.
138. Sood ED, Pallanti S, Hollander E. Diagnosis and treatment of pathologic gambling. Curr Psychiatry Rep 5:9-15, 2003.
139. Hollander E, Simeon D. Anxiety disorders. In Essentials of Clinical Psychiatry, 2nd Edition, Hales RE and Yudofsky SC eds. Arlington, Va., American Psychiatric Publishing, 2004, pp. 339-422.
140. Hollander E, Bartz J. A 48-year-old man with a history of obsessive-compulsive disorder, comorbid bipolar, panic disorders. Psychiatric Annals 34(11):808-810, 2004.
141. Hollander E, Kaplan A, Pallanti S. Pharmacological Treatments. In Pathological Gambling: A Clinical Guide to Treatment, Grant JE, Potenza MN, eds. Washington, D.C.: American Psychiatric Publishing, Inc., 2004, pp. 189-205.
142. Simeon D, Hollander E. Anxiety disorders. In Simon RI, Hales RE, Textbook of Suicide Assessment and Management. Washington, D.C.: American Psychiatric Publishing, 2006, p. 313-32.
143. Hollander E. Evidence-based therapies in social anxiety disorder (monograph). New York: Summit Communications, 2006. (in preparation)
144. Bandelow B, Zohar J, Hollander E, Kasper S, Moller H-J und die WFSBP Task Force on Treatment Guidelines for Anxiety, Obsessive-Compulsive and Posttraumatic Stress Disorders. Medikamentöse Behandlung von Angstund Zwangsun posttraumatischen Belastungsstörungen. Edition Psychopharmakotherapie. Stuttgart, Germany: Wissenschaftliche Verlagsgesellschaft mbH Stuttgart, 2005.
145. Hollander E. Do you need a psychopharmacologist? Bottom Line 19(9):13-14, 2005.
146. Bandelow B, Zohar J, Hollander E, Kasper S, Moller H-J und die WFSBP Task Force on Treatment Guidelines for Anxiety, Obsessive-Compulsive and Posttraumatic Stress Disorders. Medikamentöse Behandlung von Angst-und Zwangsun posttraumatischen Belastungsstörungen.: Behandlungsleitlinien der World Federation of Societies of Biological Psychiatry (WFSB). Stuttgart, Germany: Wissenschaftliche Verlagsgesellschaft mbH, 2005.
147. Hollander E, Dell’Osso B. Impulse disorders: new developments in an evolving field. Psychiatric Times 22(8):17, 2005.
148. Sussman, N. (interviewer) Profiles in Psychiatry. In session with Eric Hollander, M.D. Primary Psychiatry 12(3): 24-27.
149. Allen A, Hollander E. Diagnosis and treatment of obsessive-compulsive disorder. Primary Psychiatry 12(12):34-42, 2005.
150. Hollander E, Dell’osso B. Advancing the understanding of dysmorphic disorder. In Maj M, Akiskal HS, Mezzich J, Okasha A, eds, Somatoform Disorders, Volume 9, NJ: Wiley Publishing, Inc., 2005.
151. Hollander E, Baker BR, Kahn J, Stein DJ. Conceptualizing and assessing impulse-control disorders. In Hollander E, Stein DJ (editors): Clinical Manual of Impulse Control Disorders. American Psychiatric Publishing, Inc., Washington, DC, 2006, pp. 1-18.

152. Allen A, Hollander E. Sexual compulsions. In Hollander E, Stein DJ (editors): Clinical Manual of Impulse Control Disorders. American Psychiatric Publishing, Inc., Washington, DC, 2006, pp. 87-114.
153. Pallanti S, Baldini Rossi N, Hollander E. Pathological gambling. In Hollander E, Stein DJ (editors): Clinical Manual of Impulse Control Disorders. American Psychiatric Publishing, Inc., Washington, DC, 2006, pp. 251-289.
154. Stein DJ, Harvey B, Seedat S, Hollander E. Treatment of impulse-control disorders. In Hollander E, Stein DJ (editors): Clinical Manual of Impulse Control Disorders. American Psychiatric Publishing, Inc., Washington, DC, 2006, pp. 309-325.
155. Simeon D, Hollander E. Treatment of Personality Disorders. In Schatzberg AF, Nemeroff CB Essentials of Clinical Psychopharmacology, Second Edition. American Psychiatric Publishing, Washington, DC, 2006, pp. 689-705.
156. Hollander E, Simeon D. Anxiety disorders. In American Psychiatric Publishing Textbook of Psychiatry, 5th edition. Washington, D.C.: American Psychiatric Publishing, 2008, pp. 505-607
157. Hollander E, Berlin HA, Stein, DJ. Impulse control disorders not elsewhere classified. In American Psychiatric Publishing Textbook of Psychiatry, 5th edition. Washington, D.C.: American Psychiatric Publishing, 2008, pp. 777-820.
158. Hollander E, Allen A. Beauty is in the eye of the beholder: new insights in imagined ugliness. *Primary Psychiatry* 13(7):37-38, July 2006.
159. Hadley SJ, Kim S, Priday L, Hollander E. Pharmacologic treatment of body Dysmorphic disorder. *Primary Psychiatry* 13(7):61-69, July 2006.
160. Hollander E, Swanson E, Anagnostou E, Phillips A, Chaplin W, Wasserman S. Liquid Fluoxetine versus placebo for repetitive behaviors in childhood autism. In Progress in Neurotherapeutics and Neuropsychopharmacology, Vol 1. Cambridge University Press, Cambridge, UK, 2006.
161. Bartz J, Kaplan A, Hollander E. Obsessive-compulsive personality disorder. In Personality Disorders: Toward the DSM-V, O'Donohue W, Fowler KA, Lilienfeld SO, eds. California, Sage Publications, Inc., 1997, pp. 325-351.
162. Hollander E, Berlin HA. Neuropsychiatric aspects of aggression and impulse control disorders. In Yudofsky SC and Hales RE, eds. The American Psychiatric Publishing Textbook of Neuropsychiatry and Behavioral Neurosciences, Fifth Edition. Washington DC, American Psychiatric Publishing, Inc, 2008, pp. 535-565.
163. Hollander E, Berlin HA. Impulse-control disorders measures. In Rush AJ, First MB, Blacker D. Handbook of Psychiatric Measures, Second Edition. American Psychiatric Publishing, Inc. Arlington, VA, 2008, pp. 667-686.
164. Taylor BP, Hollander E. Comorbid Obsessive-Compulsive Disorders. In Autism Spectrum Disorders. Oxford University Press, 2011, pp. 270-284.
165. Bandelow, B., Allgulander, C., Baldwin, D. S., Costa, D. L. D. C., Denys, D., Dilbaz, N., Domschke, K., Eriksson, E., Fineberg, N. A., Hättenschwiler, J., Hollander, E., Kaiya, H., Karavaeva, T., Kasper, S., Katzman, M., Kim, Y. K., Inoue, T., Lim, L., Masdrakis, V., Menchón, J. M., ... Zohar, J. (2023). World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for treatment of anxiety, obsessive-compulsive and posttraumatic stress disorders - Version 3. Part I: Anxiety disorders. *The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry*, 24(2), 79–117. <https://doi.org/10.1080/15622975.2022.2086295>
166. Bandelow, B., Allgulander, C., Baldwin, D. S., Costa, D. L. D. C., Denys, D., Dilbaz, N., Domschke, K., Hollander, E., Kasper, S., Möller, H. J., Eriksson, E., Fineberg, N. A., Hättenschwiler, J., Kaiya, H., Karavaeva, T., Katzman, M. A., Kim, Y. K., Inoue, T., Lim, L., Masdrakis, V., ... Zohar, J. (2023). World Federation of Societies of Biological Psychiatry

(WFSBP) guidelines for treatment of anxiety, obsessive-compulsive and posttraumatic stress disorders - Version 3. Part II: OCD and PTSD. *The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry*, 24(2), 118–134. <https://doi.org/10.1080/15622975.2022.2086296>

167. Nezgovorova, V., Ferretti, C. J., Pallanti, S., & Hollander, E. (2022). Modulating neuroinflammation in COVID-19 patients with obsessive-compulsive disorder. *Journal of psychiatric research*, 149, 367–373. <https://doi.org/10.1016/j.jpsychires.2021.11.025>

168. Taoulost, S., Rasgon, N., Ferretti, C. J., & Hollander, E. (2023). The role of ketogenic therapy in developmental disorders. *Journal of psychiatric research*, 161, 307–309. <https://doi.org/10.1016/j.jpsychires.2023.03.025>

169. Pallanti, S., Grassi, E., Makris, N., Gasic, G. P., & Hollander, E. (2020). Neurocovid-19: A clinical neuroscience-based approach to reduce SARS-CoV-2 related mental health sequelae. *Journal of psychiatric research*, 130, 215–217. <https://doi.org/10.1016/j.jpsychires.2020.08.008>

170. Fineberg, N. A., Menchón, J. M., Hall, N., Dell'Osso, B., Brand, M., Potenza, M. N., Chamberlain, S. R., Cirnigliaro, G., Lochner, C., Billieux, J., Demetrovics, Z., Rumpf, H. J., Müller, A., Castro-Calvo, J., Hollander, E., Burkauskas, J., Grünblatt, E., Walitza, S., Corazza, O., King, D. L., ... Zohar, J. (2022). Advances in problematic usage of the internet research - A narrative review by experts from the European network for problematic usage of the internet. *Comprehensive psychiatry*, 118, 152346. <https://doi.org/10.1016/j.comppsy.2022.152346>

171. Uzunova, G., Pallanti, S., & Hollander, E. (2021). Presentation and management of anxiety in individuals with acute symptomatic or asymptomatic COVID-19 infection, and in the post-COVID-19 recovery phase. *International journal of psychiatry in clinical practice*, 25(2), 115–131. <https://doi.org/10.1080/13651501.2021.1887264>

172. Piccoli, E., & Hollander, E. (2022). Editor's Commentary: Problematic Use of the internet in Autism Spectrum Disorder: A canary in the coal mine?. *Journal of psychiatric research*, 155, 260–262. <https://doi.org/10.1016/j.jpsychires.2022.09.002>

173. Racine, E., Taylor, B. P., Ferretti, C. J., Doernberg, E., Noone, R., Nezgovorova, V., Vats, T., & Hollander, E. (2022). Challenges in assessing change in autistic adults: scale limitations and discrepancies in reporting in clinical trials. *International journal of psychiatry in clinical practice*, 26(1), 3–7. <https://doi.org/10.1080/13651501.2021.1900871>

174. Fineberg, N. A., Hollander, E., Grant, J. E., Chamberlain, S. R., Drummond, L. M., Pellegrini, L., Laws, K. R., Wellsted, D., Reid, J., Nezgovorova, V., & Baldwin, D. S. (2022). Commentary on the article: "Maintenance of wellness in patients with obsessive-compulsive disorder who discontinue medication after exposure/response prevention augmentation A randomized clinical trial" Foa EB et al., JAMA Psychiatry. 2022;79(3):193-200 (1). *Comprehensive psychiatry*, 116, 152323. <https://doi.org/10.1016/j.comppsy.2022.152323>

175. Castle, D., Beilharz, F., Phillips, K. A., Brakoulias, V., Drummond, L. M., Hollander, E., Ioannidis, K., Pallanti, S., Chamberlain, S. R., Rossell, S. L., Veale, D., Wilhelm, S., Van Ameringen, M., Dell'Osso, B., Menchon, J. M., & Fineberg, N. A. (2021). Body dysmorphic disorder: a treatment synthesis and consensus on behalf of the International College of Obsessive-Compulsive Spectrum Disorders and the Obsessive Compulsive and Related Disorders Network of the European College of Neuropsychopharmacology. *International clinical psychopharmacology*, 36(2), 61–75. <https://doi.org/10.1097/YIC.0000000000000342>

CASE LIST FOR LAST FIVE YEARS:

1. *In re: Acetaminophen - ASD-ADHD Products Liability Litigation*, No. 1:2022mc03043 (S.D.N.Y. 2024)